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Abstract 
 
The aim of the project is to produce fluorinated rapamycin analogues using precursor 
directed biosynthesis in order to have a better understanding of the binding of 
rapamycin with FKBP12 and FRAP forming together a ternary complex responsible for 
rapamycin ’s immunosuppressant and anticancer activity. Fluorinated starter units must 
be synthesised and fed to S. hygroscopicus MG-210 a modified organism that does not 
produce the natural starter unit derived from the shikimic acid pathway. The strain S. 
hygroscopicus MG-210 was produced and provided by Biotica Technology Ltd. 
3-Fluorocyclohexanecarboxylic acid, 4-fluorocyclohexanecarboxylic acid and 3-
fluorocyclohexenecarboxylic acid were first synthesised and fed to S. hygroscopicus 
MG-210, but no incorporation was observed. Previous feedings carried out by Biotica 
Technology Ltd correlated to the non incorporation of the fluorinated starter units led to 
the conclusion that a fluorinated starter unit could only be incorporated if a hydroxyl 
group is present in position 3 or 4 of the fluorocyclohexanecarboxylic acid. A range of 
six fluorohydrins (1R*, 3S*, 4S*)-ethyl 4-fluoro-3-hydroxycyclohexanecarboxylate, 
(1R*, 3S*, 4S*)-ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate, (1R*, 3R*, 4R*)-
ethyl 4-fluoro-3-hydroxycyclohexanecarboxylate, (1R*, 3R*, 4R*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate, (1R*, 3R*, 4S*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate and (1R*, 3S*, 4R*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate were synthesised and fed to S. hygroscopicus MG-210 
producing for the first time 6 different fluorinated prerapamycin analogues, with various 
production levels. The incorporation levels indicate that for optimum incorporation the 
hydroxyl group has to be in position 4 and that both ester and hydroxyl group must 
stand in the equatorial position. The best incorporated molecule was the all equatorial  
(1R*, 3R*, 4R*)-ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate. It was fed at a larger 
scale and the corresponding fluorinated prerapamycin analogue was isolated and its 
structure characterised using various 2D NMR techniques.  
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1 INTRODUCTION 
1.1 Pharmaceutical Drugs and Natural Products. 
Pharmaceutically active natural products have been in use since ancient times to prevent 
or cure illnesses. They have also found use as poisons and for recreational purposes. 
One early example was the use of curare, extracted from plants of the Amazon (by the 
indigenous South Americans), as a poison with which to coat arrow tips.1 In controlled 
doses, the neuromuscular inhibitory property of this compound and its derivatives has 
found a modern use as an anaesthetic. Around two hundred years ago, Friedrich 
Sertürner, a young pharmacist, isolated morphine 1.1.2 It was the first time a natural 
product was isolated. Morphine 1.1 could therefore be precisely dosed for 
pharmaceutical usage as an analgesic to relieve severe pains. Historically the majority 
of patented pharmaceutical drugs are derived from natural products.2 Though many of 
these natural products and derivatives are prepared synthetically, a few commercially 
important natural product derived drugs are still extracted from their original natural 
source. One such example is morphine 1.1 produced by opium poppies Papaver 
somniferum,2 or tetrahydrocannabinol 1.2 (THC) from the cannabis plant Cannabis 
sativa. Other medicinally important natural products are produced using enhanced 
biological techniques in order to improve the yields, for example the industrial 
generation of plant cell cultures in order to produce taxol 1.32 (it was originally 
extracted from the bark of the European yew Taxus brevifolia, but it was not a 
sustainable source2) or deep-tank fermentation for mass production of penicillin G 1.4, 
erythromycin 1.5 and other antibiotics (Figure 1.1).  
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1.2: THC                                      1.1: R: H   Morphine
                                                    1.6: R: Me Codeine
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O
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O
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OHHO
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1.5: R: H Erythromycin A
1.8: R: CH3 Clarythromycin
 
Figure 1.1: Example of unmodified natural products and semi synthetic derivatives. 
 
A large number of drugs are semi synthetic derivatives of the natural metabolites, such 
as codeine 1.6, ampicillin 1.7 or clarythromycin 1.8 (see Figure 1.1). Originally 
isolated from opium poppies like morphine 1.1 but in much smaller quantities, codeine 
1.6 is produced industrially by phenolic O-methylation of morphine 1.1.3 
Clarythromycin 1.8 is produced by O-methylation of erythromycin A 1.5. Ampicillin 
1.7 is an aminated derivative of penicillin G 1.4. An alternative to the traditional 
chemical semi synthetic route is an efficient two-step, one-pot enzymatic synthesis of 
ampicillin 1.7 from penicillin G 1.4 recently reported by Lin and coworkers using a 
Penicillin acylase in the presence of D-phenylglycine methyl ester in the presence of 
organic solvents and water.4  
Parts of the pure synthetic drugs mimic the structure of natural products, such as aspirin 
1.9. Salicylic acid 1.10, the active form is also obtained as a metabolite of salicin 1.11 
present in willow bark (used by ancient civilisations as a pain killer Figure 1.2).1  
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O
Aspirin
OH
O
Salicylic acid
OH
Salicin
O
HO
HO OH
OH
OOH
O
O
OH
1.9                                                1.10                                          1.11
 
Figure 1.2: Chemically synthesised aspirin and natural product salicilin have salicylic 
acid as their common active metabolite. 
 
More recently, some natural products have also been produced through biosynthetic 
engineering. This often involves introducing a gene sequence from the wild type 
organism coding for the synthesis of the metabolite in a host organism. Human insulin 
is mainly synthesised in modified Escherichia coli by pharmaceutical companies, the 
traditional alternative being extracting similar insulin exclusively from animal 
pancreas.5 
Biosynthetic engineering has also been used more recently on molecules, for which 
biosynthetic genes have been sequenced to generate new designer natural product 
analogues. This involves genetically modifying the sequence responsible for the 
synthesis of the metabolite introducing, replacing, or deleting genes to obtain a 
modified metabolite. Most of these compounds originate from polyketide biosynthesis 
and NRPS. Simvastatin 1.12, an analogue of Lovastatin 1.13 was produced using an 
engineered biosynthetic approach by Tang and co-workers using a modified strain of 
Aspergillus terreus6 (produced traditionally in a semi synthetic manner).2 The Nystatin 
analogue 1.15 also obtained in this manner is currently in clinical trials and is showing 
an improved antifungal activity and lower toxicity compared to the parent compound 
1.14 (Figure 1.3).   
O
OHO
HO
O
R
1.12  R: CH3 Simvastatin
1.13  R: H      Lovastatin
O
OH
NH2
HO
O
O
O OH OH OH
OH
R1
OH
O
OH
OHHO
R2
1.14  R1: COOH  R2: single bond   Nystatin         
1.15  R1: CH3      R2: double bond  Nystatin analogue
Figure 1.3: Example of analogues obtained biosynthetically by a bioengineered 
organism. 
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Although very promising, producing new analogues, by using combinatorial 
biosynthesis is very time consuming and complicated, making the new analogues fairly 
expensive to produce.  
An alternative approach which combines chemistry and biosynthesis is precursor 
directed biosynthesis. This usually consists of feeding an exogenous alternative starter 
unit to the natural producing microorganism to obtain, if incorporated, a mixture of the 
natural metabolite and the new analogue. Once the flexibility of the starter unit is 
demonstrated, the yields can be improved by bioengineering a modified microorganism, 
inhibiting the production of the natural precursor which previously is in competition 
with the exogenous one. The alternative starter unit can then be fed to the modified 
microorganism, obtaining the new analogue in a higher yield. Some substrates 
previously not significantly incorporated by the wild type organism, can be incorporated 
by the mutant because of the lack of competition with the natural starter unit. 
This procedure entitled ‘mutasynthesis’ was first reported in 1969.7 Neomycin B 1.19 
and C 1.20 analogues naturally produced by Streptomyces fradiae were produced in this 
manner by Shier and coworkers (Scheme 1.1).7 A mutant strain of Streptomyces 
fradiae, in which the production of the natural precursor deoxystreptamine was 
abolished, successfully incorporated endogenous deoxystreptamine 1.16, streptamine 
1.17 and epistreptamine 1.18. This resulted in the production of the expected neomycin 
B 1.19 and C 1.20 when deoxystreptamine 1.16 was fed, but also hydroxylated 
analogues 1.20 and 1.21 when streptamine 1.17 was fed, and diastereomeric 
hydroxylated analogues 1.23 and 1.24 when epistreptamine 1.18 was fed. The mutant 
strain at the time had been obtained by a random mutation caused by chemical 
mutagenesis through the use of N-methyl-N'-nitro-N-nitrosoguanidine (Scheme 1.1). 
O
HO
HO
R3 O
OH
O
HO
R1
O
HOCH2
H2N
R2
NH2
O
O
CH2NH2
HO
HO
H2N
HO
HO
R1H2N
R2
NH2
HO
           Starter unit          R1       R2                          Antibiotic           R3            R4
1.16 Deoxystreptamine  H         H                1.19  Neomycin B        H            CH2NH2
1.16 Deoxystreptamine  H         H                1.20  Neomycin C       CH2NH2      H
1.17 Streptamine            H        OH              1.21  Hybrimicyn A1    H            CH2NH2 
1.17 Streptamine            H        OH              1.22  Hybrimicyn A2   CH2NH2      H
1.18 Epistreptamine       OH      H                 1.23  Hybrimicyn B1    H            CH2NH2
1.18 Epistreptamine       OH      H                 1.24  Hybrimicyn B2   CH2NH2      H
R4
H2N
 
Scheme 1.1: First precursor directed biosynthesis. 
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At this time mutant organisms were obtained usually with mutagenic chemicals or 
radiation by random screening. Until the 1990s precursor directed biosynthesis 
combined with mutagenesis was not a common method, as the mutations occurred in a 
random manner. More recently the progress of gene sequencing technology means that 
specific mutations can be made based on known sequences, therefore the method of 
mutasynthesis is more frequently used. The genes responsible for production of a 
precursor can be easily localised and inhibited, and the range of synthetic molecules and 
methods to produce them have advanced. 
Erythromycin D 1.31 and analogues 1.32, 1.33 were obtained and reported by John R. 
Jacobsen and co-workers (Scheme 1.2) in 1997 using mutasynthesis.8 The exogenous 
precursors 1.25, 1.26, 1.27, 1.34 were fed to a modified mutant of the 
deoxyerythronolide B synthase enzyme (DEBS) with an inhibited production of the 
natural precursor N-acetyl cysteamine. Naturally DEBS produces 6-dEB 1.28 an 
intermediate to erythromycin D. Exogenous N-acetyl cysteamine 1.25 was incorporated 
producing 6-dEB 1.28. Three other alternative starter units 1.26, 1.27, 1.34 gave three 
new analogues of 6-dEB 1.29, 1.30 and 1.35 one of which 1.35 had an extended lactone 
ring from fourteen to a sixteen membered one (Scheme 1.2). The two fourteen- 
membered lactone analogues 1.29, 1.30 and 6-dEB 1.28 produced by the modified 
DEBS were then fed to an engineered strain of Saccharopolyspora erythrea (natural 
producer organism of Erythromycin D) in which the production of 6-dEB was inhibited. 
This enabled the glycolisation of the macrocycle, erythromycin D 1.31 and two new 
analogues 1.32 and 1.33 were obtained in this manner (Scheme 1.2). 
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1.25 R: CH3                                      1.28 R: CH 3 6-dEB                   1.31 R: CH3 Erythromycin D  
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OOH
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S O
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OHO
OH
OH
OR
O
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N
S O
OH
O
OH
OHO
OH
OH
O
GM DEBS
GM DEBS
GM
S. erythrea
      1.34                                                            1.35
Scheme 1.2: First reported erythromycin analogues produced by precursor directed 
biosynthesis.8 
 
Rapamycin 1.36 (Scheme 1.3), like erythromycin, is a biologically active natural 
product of polyketide origin. It is currently used as an immunosuppressive for kidney 
transplant patients. Two semi-synthetic derivatives Temsirolimus 1.37 and Everolimus 
1.38 with a modified cyclohexyl moiety have recently been accepted as an anticancer 
treatment (Scheme 1.3). Precursor directed biosynthesis produced analogues of 
rapamycin with a modified cyclohexyl ring were first reported by Leadlay, Staunton and 
coworkers in 1996.9 Exogenous deuterated synthetic putative starter units 1.39 was fed 
to the natural producing microorganism S. hygroscopicus which led to the production of 
deuterated rapamycin analogue 1.40, in parallel with normal rapamycin 1.36 (Scheme 
1.3). Precursor directed biosynthesis was also used to make pipecolinate analogues of 
rapamycin by Leadlay and coworkers in 1998.10 Proline 1.41 was fed to wild type S. 
hygroscopicus and an engineered variant with reduced production of the pipecolinyl 
acid. In both cases the proline rapamycin analogue 1.42 was produced (Scheme 1.3).10  
Wild type S. hygroscopicus demonstrates a level of substrate flexibility. Modified 
strains of S. hygroscopicus (generated by Biotica Technology Ltd), in which production 
of the starter unit responsible for the formation of the cyclohexyl moiety is inhibited, 
have been used for this research. Exogenous starter units can then be fed to the modified 
S. hygroscopicus in order to create a bigger range of rapamycin analogues. The activity 
of the new analogues can then be investigated. 
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O OMe
O
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O
MeO
1.36 R: H Rapamycin
Semi-synthetic analogue R:
O OMe
O
OHOON
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O
OH
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O
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O OMe
O
OHOON
OHO
O
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O
MeO
OH
N
H O
HOOC
OH
OH
D D
S. hygroscopicus
wild type
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D D
D
D
D
D
R: O OHOH
R:
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OH1.38 Everolimus
1.39
1.40
1.41
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Scheme 1.3: Rapamycin, two semi-synthetic rapamycin analogues currently used for 
cancer treatment and two different examples of precursor directed biosynthetic 
analogues obtained with the wild type microorganism. 
 
In addition to its anticancer and immunosuppressive properties, rapamycin shows 
promising results for treatment of a whole range of conditions from autism to tuberous 
sclerosis. It was recently reported in Nature that rapamycin could extend the life of 
mice.11 Rapamycin has great therapeutic potential, but it was only due to the 
perseverance of Sehgal, the researcher who discovered rapamycin, that it was ever 
developed.   
 
1.2 The History of Rapamycin 
Rapamycin is a secondary metabolite produced by Streptomyces hygroscopus an 
actinomycete originally discovered in a soil sample of Rapa-Nui (the native name of the 
Easter Island).12, 13 It was first isolated in 1972 by Ayerst Research Laboratories in 
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Montreal, and its structure was published in 1975.12 Rapamycin is a 31-membered 
macrolactone polyketide featuring a cyclohexyl moiety derived from the shikimic acid 
pathway, a pipecolinyl ring and a triene in its structure. It was first developed for its 
antifungal proprieties,14 but was abandoned when it was shown, that it caused atrophy 
of the thymus and the spleen.15 Although it was dropped as a potent antifungal, it was 
found to have immunosuppressive and antiproliferative activity but this was not 
exploited at the time. Dr Suren Sehgal who was part of the Ayerst team of scientists that 
isolated rapamycin, believed it could have anticancer properties and sent a sample to the 
National Cancer Institute (NCI). The NCI found that it had a remarkable activity against 
solid tumours and it was placed on their priority list. It was the first potential anticancer 
agent with cytostatic and not cytotoxic activity. After difficulties by Ayerst to develop 
an intravenous formulation for clinical trials the rapamycin project was dropped after 
financial restructuration of the company. In 1987, Ayerst merged with Wyeth and 
changed management. This, combined with the fact that FK506, structurally related to 
rapamycin, was identified as a potential immunosuppressive drug, led to rapamycin 
being tested on animals under the direction of Dr Suren Sehgal. The results convinced 
Wyeth-Ayerst to redevelop rapamycin as an immunosuppressant, and continue 
investigating its antitumor and antiproliferative properties. In 1999 it was approved as 
an anti-rejection drug under the name Rapamune. It is particularly used for kidney 
transplants as it presents very little nephrotoxicity compared to cyclosporin A and 
FK506, which were generally used previously.  
Moreover after a range of semi-synthetic rapamycin analogues were tested as 
inmmunosupressives and potential anticancer agents, two compounds were approved 
after clinical trials as anticancer drugs, Temsiromilus 1.37 in 2007, sold as Torisel by 
Wyeth and Everolimus 1.38 in 2009 sold as Afinitor by Novartis (Scheme 1.3). They 
are both used more specifically against kidney cancer. Everomilus had previously been 
approved as an immunosuppressive for kidney transplants under the name Certican. 
 
2 RAPAMYCIN’S SPECIFIC IMMUNOSUPPRESSIVE 
PATHWAY 
2.1 Natural Products and Immunosuppression  
The natural product cyclosporin A 1.43 produced by the fungus Beauveria nivea first 
isolated from a soil sample in Norway revolutionised transplantation (Figure 1.4). It 
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allowed successful heart and liver transplantation and turned kidney transplantation into 
a fairly common procedure in spite of its nephrotoxic properties.15 Previously a mixture 
of azathioprine and steroids were used for kidney transplants, but only around 50% of 
people would live more than a year. Other transplantations such as heart or liver were 
experimental and would always lead to rejection of the organ and death of the subject. 
Later FK506 1.44 also known as Fujimycin produced by Streptomyces tsukubaensis was 
isolated from a soil sample in Japan (Figure 1.4).15 This was found to have similar 
activity to cyclosporin in heart and renal transplants and even had enhanced results in 
liver transplant at a lower dosage.15 An ethyl analogue of FK506 named FK520 1.45 
also showed immunosuppressive activity. It was produced by S. hygroscopicus like 
rapamycin. FK520 is mainly used for treating dermatitis. Rapamycin 1.36, FK506 1.44 
and FK520 1.45 are structurally related (Figure 1.4). 
 
O
O
OO
O
O O
OH
OMe
MeO
HOH
MeO
HO
N
OH
O
HOOH
OMe
O
ON
O O
OMe
HO
MeO
R
      1.44   FK506, R =CH2-CH=CH
      1.45 FK520, R = Et        Rapamycin
N N
H
H
N N
H
N
O
O O
O
O
NO
N O
N
O
N
R
O
H
N O
N
O
HO
Cyclosporin A
       1.43
In red: common structure
 of Rapamycin and FK506
 binding to FKBP12.
  1.36
 
Figure 1.4: Main natural products with immunosuppressive activity. 
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2.2 Comparison between Rapamycin, FK506, Cyclosporin 
Immunosuppressive Pathways. 
2.2.1 T lymphocyte: the base of the immune response. 
 
The T lymphocyte is the most important cell involved in an immunological response. 
Most research on immunosuppressive compounds is directed toward establishing the 
mechanism of inhibition of the T cell. 
In its early stages the T cell travels in the thymus and the glycoprotein antigen receptor 
present on its surface either reacts with a self-antigen and will receive an apoptotic 
signal resulting in cell death (negative selection) or it develops and interacts with a 
foreign antigen presented by MHC (major histocompatability complex) and will receive 
a survival signal (positive selection). The cell will then migrate to the peripheral lymph 
nodes and will be able to initiate an immune response when its receptor associates with 
a foreign antigen presented by MHC. The immune response involves a cascade of 
intracellular signalling events leading to an activation and proliferation of T- cells and 
other cells also involved in the process and the production of a variety of effector 
molecules like interleukin-2 (IL-2).16 The signalling pathway of the immune response is 
not yet fully known in intimate detail. 
 
2.2.2 Differences and similarities in their proteomic targets and pathway. 
 
A) The proteomic targets  
 
Due to their common structure it was first believed that the immunosuppressive mode of 
action of rapamycin and FK506 were similar. Moreover rapamycin and FK506 
antagonise each others action probably through competitive binding to a common 
receptor. Early crystal structures of binary complexes17 confirmed that rapamycin shares 
the same cellular target as FK506, an immunophilin (peptidyl-prolyl isomerase) called 
FKBP12 (FK506 binding protein) due to their common structure (Figure 1.4) whereas 
cyclosporin A binds to a different type of immunophilin called cyclophilin.18 FKBP12 
and cyclophilin are two different enzymes, both catalyzing the isomerisation of cis and 
trans amide bonds of peptide and protein substrates.19 Both rapamycin and FK506 
inhibit FKBP12’s peptidyl-prolyl isomerase activity. Although FKBP12 is inhibited by 
both immunosuppressants, FKBP12 was found not be directly implicated in the immune 
response. Both molecules were found to inhibit different pathways. Although FK506 
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and cyclosporin A bind to a different immunophilin their mode of action is identical, 
they both inhibit calcineurin, whereas rapamycin inhibits FRAP, also named mTOR 
(mammalian target of rapamycin).18 FRAP is a serine/threonine protein kinase that 
regulates cell growth, cell proliferation, protein synthesis and transcription. 
Cyclosporin A binds with cyclophilin and calcineurin and FK506 binds with FKBP12 
and calcineurin: the formation of both ternary complexes results in the inhibition of 
calcineurin. Calcineurin intervenes in the early stage of the immune response interfering 
with a calcium dependant signalling pathway. By inhibiting calcineurin the T cell cycle 
is stopped from G0 (resting phase of the cell Figure 1.5) to G1 (growth of the cell 
synthesising all the enzymes necessary for DNA synthesis Figure 1.5). 
Rapamycin binds with FKBP12 and FRAP. The formation of this ternary complex 
results in the inhibition of FRAP. FRAP intervenes in the later stage of the immune 
response interfering with a calcium independent signalling pathway. As a result of the 
inhibition of FRAP, the cell cycle is stopped from G1 to S (DNA replication Figure 
1.5). 
G2
(Gap 2 )
M 
(mitosis)
G1
(Gap1)S phase(DNA replication) G0
(Gap 0)
 
Figure 1.5: Cell cycle diagram 
 
B) The immune response and its inhibition by cyclosporin A, FK506 and 
rapamycin. 
 
The binding of the antigen with the T cell receptor leads to the activation of different 
kinases that activate various enzymes by phosphorylating them. This results later, in the 
production of IP3 (Inositol trisphosphate). IP3 is responsible for the opening of Ca2+ 
channels. This leads to an increase in the cytoplasmic level of calcium, which activates 
calcineurin.16 FK506 and cyclosporin disrupt the activation of calcineurin. 
Activated calcineurin will normally activate NFAT (nuclear factor of activated T cells) 
by dephosphorylating it.16 NFAT is a transcription factor regulating interleukin 2 (IL-2). 
Once dephosphorylated, NFAT translocates into the T cell nucleus by diffusion and 
associates with other transcription factors from the AP1 family in order to transcript 
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interleukin-2 (IL-2). IL2 once produced will bind to IL-2 receptors on various cells 
including T-lymphocytes. Once IL-2 binds to its growth factor receptor, a multiprotein 
complex called CmTOR1 containing FRAP (also called mTor) is activated. If 
Rapamycin-FKBP12 is present it will disrupt the activation of the FRAP complex, by 
binding to FRAP.  
The FRAP complex (CTOR1), once activated, can phosphorylate the p70 ribosomal 
protein S6 kinase (P70S6k) on threonine 389 within its hydrophobic motif.20, 21 This 
phosphorylation is necessary for its activation. Once activated P70S6K will 
phosphorylate a serine residue on the 40S ribosomal subunit S6 protein responsible for 
translating certain m RNA’s encoding for ribosomal proteins and elongation factors 
which are essential for the cell cycle to progress from G1 to S (Figure 1.6).22  
When rapamycin is present this pathway is inhibited and results in the non proliferation 
of the T cells and therefore immunosuppression.  
 
      TCR
T-cell receptor GFR-growth
 factor receptor
kinases FRAP
Ca2+              calceuneurin
                    p70S6K
FKBP12-
rapamycin
Ca2+ independant GFR signallling
  G1                           SG0                           G1
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 TCR signalling
+cyclindependent 
kinase
 NFAT
FKBP12-FK506
IP3
or Cyp -  CsA
              
Figure 1.6: Pathways inhibited by rapamycin, cyclosporin and FK506.16 
Calcineurin is usually specific to T cells whereas FRAP is a pivotal regulator of cell 
growth and proliferation of different types of cells including T cells.23 It is present in 
many cells from yeast to humans and binds to growth factors such as IL-2 receptors as 
previously seen, IL-3 receptors, platelet-derived growth factor, epidermal growth factor, 
and insulin receptors. Therefore this confers rapamycin not only immunosuppressive 
activity but also antifungal and antitumor activities as it blocks the proliferation of 
various cells. Those cells can be tumour cells or healthy cells, T cells as seen previously 
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or fungal cells. Moreover in cancer cells the mTor signalling pathway is stimulated, 
with in certain cases like breast cancer, an over expression of p70S6K.24 More recently 
this pathway was shown to be involved in aging. Rapamycin extended the life 
expectancy of mice living in aseptic conditions.11, 25 
The activity of rapamycin is linked to its capacity to inhibit FRAP, by binding with it 
and with FKBP12. FKBP12 or rapamycin on their own do not inhibit FRAP. The 
capacity of rapamycin to form this ternary complex with FRAP and FKBP12 is essential 
for its immunosuppressive activity. 
 
2.3 The Origin of Rapamycin’s Immunosuppressive Activity: 
Structure and Activity of the Ternary Complex.  
2.3.1 Crystal structure of the ternary complex compared to the binary 
complex. 
 
Before rapamycin and the 12 kDa protein FKBP12 bind to FRAP to form a ternary 
complex they first bind to each other. Choi and coworkers observed from a crystal 
structure of the FKBP12-rapamycin binary complex that rapamycin binds to a 
hydrophobic pocket of FKBP12, leaving about 50% of its surface exposed on the 
exterior of the complex.26  
The FKBP12-rapamycin complex binds to FRAP through a 100 amino acid domain27 
called FRB that can be expressed as a 12 kDa soluble protein.26 The entire FRAP 
protein is 289 kDa. 
Once the FKBP12-rapamycin-FRB ternary complex was obtained, Choi solved the 
crystal structure using a combination of molecular isomorphous replacements.26 The 
crystal structure showed that FRB and FKBP12 bind together with rapamycin 
occupying two different hydrophobic binding pockets simultaneously, one in the FRB 
domain and the other in FKBP12. Both binding pockets are composed of aromatic 
residues. The structure showed extensive interactions between rapamycin and both 
proteins in both binding pockets, but fewer between the proteins themselves. 
The ternary complex was described by Choi as a roughly rectangular shape with overall 
dimensions of 60 Å, 45 Å and 35 Å. The size of FRB and FKBP12 is roughly 
equivalent and rapamycin is almost completely buried between both proteins.  
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Figure 1.7: Structure of the ternary complex resolved by Choi and coworkers showing 
in red the FRB domain, in blue the FKBP12 and in green rapamycin.26 
 
FKBP12 contains a large β sheet composed of five anti- parallel β strands pressed 
against a short amphipathic α helix. Together the β sheet and α helix form the 
hydrophobic pocket in which rapamycin binds. Three loops surround and contribute to 
the binding pocket; the 40s loop described as a bulge in β5,26 the 50s loop linking β5 to 
α, and the 80s loop connecting β2 to β3 (Figure 1.7).26 Choi described the structure of 
FKBP12-rapamycin in ternary complex as very similar to the one of the binary complex 
without rapamycin.  
Choi described the structure of the FRB domain of FRAP as a bundle of four helices 
linked to each other through short underhand connections. All four helices (ignoring the 
first 10 residues of α 3) are about 26 Å long, each helix containing between 16 to 19 
residues. The α1 and α2 helices seem almost parallel (interhelical angle of 22°), and so 
do α3 and α4 (20°). The crossing angle between α1, α2 and α3, α4 ranges from 30° to 
60°.26 The parallel helices are closer to each other and show the shortest interhelical 
distances. Most of the hydrophobic and aromatic residues are found in the interhelical 
regions, and the hydrophilic residues are exposed to solvent. Choi determined that the 
crossing of α1 and α4 formed close to its crossing point a deep crevice lined by six 
aromatic side chains constituting the hydrophobic pocket in which rapamycin binds to 
FRB.26 
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Figure 1.8: Structure from Choi and coworkers showing the interactions of rapamycin 
with FKBP12 and FRB.26 
 
Rapamycin’s interactions with FKBP12 in the ternary complex are very similar to those 
of the binary complex. The crystal structure showed that rapamycin has extensive 
hydrophobic contacts with aromatic residues of FKBP12, and establishes five hydrogen 
bonds (Figure 1.8) with FKBP12. Trp59 forms the base of the binding pocket and is in 
contact with the most buried portion of rapamycin the pipecolinyl ring. C3, C4 and C5 
of the pipecolinyl ring are involved in hydrophobic contacts with FKBP12. Other 
hydrophobic contacts with FKBP12 involve the methyl groups on C29, C31, C35 and 
C11. C41 and C42 of the cyclohexyl moiety are also involved in hydrophobic contacts 
with FKBP12 and so is C9. Three of the five hydrogen bonds involve hydroxyl groups 
on C10, C28 and the C40 of the cyclohexyl moiety. The two final hydrogen bonds 
concern the double bonded oxygens on C1 and C8 (Figure 1.8 and 1.9).26 
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Figure 1.9: Rapamycin with regions extensively in hydrophobic contacts with FKBP12 
and FRB indicated in blue, and in red atoms involved in hydrogen bonding with 
FKBP12. 
 
Choi observed a slight change in conformation of rapamycin in the binary complex 
compared to the ternary complex. The triene arm is usually planar with the 3 double 
bonds conjugated but in the ternary complex the conjugation is slightly lost with a 
rotation of -15° between C18 and C19 and about 37° between C20 and C21, allowing 
the part of the molecule containing the triene to go deeper in the hydrophobic pocket of 
the FRB domain. The most buried part of the molecule in FRB is the methyl group on 
C23 that goes into a small crease between a Phe2108 and Leu 2031 of the FRB domain 
(Figure 1.8 and 1.9). 
Choi believes rapamycin’s macrocyclic loop, which is eight carbons longer than 
FK506’s macrocycle, and its triene arm, reduce the conformational flexibility of the 
loop. This difference with FK506 is believed to be responsible for rapamycin’s capacity 
to bind in a deep pocket of FRB compared to FK506 that does not bind to FRB.26 
Rapamycin interacts with FRB through close contacts with aromatic residues, and a 
series of interactions along the triene arm of rapamycin from C16 to C23, but does not 
establish any hydrogen bonds with FRB. The hydrophobic interactions concern the 
methyl of the methoxy group on C16, the methyl group on C23 and the alkenyl groups 
on C19, 20, 21, 22 of the triene. Thirty three percent of the solvent accessible surface 
area of rapamycin participates in the interaction with the FRB domain.26  
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2.3.2 Interactions between both proteins. 
 
Rapamycin has numerous binding interactions with FKBP12 and FRB but very few 
interactions were observed between FKBP12 and FRB, in the ternary complex from the 
crystal structure. Choi identified two regions of the complex showing interaction 
between both proteins the 40s loop of FKBP12 with the α4 helix of FRB, and the 80s 
loop of FKBP12 with the α1 α2 region of FRB. In the first region Choi found that the 
hydroxyl group of Tyr2105 from FRB and the oxygen of Lys47 from FKBP12 make a 
short contact. There is also a water-mediated salt bridge. In the second region Choi 
discovered that the amine group of Arg2042 from FRB makes short contacts with the 
hydroxyl group of Thr85 and the oxygen of Gly86 of FKBP12, and there are two water 
mediated interactions. In that same region Choi also found that FKBP12’s structure 
differs from the binary complex in the 80’s loop with a major change around Ile90 with 
both side chains and main chain angle deviating. This deviation moves the FKBP12 
away from the FRB domain showing a possible repulsion between both proteins.  
In order to measure the binding constants and have a better understanding of the 
interactions between FKBP12, FRAP and rapamycin Banaszynski27 and coworkers ran 
a series of experiments using 3 different physical techniques: Fluorescence Polarization 
Assays, Surface Plasmon Resonance and 3D NMR experiments. Previously the 
dissociation constant between rapamycin and FKBP12 had been measured by Schreiber 
and coworkers Kd= 0.2 nM.28 The binding constants were obtained independently using 
two different types of methods.  
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Figure 1.10: Rapamycin analogues used in the experiments of Banazynski.27 
 
Fluorescence Polarization Assays involve the excitation of fluorescent molecules, and 
the detection of the resulting fluorescence polarization signals emitted by those 
molecules, allowing them to be quantified. The alcohol group on the C40 of rapamycin 
was esterified with a fluorescein group. This hydroxyl on C40 was chosen as it is found 
on one of the most distant parts of the molecule from FRB in the crystal structure of the 
tertiary complex. The new rapamycin tracer was named Fl-rapamycin 1.46 (Figure 
1.10). A fixed concentration of Fl-rapamycin was added to various concentrations of 
FRB, and formation of the Fl-rapamycin FRB complex was quantified by measuring the 
increase in polarization. Once FRB was complexed with Fl-rapamycin various 
concentrations of rapamycin were introduced in order to establish a competition binding 
experiment. The substitution of Fl-rapamycin with rapamycin in the binary complex 
involving FRB will correspond to a decrease in polarity. The results were only partial 
because of rapamycin solubility issues. The partial data was fitted to a mathematical 
model, the best fit corresponding to Kd rapamycin-FRB= 5.2 µM. The same studies 
were repeated adding FKBP12 in order to establish the binding constant of FKBP12-
rapamycin with FRB. The competition results were incomplete because the fluorescein 
group on C40 interferes with the binding to FKBP12 as the hydroxyl group on C40 of 
rapamycin is involved in hydrogen bonding with FKBP12 and both methylene groups 
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of C41 and C42 are involved in hydrophobic interactions with FKBP12. However using 
another mathematical fit and considering the previous result Kd rapamycin-FRB= 5.2 
µM as a primary dissociation constant, they found as a secondary dissociation constant 
Kd FKBP12rapamycin-FRB= 6.2nM.  
In order to validate the method and the mathematical fits the Kd of FKBP12-rapamycin 
had to be measured. This could not be achieved with Fl-rapamycin as previously 
because of the proximity of the fluorescein group to the cyclohexyl moiety which is 
involved in the bonding to FKBP12. A molecule was synthesized which included a 
fluorescein moiety spaced from a diketone linked to a pipecolinyl ring (in red Figure 
1.10) and was named Fl-SLF 1.47 (Figure 1.10). The diketone and the pipecolinyl ring 
are common to rapamycin and are involved in the binding to FKBP12. The pipecolinyl 
ring as previously reported in the crystal structure26 is the most buried portion of 
rapamycin in FKBP12. The experiments used Fl-SLF in competition with rapamycin to 
bind FKBP12. After using their mathematical model the best fit was Kd FKBP12-
rapamycin = 0.35nM, this was in the same range as the value previously found in the 
literature 0.2 nM.28 
In order to confirm these results Surface Plasmon Resonance (S.P.R.) was used to 
establish the different dissociation constants. S.P.R. measures the adsorption of 
molecules and proteins to a surface. The experiment started by immobilizing rapamycin 
molecules on separate chips and exposing them to a flow of FRB measuring the change 
in adsorption. In order to immobilize rapamycin a Biotin-LC moiety was fixed on the 
hydroxyl group of C40. Biotin-LC-rapamycin 1.48 (Figure 1.10) was fixed to a 
Neutrividin, which was itself fixed to a chip via amine coupling. The LC part, an 
aminohexanoic acid spacer, is there to limit the possible interactions between FRB and 
Neutrividin. After using Bio evaluation software analysis on the results, Banaszynski 
and coworkers found that Kd rapamycin-FRB was 26 ± 0.8 µM.  
In order to measure the affinity of FRB to FKBP12, FKBP12 to rapamycin and 
FKBP12-rapamycin to FRB, FKBP12 had to be immobilized on separate chips. A 
Glutathione S-transferase-FKBP12 (GST-FKBP12) fusion protein was fixed to an anti-
GST antibody immobilized on the dextran surface of the chip. The interactions between 
FRB and FKBP12 were too small to be detected. After using the Bio evaluation analysis 
software the value of Kd rapamycin-FKBP12 was found to be 0.27 kDa very similar 
value to the previous results. In order to calculate the affinity of FRB to the rapamycin-
FKBP12 binary complex, the immobilized FKBP12 was saturated with rapamycin and 
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then later exposed to FRB. It was found that KdFKBP12rapamycin-FRB was 12 ± 0.8 
nM.  
The final set of experiments carried out by Banaszynski were 3 dimensional NMR 
correlating experiments using 13C and 15N labeled FRB exposed to different 
concentrations of rapamycin and FKBP separately. Correlating those results with the 
crystal structures26 suggested that Van der Vals interactions exist between rapamycin 
and FRB as a binary complex and confirmed that the interactions between both proteins 
without rapamycin were minimal. 
Both Fluorescence Polarization Assays and Surface Plasmon Resonance show very 
similar results on the binding of FKBP12 to rapamycin which is close to the previous 
literature value,28 suggesting that they are reliable methods for establishing binding 
constants. Banaszynski found that FRB binds to rapamycin but the affinity is too small 
for them to bind in physiological conditions. From the NMR experiments they 
established that stabilizing Van der Waals interactions between both FRB and 
rapamycin existed. In the first experiment FRB was bound to rapamycin-FKBP12 
roughly a thousand fold more than with just rapamycin on its own and the second 
experiment demonstrated a 2000 fold increase in binding. The second experiment also 
showed that the interactions between FRB and FKBP12 without rapamycin were 
negligible and this was confirmed by the NMR experiments. Banaszynski concluded 
that this 1000 to 2000 increase in binding of rapamycin with FKBP12 to FRB compared 
to rapamycin on its own with FRB suggests strong stabilizing interactions between both 
proteins in the ternary complex. Although Choi and coworkers from the crystal structure 
of the ternary complex had only found 2 zones of interactions between both proteins in 
the ternary complex and found some possible repulsions, Banaszynski’s experiments 
suggest many more stabilizing interactions than destabilizing ones between both 
proteins in the tertiary complex.  
 
2.3.3 Chemical modification on rapamycin and consequences on its 
binding and activity.  
 
Sedrani, Kallen and coworkers29 methylated the hydroxyl group on C28 of rapamycin. 
They ran competitive binding assays between 28-O-methylrapamycin 1.49 and 
rapamycin 1.36 (Figure 1.11) toward FKBP12, and were surprised to find that the 
binding of the new analogue to FKBP12 had not significantly reduced compared to 
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rapamycin. The hydroxyl on C28 of rapamycin is usually involved in hydrogen bonding 
with Glu54 of FKBP12 (Figure 1.8). Kallen expected that the potential loss of at least 
one of the 5 hydrogen bonds involved between rapamycin and FKBP12 and the sterics 
of the methyl group in proximity to FKBP12 would affect the binding in a more severe 
manner. 28-O-Methylrapamycin 1.49 was then tested for its immunosuppressive 
activity. It was found to be reduced of a 1000 fold compared to rapamycin, although the 
binding was hardly affected. A crystal structure of the new analogue bound to FKBP12 
was then obtained and compared to the crystal structure of the binary complex FKBP12-
rapamycin. Sedrani found that the conformation of the methoxy group on C40 had 
hardly changed compared to the previous hydroxyl group of rapamycin. The rest of the 
macrocycle was also unchanged except for the orientation of the cyclohexyl moiety. 
Two hydrogen bonds involving hydroxyl groups in rapamycin disappeared because of 
the C28 hydroxyl becoming a methoxy and the different orientation of the cyclohexyl 
moiety including the hydroxyl group on C40 that usually establishes a hydrogen bond 
with Gln 53 of FKBP12. The loss of hydrogen bonding with the methoxy group on C28 
was expected as it was previously a hydroxyl group, but the loss of hydrogen bonding 
of the hydroxyl group on C40 and the shift in orientation of the cyclohexyl moiety was 
not expected. Sedrani had two possible explanations for the loss in activity. The first 
was due to an unfavourable steric interaction of the cyclohexyl ring, in its new position 
with FRAP. The alternative one was that the cyclohexyl moiety and possibly the ethyl 
side chain could play a functional role in target recognition, making it part of the 
effector domain. 
In order to discriminate between the two hypotheses Sedrani oxidatively cleaved the 
cyclohexyl moiety of rapamycin (Figure 1.11).30 Hydroxyls at position 28 and 40 of 
rapamycin 1.36 were first silylated, the 40-O-triethylsilyl protecting group was then 
selectively removed and the resulting free hydroxyl was oxidised to the ketone using a 
Swern oxidation, then oxidised to the lactone-acetal through a Baeyer-Villiger 
oxidation. The ring was then cleaved by mild acidic hydrolysis leading to the acid-
aldehyde. The acid was then esterified, and the aldehyde selectively reduced and finally 
the triethylsilyl protecting group of the hydroxyl in position 28 was removed resulting 
in the cleaved rapamycin 1.50 (Figure 1.11).30 
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Figure 1.11: 28-O-Methylrapamycin, rapamycin and oxidatively cleaved rapamycin.  
 
The cleaved rapamycin 1.50 was found to have a 6-fold loss in binding with FKBP12 
compared to rapamycin, but its immunosuppressive activity was reduced by 380 fold. 
This loss of activity could be due to the decreased affinity between the FKBP12-
rapamycin complex and FRAP. This loss of affinity cannot be explained by steric 
factors. The new cleaved cyclohexyl ring is not more hindering than the cyclohexyl 
moiety. Sedrani deduced from the crystal structure of the tertiary complex, by Choi that 
the cleaved cyclohexyl moiety should fit between FKBP12 and FRB without disturbing 
the formation of the ternary complex. The most plausible explanation is that part of the 
cyclohexyl ring is necessary to bind strongly enough to FKBP12 so that it can strongly 
bind to the FRB domain and inhibit FRAP. The efficacy of rapamycin in binding 
proteins FKBP12 and FRAP is postulated to be linked to the compounds 
immunosuppressive activity. Sedrani postulated that the cyclohexyl moiety is probably 
part of the effector domain. The hydroxyl group on C40 of rapamycin is involved in 
hydrogen bonding with Gln 53 of FKBP12 and both methylene groups of C41 and C42 
are involved in hydrophobic interactions with FKBP12.   
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3 BIOSYNTHESIS OF RAPAMYCIN 
3.1 Starter Unit of the Polyketide Synthesis 
3.1.1 The shikimic acid pathway   
 
The main structure of the rapamycin macrocyclic ring is derived from polyketide 
biosynthesis, using as a starter unit (4R, 5R)-4,5-Dihydroxy-cyclohex-1-enecarboxylic 
acid derived from the shikimic acid pathway.  
In the first step catalysed by 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) 
synthase, phosphoenol pyruvate 1.51 reacts with erythrose-4-phosphate sugar 1.54 to 
produce 3-deoxy-D-arabino-heptulosonate-7-phosphate DAHP 1.55 (Scheme 1.4).31 
Isotopically labelled enol pyruvate experiments indicated that the P-O bond of 
phosphoenol pyruvate 1.51 is first substituted by a C-O bond before being cleaved 
(Scheme 1.4).31, 32 The enzyme, through a carboxylic group, performs a nucleophilic 
addition on the most substituted part of the double bond to produce intermediate 1.52. 
Then the phosphate group eliminates to form the enzyme associated oxiacrylate 1.53. 
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In the second step DAHP 1.55 dephosphorylates to intermediate 1.56 and then cyclises 
to 3- dehydroquinate 1.57. Knowles suggested a mechanism for step 2 involving DAHP 
1.55 in its hemi-ketal form (Scheme 1.5).31, 33 In this mechanism one of the hydroxyl 
group’s of hemi-ketal 1.55 is oxidised to ketone 1.60 by NAD+. The phosphate in 1.60 
acts as an internal base and abstracts the proton on the carbon in alpha of the ring 
oxygen (1.61), facilitating the elimination of the phosphate group (1.62). The ketone of 
1.62 is reduced back to the alcohol of 1.63 by NADH. After a base deprotonation of the 
alcohol on the carbon in between the double bond and the carboxylate group, the ring 
opens (1.64), and rearranges to form 3-dehydroquinate 1.57 after cyclisation (Scheme 
1.5). 
O OP
OH
HO
OH
-O2C O O
HO
OH
-O2C
O
P O
O-
-OH
O
O
HO
OH
-O2C
O-
P
O
HO
O
HO
O
-O2C
HB
O
HO
-O2C
O
OH
O
HO
OH
-O2C
O
OH
HO
-O2C
OO
OH
O
OH
OH
-OOC
HO
NAD+
NADH
-O
H+
OH
O OH
PO
CO2-
O
OH
OH
H OH
CO2-
O
H
H PO
O
OH
OH
CO2-HO
    DAHP
O OP
OH
HO
OH
-O2C
OH
OH
CO2-HO
O
OP
1.55                                   1.55                             1.55                                         1.55
1.55                                              1.60                                  1.61
1.621.63
1.64
1.64
1.57                                          1.57
=
=
 
Scheme 1.5: Plausible mechanism between 1.55 and 1.57 proposed by Knowles.31, 33 
 
The third step transforms 3-dehydroquinate 1.57 into 3-dehydroshikimate 1.58 through a 
syn elimination of water. The suggested mechanism by Man (Scheme 1.6) starts with 
the condensation of 3-dehydroquinate 1.57 by an enzyme forming the imine 1.65.  
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Scheme 1.6: Suggested mechanism for the syn elimination of water by Mann.31, 34 
 
A base-mediated deprotonation of the proton alpha to the imine, is followed by a 
rearrangement to form 1.66, followed by the elimination of a hydroxide to form 1.67. 
Finally the enzyme is hydrolysed and 3-dehydroshikimate 1.58 is obtained (Scheme 
1.6). The final step is the reduction of the ketone of 3-dehydroshikimate into the alcohol 
yielding shikimic acid in its carboxylate form 1.59 (Scheme 1.4). 
 
3.1.2 Route from shikimic acid to the determination of the true starter unit 
 
The shikimic acid pathway has been well defined. Shikimic acid can undergo various 
biosynthetic conversions into aromatic amino acids and secondary metabolites. 
Previously Floss and coworkers35 had investigated the biosynthesis of the 
cyclohexanecarboxylic acid starter unit of ω-cyclohexyl fatty acids in Alicyclobacillus 
acidocaldarius which is also derived from shikimic acid. The first step of the starter unit 
from shikimic acid toward cyclohexanecarboxylic acid was identified as the first step 
toward rapamycin’s starter unit.36 After isotopic incorporating experiments Reynolds 
and coworkers identified the rest of the pathway leading to the starter unit of rapamycin 
and FK506.37 This was confirmed by further isotopic incorporation experiments led by 
Leadlay, Staunton and coworkers the stereochemistry of the mechanism was defined 
(Scheme 1.7).9, 36 
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Scheme 1.7: Biosynthetic pathway to DHCHC 11 in FK520 and rapamycin.36 
 
The first step a is the 1,4 anti- conjugate elimination of water from shikimic acid 1.68 to 
yield 3,4-dihydroxy-cyclohexa-1,5-dienecarboxylic acid 1.69, this is followed by the 
syn reduction of the double bond and a suprafacial 1,3-allylic rearrangement to yield 
4,5-dihydroxy-cyclohex-1-enecarboxylic acid 1.70. Finally an anti reduction of the 
conjugated double bond was established to yield (1R, 3R, 4R)-3,4-
dihydroxycyclohexanecarboxylic acid 1.71 (Scheme 1.7).  
Leadlay, Staunton and coworkers defined the stereochemistry of the mechanism 
involved in step a (Scheme 1.7) by feeding stereospecifically deuterated shikimic acid 
1.72 and 1.73 (Figure 1.12). No deuterated rapamycin was produced by feeding 1.72, 
but deuterated rapamycin was obtained when 1.73 was fed, proving that the pro R 
proton eliminates in anti. 
In order to determine which of these molecules was the original starter unit, feeding 
experiments of deuterated labelled compounds were also carried by Leadlay, Staunton 
and coworkers9 on 1.68, 1.69, 1.70 and 1.71 (Scheme 1.7) deuterated analogues 
respectively named 1.73, 1.74, 1.75 and 1.76 (Figure 1.12). They were synthesised and 
fed separately to S. hygroscopicus.36, 38, 39 The specific incorporation of 1.73 was 
measured at 25%, 1.74 79%, 1.75 87%, and 1.76 52%. 1.75 was the most incorporated 
and 1.70 could be the true starter unit. 
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Figure 1.12: Deuterated molecules incorporated and competition experiments in 
Streptomyces hygroscopicus. 
 
From the previous results and the structure of rapamycin only 1.70 or 1.71 can be the true 
starter unit for the rapamycin polyketide synthesis. In order confirm that 1.70 is the starter 
unit, 1.70 and 1.71 were incorporated in competition, in cross experiments between 1.75 
and 1.71, and 1.76 and 1.70 for different concentrations (Figure 1.12). Experiments tend 
to show that 1.70 has higher incorporation levels than 1.71 for identical conditions and 
that 1.70, even at small concentrations compared to 1.76, strongly inhibits the 
incorporation of 1.76. The incorporation of 1.75 was not inhibited by the presence of a 
four times more concentrated solution of 1.71. 4, 5-Dihydroxy-cyclohex-1-enecarboxylic 
acid 1.70 is the true starter unit. The observation that 1.68, 1.69, 1.70 and 1.71 can be 
directly incorporated using wild type S. hygroscopicus seems to indicate a broad substrate 
specificity that would allow the production of rapamycin analogues by feeding different 
starter units.      
 
3.2 The Polyketide Biosynthesis  
3.2.1 Common elements between fatty acid biosynthesis and PKS Type 1, 
2, 3 
 
Fatty acid biosynthesis and polyketide biosynthesis have strong homologies,40 they are 
both used by nature for chain extension, and have a common group of precursors and 
catalytical domains that are used for chain assembly.  
All fatty acid synthases have the same set of catalytic domains: the ketosynthase (KS), 
acyl carrier protein (ACP), ketoreductase (KR), dehydratase (DH), enoyl reductase (ER), 
thioesterase (TE) and a malonyl-acetyl transferase (MAT).40 MAT is the only domain that 
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is not common to polyketide synthase (PKS). Instead PKS has an acyl transferase (AT) in 
order to transfer various acyl units usually from one module to another. It also has CoA 
ligase (CoL) in order to load the starter unit. Contrary to fatty acid synthase not all those 
modules are involved in all PKS, and are not always on the same protein. PKS have been 
classified into three groups PKS I, II and III.  
PKS I are single large multifunctional enzymes organised into modules and are ACP 
dependant. Each module is responsible for chain elongation. PKS I has been subdivided 
in modular PKS I and iterative PKS I. In modular PKS I all the modules are used 
successively only once. The number of chain extensions is equal to the number of 
modules making the biosynthesis potentially predictable. Iterative PKS I only has one 
module repetitively used, but the chain extension unit can vary and not all the domains are 
reused for each chain extension making it difficult to predict. PKS II are multienzyme 
complexes, each enzyme only corresponding to one domain used repetitively or not. PKS 
II are also ACP-dependent. PKS III are single multifunctional enzymes with multiple 
modules, repetitively used but does not use ACP in its cycle. 
Modular PKS I due to their non iterative mechanism build more complex structures, than 
the other iterative PKS. Rapamycin results from modular PKS I. 
 
3.2.2 Rapamycin’s PKS  
 
The extension cycles of rapamycin are similar to fatty acid synthesis. The first module of 
the rapamycin PKS once the starter unit is loaded is very similar to the fatty acid first 
extension cycle.  
Fatty acids are built from C2 units by repeated head to tail linkage, until a chain of 
required length is assembled.40 A starter acyl on a KS domain 1.77 is condensed with a 
malonyl unit on an ACP 1.78 in a similar fashion to a Claisen condensation (Scheme 1.8). 
The ACP-malonyl 1.78 goes through a decarboxylation and condenses on the carbonyl of 
KS-acyl 1.77, resulting in the transfer of the acyl group from KS to the ACP chain 1.79 
(Scheme 1.8). The resulting beta ketoester of 1.79 is then reduced to the hydroxyl group 
of 1.80 through a keto reductase domain (KR), using NADPH as a cofactor. Catalysed by 
a DH domain the new hydroxyl group dehydrates and 1.81 is obtained. Finally the double 
bond of 1.81, resulting from the dehydration, is reduced by an ER using NADPH as a 
cofactor. The resulting chain of 1.82 is then 2 carbons longer than the original 1.77 
(scheme 1.8). 
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Scheme 1.8: Similarities between first extension cycle of the fatty synthase and the first 
cycle of chain extension catalysed by module 1 of rapamycin's polyketide synthesis. 
 
The differences between the first extension cycle of both fatty acid synthesis and 
polyketide synthesis of rapamycin are the starter units and the extension units (Scheme 
1.8). The starter unit of rapamycin being the dihydroxycyclohexyl moiety and the 
extender unit identified as methyl malonate (Scheme 1.8).  
Isotopic labelled acetate and propionate units were fed to S. hygroscopicus by Demain 
and co-workers.41 The experiment identified that during the PKS assembly rapamycin 
incorporates seven acetate and seven propionate units in its structure (Figure 1.13).40, 41 
The 7 Propionate (P) and 7 acetate (A) units are incorporated in this sequence (A): P-A-P-
P-A-P-P-A-A-P- A-A-P-A.  
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Figure 1.13: Acetate and propionate units incorporated in rapamycin’s structure. 
 
Propionate and acetate units are first carboxylated to form the more reactive malonyl 
and methyl malonyl CoA derivatives. 
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In order to achieve the carboxylation of acetate and propionate, both first associate to 
coenzyme A (CoA) in an ATP dependant reaction (Scheme 1.9).42 
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Scheme 1.9: Reaction between the carboxylic acid and CoA. 
 
Once associated with CoA the starter units can be carboxylated through a carboxylase 
enzyme (acetyl-CoA carboxylase or propionyl-CoA carboxylase). Those enzymes are 
biotin-dependant, and have two catalytic activities: -biotin carboxylase and 
carboxyltransferase. The first uses a carbonate to produce CO2 and biotin in order to trap 
it as a carbamate. A pyruvate group from ATP is also involved in the mechanism 
(Scheme 1.10). 
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Scheme 1.10: Biotin carboxylase trapping CO2 from carbonate.42  
 
The second catalytic role is as a carboxyltransferase. The carboxylated biotin releases 
CO2 and acts as a base with the acyl-CoA allowing it to condense on the CO2 
transforming acetyl-CoA into malonyl-CoA and propionyl-CoA into methylmalonyl-CoA 
(Scheme 1.11). These substrates undergo decarboxylative condensation mediated by the 
PKS. 
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Scheme 1.11: Carboxyltransferase releasing CO2 and carboxylating the acetylCoA 
 
The organization of the biosynthetic gene cluster for rapamycin in Streptomyces 
hygroscopicus was determined by Leadlay, Staunton and coworkers.43 The different 
domains identified in the rapamycin PKS are CoA ligase (CoL), enoyl reductase (ER), 
acyl carrier protein (ACP), ketosynthase (KS), ketoreductase (KR), dehydratase (DH), 
and acyltransferase (AT). No thioesterase (TE) is involved. In total fourteen modules 
were identified. Each module contains three domains required to catalyse one cycle of 
chain extension KS, AT, ACP, as well as a variable set of the other 4 domains.  
The structural genes responsible for rapamycin polyketide synthase are a cluster formed 
by three very large open reading frames encoding the multi enzymes RAPS 1 (900 kDa, 4 
modules), RAPS 2 (1.07 MDa, 6 modules) and RAPS 3 (660 kDa, 4 modules). In total the 
three proteins contain 70 catalytic functions, making this one of the most complex 
multienzyme systems identified in nature (Figure 1.14).40  
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Figure 1.14: Domain organisation of PKS by Wiseman and Staunton.40 
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The domain in grey in Figure 1.14, DH, ER, KR in module 3, and DH and KR in module 
6 all appear to be active but do not intervene in the polyketide chain synthesis. Staunton 
suggested a possibility that these sites are involved in a later oxidation of the molecule 
after the macrocycle has formed.40 Before the first extension, rapA encodes for 3 domains 
CoL (CoA-ligase), ER and ACP. These load the starter unit and probably reduce the 
double bond of the starter unit.44 As it has been previously established by Leadlay, 
Staunton and coworkers36 the true starter unit still had a double bond. At the end of 
module 14 the pipecolic ring is still not featured in the structure. 
 
3.3 The Pipecolic Ring 
Leadlay and coworkers10 produced a modified S. hygroscopicus strain suppressing a gene 
named rapL L-lysine Cyclodeaminase, believed to be responsible for the formation of the 
pipecolic ring in rapamycin. The production levels of rapamycin were very low, but once 
exogenous pipecolic acid was fed the production levels went back to wild type levels. 
This experiment demonstrates that pipecolic acid is the precursor of the pipecolic ring in 
rapamycin, and that rapL is responsible for the synthesis of pipecolic acid.10  
Paiva and coworkers fed exclusively isotopically labelled L-14C-lysine and D,L-3H-
pipecolate in separate experiments to S. hygroscopicus cultivated in medium deprived of 
natural lysine.45 They observed the production of isotopically labelled rapamycin in both 
cases, proving that pipecolic acid is the origin of the pipecolic ring in rapamycin and that 
lysine is the precursor of pipecolic acid in the rapamycin biosynthesis.   
Walsh and coworkers later expressed rapL coding for L-lysine Cyclodeaminase in E. coli. 
Walsh observed lower levels of NAD+ in the overexpressed rapL compared to the normal 
levels in rapamycin biosynthesis.46 In order to understand the mechanism of the formation 
of pipecolic acid from lysine Walsh fed different types of isotopically 15N and 2H labeled 
lysines, with extra NAD+ to L-lysine Cyclodeaminase in separate experiments. Labeled 
lysines 1.83, 1.84 and 1.85 were fed and the corresponding pipecolic acids 1.86, 1.87 and 
1.88 were obtained (Scheme 1.12). 
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Scheme 1.12: Feeding experiments by Walsh and coworkers.46 
 
The results indicated that the nitrogen present on the ring of pipecolic acid originates from 
the amine on the ε-carbon of L-lysine. The stereochemistry on the α-carbon was retained. 
Walsh proposed the mechanism below (Scheme 1.13).46 
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Scheme 1.13: Mechanism proposed by Walsh merging the results of the labelled 
incorporation experiments.46, 47 
 
The amine performs a nucleophilic attack on the carbon α to the carboxylic acid assisted 
by the oxidation by NAD+ resulting in cyclisation. The amine group eliminates as 
ammonia assisted by the ring nitrogen. The double bond is finally reduced by NADH 
restoring the hydrogen and the S configuration on the carbon α to the carboxylic acid 
(Scheme 1.12 and 1.13).  
 
3.4 The Assembling of the Macrocycle and the End of the 
Biosynthesis of Rapamycin.  
Within the polyketide synthase genes is a gene called rapP, this has sequence similarities 
with non ribosomal polypeptide biosynthesis.40, 48 It codes for a protein called pipecolate-
incorporating enzyme (PIE). PIE is believed to catalyse the formation of ester and amide 
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bonds to pipecolic acid. The pipecolic acid first associates with PIE through a thioester 
bond. The amine group on the pipecolic ring of 1.83 attacks the carbonyl of the thioester 
linking the polyketide structure to PKS module 14 1.84 releasing module 14 and linking 
the polyketide structure to the pipecolic thioester linked to PIE obtaining 1.85. Next the 
terminal hydroxy group attacks the thioester to form the macrolide 1.86, releasing it from 
PIE (Scheme 1.14).40 
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Scheme 1.14: Formation of macrocyclic structure of rapamycin.40 
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In the macrolactone 1.86 the hydroxyl on carbon 14 attacks the ketone on carbon 10 
forming a 6 membered lactone.  
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Scheme 1.15: Final steps of the biosynthesis of rapamycin. 
 
This molecule 1.87 is called prerapamycin and was first isolated by Leadlay and 
coworkers (Scheme 1.15).49 They first produced a modified strain of S. hygroscopicus 
named MG-210 with the region rapIJKLMNOQ of the rapamycin cluster, which encode 
the processing genes, removed using a double recombination strategy. 
At first no rapamycin related compound was produced. S. hygroscopicus MG2–10 was 
then independently complemented with full-length copies of each of the genes which had 
been removed using integrative expression plasmids.49 The only productive strain was 
found when rapK was reintroduced leading to the production of prerapamycin. The strain 
was named S. hygroscopicus NRRL5491.  
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Figure 1.15: 16-O-desmethyl-27-desmethoxyrapamycin, prerapamycin and rapamycin. 
 
Sheridan and coworkers discovered that S. hygroscopicus MG-210 produced 
prerapamycin if the exogenous starter unit 1.71 was fed (Scheme 1.16). Sheridan deduced 
that rapK was responsible for the biosynthesis of the shikimic acid derivative starter unit. 
Previously Reeves and coworkers50 produced 16-O-desmethyl-27-desmethoxyrapamycin 
1.88 using a strain of S. hygroscopicus with rapQONML genes knocked out, feeding 
pipecolic acid because of the lack of rapL (Figure 1.15). They identified that rapJ and 
rapN coded for two cytochrome P450 monooxygenases responsible for oxidation of C27 
and C9. RapI, rapM and rapQ code for three O-methyl transferases, probably responsible 
for the methylation of the hydroxyl groups on C39, C27 and C16.  
Sheridan and coworkers later assigned each gene51using MG-210, first complementing it 
with rapK and rapL allowing the production of prerapamycin, and then introducing 
separately rap I, J, M, [N, O], Q and analysing individually their production by 3 D NMR 
and MS. RapN and rapO were always associated as rapO and rapN are translationally 
fused. RapO codes for a ferridoxin that supports electron transfer to the cytochrome 
encoded by rapN.51 
The genes were also sometimes reintroduced two by two in order to confirm the results. 
Twenty four analogues were obtained in this manner and structurally elucidated by MS 
and NMR. In order to verify the results the genes were separately expressed in S. lividans 
TK24 feeding the appropriate previous analogues were fed in order to confirm their 
function. Sheridan proposed that rapI first O-methylates the hydroxyl on C39. Next rapJ 
introduces the keto group on C9. RapM O-methylates the hydroxyl on C16. RapN 
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hydroxylates C27 in collaboration with rapO. Finally rapQ O-methylates the hydroxyl on 
C27, forming rapamycin. 
 
Sheridan and coworkers (Biotica Technology Ltd) also found that different types of 
substrates were incorporated by MG-210. Substrates 1.71, 1.89, 1.90, 1.91, 1.92 and 1.93 
were then fed and different prerapamycin analogues were obtained, showing high 
substrate flexibly compared to the wild type (Scheme 1.16). Sheridan also observed that 
some of the starter units 1.89, 1.90, 1.92 and 1.93 had been hydroxylated during the 
process (Scheme 1.16). 
 
COOHHO
HO
COOH
COOH
CO2H
O
COOH
O
O
N
O
O
O
OH
OOH
HO
Starter units cyclohexyl moiety R of prerapamycin analogue
HO
HO
R
HO
HO
O
COOH
HO
hydroxylated
from the mass spectrometer
structure not fully elucidated
low levels of incorporation
low levels of incorporation
1.71
1.89
1.90
1.91
1.92
1.93
 
Scheme 1.16: Alternative starter units that were successfully fed by Biotica Technology 
Ltd.44 
 
No hydroxylation was obtained for tetrahydro-2H-pyran-4-carboxylic acid 1.91. 
Previously the norbornane moiety 1.93 had not been incorporated by S. hygroscopicus 
wild type. The removal of competition allows greater substrate flexibility. S. 
hygroscopicus MG-210 can potentially produce a whole new range of rapamycin 
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analogues by feeding new starter units and also by reintroducing some genes, both 
techniques can be combined.  
 
In order to have a better understanding about the hydroxylation process and the 
importance of the hydroxyl group for incorporation, starter units with hydroxyl groups in 
different positions were fed to S. hygroscopicus. 4-Hydroxycyclohexanecarboxylic acid 
1.94, 3-hydroxycyclohexanecarboxylic acid 1.95, 2-hydroxycyclohexanecarboxylic acid 
1.96, 3-hydroxycyclohex-1-enecarboxylic acid 1.97 was fed to S. hygroscopicus MG-
210 (Scheme 1.17).52  
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Scheme 1.17: Hydroxylated starter units fed to S. hygroscopicus MG-210 and produced 
prerapamycins.52 
 
4 AIMS OF THE PROJECT  
 
The cleavage of the cyclohexyl moiety of rapamycin by Sedrani and workers 
corresponded with a slight loss in binding with FKBP12 combined to a huge loss of 
activity in the inhibition of FRAP, and therefore a loss in its immunosuppressive 
activity.30 This suggests that the cyclohexyl moiety of rapamycin is part of the effector 
domain. The crystal structure of the ternary complex by Choi and coworkers indicate that 
a crucial hydrogen bond is established between Gln53 of FKBP12 and the hydroxyl 
group on C40. This hydrogen bond is believed to be crucial to rapamycin’s 
immunosuppressive activity. A fluorine carbon bond (1.39 Aο) is isosteric to a hydroxyl 
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group (1.43 Aο), but fluorine is only a hydrogen bond acceptor compared to a hydroxyl 
group that is also a donor. By replacing the hydroxyl group by fluorine this could provide 
clues as to the origin of rapamycin’s immunosuppressive activity. The presence of 
fluorine could also possibly enhance rapamycin’s activity.  
Around 20 to 25% of pharmaceutical drugs contain fluorine in their structure, the most 
famous being Prozac.53 Although fluorine is the most abundant of halogens on earth only 
thirteen fluorinated natural products have been isolated out of more than 3000 isolated 
halogenated natural products54 and only one enzyme with the capacity to fluorinate has 
been isolated: a fluorinase from Streptomyces cattleya.55 Out of those thirteen fluorinated 
compounds 8 are ω-fluorinated homologues of long chain fatty acid derivatives found as 
co-metabolites in the seeds of the same plant.54 Only six original fluorinated natural 
compounds have been isolated without the eight homologues (Figure 1.16).54  
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Figure 1.16: Main fluorinated natural products. 
 
The hydroxyl group of rapamycin on carbon 40 could be substituted with a fluorine, but 
the fluorine can also be placed in other positions around the ring creating a range of 
fluorinated rapamycins that could be tested for activity and could result in a better 
understanding of its mechanism. 
There are potentially four routes available through which to access fluorinated 
analogues of rapamycin. The first one is to fluorinate rapamycin chemically. Rapamycin 
is fairly acid and base labile and attempts toward direct fluorination have been reported 
as unsuccessful. The second solution is total synthesis. Five total syntheses of 
rapamycin have been published so far: Nicolaou’s,56 Schreiber’s,57 Danyshefsky’s,58 
Smith’s59 and more recently Ley’s.60 Nicolaou was the first to successfully synthesise 
rapamycin. His retrosynthetic analysis of rapamycin consists of assembling five main 
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blocks (Scheme 1.18). Block A and B were first assembled then E, then D and finally C 
(Scheme 1.18). 
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Scheme 1.18: Nicolaou’s Retrosynthetic analysis of rapamycin and the final steps of his 
synthesis.61 
 
The last 2 steps of Nicolaou’s synthesis (Scheme 1.18) include first a deprotection step 
followed by a Stille reaction integrating block C ring closing the molecule obtaining 
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rapamycin. Nicolaou’s synthesis is over 40 steps long. Steven Ley’s synthesis is the 
most recent total synthesis of rapamycin to have been completed and is less linear 
(Scheme 19). Ley’s reported retrosynthesis bellow contains 7 fragments. Fragment B 
and C were first assembled, then A was added, then G, then D, then E and finally F at 
the same time as a catechol moiety is introduced. 
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Scheme 19: Ley’s retrosynthesis of rapamycin and final steps of his synthesis.60 
 
In the final steps of Ley’s synthesis the introduced catechol group is used to achieve a 
remarkable and original ring-closure. The catechol once introduced, formed a 
macrocycle through both his alcohol groups linking respectively carbon 9 and 10 
(Scheme 19). Then using a base C9 is deprotonated and attacks C10 ring closing the 
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main frame of the rapamycin macrocycle expelling the catechol out of the macrocycle. 
Although very interesting synthetic methodology has been developed, the syntheses are 
very complex and fairly long: both Ley’s and Nicolaou’s total synthesis are over 40 
steps long and would have to be modified in order to introduce fluorine. The third 
method would be to introduce fluorinase enzymes into the biosynthesis of rapamycin 
specifically to introduce fluorine in the wanted position, but this challenge is not 
realistic. Only one fluorinase enzyme is available and has a narrow substrate specificity 
for S-adenosyl methionine and its close analogues.54 The final method, the one used in 
this project, is mutasynthesis. This is the feeding of a range of fluorinated starter units to 
a modified Streptomyces hygroscopicus lacking the rapK gene responsible for the 
production of the shikimic acid derivative starter unit. The fluorinated starter units will 
then not be in competition with the natural starter units and can have a better 
incorporation. The incorporation rates of the starter units will give us some indications 
on the rules of incorporation of S. hygroscopicus. The Goss group had previously 
produced a fluorinated analogue of erythromycin using precursor directed biosynthesis 
feeding potassium 4-fluorobutyrate to a modified Saccharopolyspora erythraea 
ERMD1 strain (Scheme 1.20).62 
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Scheme 1.20: Production of fluorinated erythromycin by Goss and coworkers using 
precursor directed biosynthesis. 
 
A range of alternative fluorinated starter units analogous to the previous incorporated 6 
membered rings will be synthesised and fed to S. hygroscopicus MG-210. 
The first series of starter units targeted will be mono fluorinated cyclohexanoic acids or 
esters and possibly difluorinated cyclohexanoic acids or esters. Fluoro cyclohexenoic 
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acid or esters could also be fed. Finally fluorohydrin cyclohexanoic acids or esters will 
be targeted by synthesis and fed to S. hygroscopicus MG-210 in order to produce for the 
first time a range of fluorinated prerapamycins (Figure 1.17).  
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Figure 1.17: Fluorinated compounds targeted for feeding to Streptomyces hygroscopicus and 
rapamycin fluorinated analogues 
 
In the fluorohydrins, in particular, the stereochemistry of the starter units could be 
modified to create a bigger range of fluorinated prerapamycins and to understand the 
stereochemical criteria necessary for incorporation.  
Once prerapamycins have been produced, Biotica Technology Ltd can then produce 
fluorinated rapamycin using the same starter unit and a modified S. hygroscopicus lacking 
only the gene rapK. The fluorinated rapamycin analogues’s binding can then be tested 
with FKPB12 and FRAP in order to have a better understanding of the mechanism of 
action of rapamycin and possibly to produce a fluorinated rapamycin with enhanced 
activity.   
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All compounds were synthesised as racemic mixtures (accept for the molecules with a 
plane of symmetry). 
 
1 SYNTHESIS TOWARD MONOFLUORINATED AND 
DIFLUORINATED CYCLOHEXANECARBOXYLIC ACIDS 
AND 3-FLUOROCYCLOHEXENECARBOXYLIC ACID.  
 
Previous feeding experiments carried out by Biotica Technology Ltd52 demonstrated that 
4-hydroxycyclohexanecarboxylic acid 1.94, 3-hydroxycyclohexanecarboxylic acid 1.95 
and 3-hydroxycyclohex-1-enecarboxylic acid 1.97 had been incorporated by S. 
hygroscopicus MG-210, and produced prerapamycin analogues.52 The hydroxyl group 
will be substituted by fluorine. Monofluorinated and difluorinated analogues will be 
targeted (Figure 2.1).   
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COOH
Incorporated hydroxylated 
molecules
Fluorinated targeted
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instead of a hydroxyl group
COOH COOH
OH
Difluorinated targeted
analogues
OH
1.94             1.95            1.97
2.1               2.2                2.3
2.4                2.5
OH
 
Figure 2.1: Previously incorporated starter units and targeted fluorinated analogues. 
 
4-Fluorocyclohexanecarboxylic acid 2.1, 3-fluorocyclohexanecarboxylic acid 2.2, 3-
fluorocyclohexenecarboxylic acid 2.3, 4,4-difluorocyclohexanecarboxylic acid 2.4 and 
3, 3-difluorocyclohexanecarboxylic acid 2.5 were first targeted.  
 
 
 
 
 58
Previously the Goss group, in order to produce all 3 monofluorinated 
cyclohexanecarboxylic acids had tried to reduce the double bonds of the equivalent 
fluorinated aromatics,52, 63 using hydrogenation at high pressure, using a range of metal 
catalysts, but it resulted in an inseparable mixture with over 90% of product with a 
cleaved fluorine group. 
A literature synthesis of 4-fluorocyclohexanecarboxylic acid 2.1 already existed prior to 
the start of the project.64 The fluorinating step was clearly the limiting factor of the 
synthesis. The displacement of the hydroxyl group by fluorine using diethyl amino 
sulphur trifluoride (DAST) only resulted in a 6.7% yield (Scheme 2.1).64  
O O
OH
O O
F
  DAST, RT, 2h
methylene chloride
R: 6.7%
 
Scheme 2.1: Previous fluorination step by LANG and coworkers leading to the 
synthesis of 4-fluorocyclohexanecarboxylic acid 2.1.64 
 
DAST is usually one of the most efficient reagents in order to substitute a hydroxyl 
group with fluorine. DAST’s sulphur is very electrophilic because of the three fluorines 
bonded to it and will readily be attacked by nucleophiles such as alcohols or even 
ketones that are not good nucleophiles. The reaction has to be carried out at a higher 
temperature in order to fluorinate ketones. Once attacked by the alcohol, DAST will 
release a fluorine anion (Scheme 2.2). Ketones are usually difluorinated; DAST releases 
two fluorine anions in that case (Scheme 2.2). 
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Scheme 2.2: Fluorination mechanism of alcohols and ketones with DAST. 
 
Once the fluorine is released it can then substitute the hydroxyl group through an SN2 
type of substitution, inverting the configuration of the molecule in case the alcohol is on 
a stereocenter. DAST due to its high reactivity has the disadvantage of being unstable to 
heat and explosive in contact with water.  
This poor yield of 6.7% during the fluorination with highly reactive DAST can be 
explained by Midleton’s hypothesis.65 The generation of fluorocyclohexanecarboxylic 
acids is not trivial; if the hydroxyl group is in an axial position the approach of the 
fluorine in an SN2 type of substitution will be difficult due to steric hindrance (Scheme 
2.3). If the hydroxyl group is in an equatorial position, then the hydroxyl group can be 
substituted by fluorine, but the fluorine anion can also act as a base leading to 
elimination of the previous hydroxyl group (Scheme 2.3). 
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Scheme 2.3: Explaination for poor yields in the fluorination of substituted 
cyclohexanols, adapted from Mange and Middleton.65 
 
We therefore set out to develop an alternative approach, to access these compounds, by 
fluorinating a flattened intermediate compound containing one or more sp2 carbons in 
its 6-membered ring, therefore limiting the steric hindrance and dehydration. The ring 
could contain a ketone or a double bond to be reduced later. A literature procedure 
towards the synthesis of 3-fluoro-cyclohex-1-enecarboxylic acid 2.3 already existed in 
the literature with a reported fluorination step with a 69% yield.66 The double bond 
could be possibly reduced and 3-fluorocyclohexanecarboxylic acid 2.2 could be 
accessed. In order to access 4-fluorocyclohexanecarboxylic acid 2.1 it was decided to 
fluorinate 4-hydroxycyclohexanone 2.8 and to try and transform the ketone into a 
carboxylic acid. The synthesis of 4-fluorocyclohexanecarboxylic acid 2.1 was first 
investigated (Scheme 2.4). 
 
1.1 Synthetic Route Toward 4-Fluorocyclohexanecarboxylic 
Acid 10 and 4,4-Difluorocyclohexanecarboxylic Acid 14. 
 
The route investigated could allow us to access the mixture of cis and trans 4-
fluorocyclohexanecarboxylic acid 2.1 and 4,4-difluorocyclohexanecarboxylic acid 2.4 
using cyclohexane-1,4-dione 2.6 as a cheap, stable, commercially available starting 
material (Scheme 2.4).  
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Diketone 2.6 would be monoreduced using sodium borohydride into 4-
hydroxycyclohexanone 2.7, then fluorinated using DAST or HF (complexed to pyridine 
or triethylamine) to give 4-fluorocyclohexanone 2.8, followed by the transformation of 
ketone 2.8 using tosyl methyl isocyanide into 4-fluorocyclohexanecarbonitrile 2.9, and 
finally hydrolysing the cyano group to give 4-fluorocyclohexanecarboxylic acid 2.1. 
In a similar fashion diketone 2.6 could be difluorinated using DAST to give 4,4-
difluorocyclohexanone 2.10, then transformed using tosyl methyl isocyanide into 4,4-
difluorocyclohexanecarbonitrile 2.11 and finally hydrolysed into 4,4-
difluorocyclohexanecarboxylic acid 2.4.  
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Scheme 2.4: Second potential synthetic route toward 4-fluorocyclohexanecarboxylic 
acid 2.1 and 4,4-difluorocyclohexanecarboxylic acid 2.4 
 
1.1.1 The reduction step (literature procedure).67 
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Scheme 2.5: Reduction of the diketone 2.6 using NaBH4 
 
Only one literature procedure was available in order to reduce cyclohexane-1,4-dione 
2.6 in 4-hydroxycyclohexanone 2.7.67 The reported procedure was vague and claimed a 
60% yield. When the procedure was repeated it only resulted in a 24% yield.  
This is a non-selective reduction and results in a mixture of starting material 2.6, 
monoreduced compound 2.7, and the di-reduced diol 2.12 (Scheme 2.5). The formation 
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of all 3 compounds was easily followed by TLC (in a 100% ethyl acetate Rf2.12: 0.15, 
Rf2.7: 0.26 Rf2.6: 0.50). In order to optimise the yield toward the mono reduced 
compound this reaction was carried out a number of times varying the number of 
equivalents of NaBH4, the reaction temperature, the time taken for the addition of 
NaBH4, and the reaction time (Table 2.1).67 
 
Exp. 
n° 
 N° of 
equivalents 
of NaBH4 
T (°C) 
RANGE 
Time 
(h) 
Addition 
time of 
NaBH4 
Isolated yield (%) 
1 1/4 -16 2.5 1s 3 
2 1/4 -16 to 25 10 + 10 1s 17a 
3        1/4 -16 to 25 10 + 10 1s 11a 
4 1/4 -10 2.5 5 min. 24 
5        1/3 -10 2.5 5 min.  36 
6 4/10 -10 2.5 5 min. 27 
7 1/3 -10 2 5 min. 21 
8 1/3 -10 3 5 min. 32 
     a
 impurities observed by 1H NMR 
Table 2.1: Summary of the main reduction attempts on diketone 2.6 with NaBH4 
 
The key factor seems to be the temperature control. At -16°C hardly any reduction 
occurs. When the temperature of the reaction is allowed to rise to room temperature, a 
high production of diol 2.12 is observed and some new impurities with similar Rf to the 
monodiol 2.7 appear. The yield is optimal at around -10°C. NaBH4 must be added very 
slowly in order to control the reaction temperature, if added too fast the temperature 
goes up and the selectivity of the reaction drops, and more diol 2.12 is produced. The 
reaction was optimised using 1/3 of an equivalent of NaBH4 (addition of more NaBH4 
resulted in higher amounts of diol 2.12) and a reaction time of 2.5 hours. The optimised 
yield in our hands was 36%. 
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1.1.2 The monofluorination step.68, 69 
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Scheme 2.6: Fluorination of the alcohol 2.7 using DAST 
 
A range of three fluorinating agents were tested in order to fluorinate 2.7: HF 
pyridine,70 HF triethyl amine71 and diethyl amino sulphur trifluoride (DAST).69 Only 
DAST resulted in fluorination of 2.7, due to its high reactivity, but elimination product 
was still detected (Scheme 2.6 and 2.7).68, 69  
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Scheme 2.7: Fluorination and Elimination mechanism.65  
 
In order to optimise the yield toward the mono fluorinated compound the reaction was 
carried out a number of times varying the concentration of DAST, the concentration of 
starting material and the reaction time (Table 2.2).    
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Experiment 
number 
[2.7]  
(mmolL-1) 
[DAST] 
(mmolL-1) 
Reaction 
time at 0°C 
 (min.) 
Isolated yield 
(%) 
1 187 7572 (neat)  30  1 
2 21.9 132  60  18 
3 19.7  132  60  21 
4 21.4 86.2  60  20 
Table 2.2: Summary of the most representative fluorination attempts on compound 2.7 
using DAST. 
 
In experiment 1, neat DAST was added to a relatively concentrated solution of starting 
material in DCM and was stirred at 0°C until completion for 30 minutes. After workup, 
this gave a mixture of the fluorinated compound (minor), elimination product (major) 
and various other impurities. After purification only 1% of compound was isolated. In 
experiment 2, 3 and 4 the reaction went to completion and the desired product was the 
major one. In these experiments much less elimination compound was observed on 
TLC. In all 4 experiments the product was purified by flash chromatography on silica 
gel using a 90:10 Petrol/ Ethyl acetate mixture. An improvement in yield was obtained 
by dilution of the DAST;69 this is the key factor in reducing levels of unwanted side 
products. Dilution of DAST prior to addition allows the reaction temperature to rise 
gently, maintaining the selectivity of the fluorination and reducing the elimination. A 
yield of 21% for the fluorination step was an improvement on the previously reported 
6.7% yield for fluorination,64 probably linked to the fact that 4-
hydroxycyclohexanedione 2.7 is slightly less sterically hindered than a cyclohexane 
ring, due to the flattening of the ring by the presence of the sp2 carbon of the ketone. 
The hydrogens on the carbons adjacent to the ketone are pseudo equatorial and pseudo 
axial this allows a slightly less hindered approach for the fluorine.  
In order to access the final compound the ketone would have to be transformed into an 
acid. This could be achieved over two steps. Biotica Technology Ltd had attempted 
Wittig reactions on similar systems previously but with little success. Nevertheless the 
Wittig reaction was attempted for this particular molecule adding 
(methoxymethyl)triphenylphosphonium chloride and sodium bis(trimethylsilyl)amide in 
THF at 0ºC to the compound, but no reaction was observed (Scheme 2.8).72 The next 
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method investigated was a Knoevenagel type reaction transforming the ketone 2.8 into 
the nitrile 2.9. 
O
F F
CH3OCH2(PPh3)Cl
[(CH3)3Si]2NNa
THF 0ºC
MeO
2.8                                                   2.13
 
Scheme 2.8: Failed Wittig reaction    
 
1.1.3 Knoevenagel type reaction converting the ketone group into a nitrile 
of the monofluorinated compound.73 
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Scheme 2.9: Knoevenagel type reaction73 
Experiment 
number 
Crude 
Yield (%) 
Purification 
method 
Degradation 
during 
purification 
Isolated yield 
after 
purification 
(%) 
1 87 Silica 
Column 
Yes 0 
2 90 Basified silica 
column 
Yes 9 
3 92 Filtration in 
ether 
No 88a 
  
a
 trace impurities 1H NMR 
Table 2.3: Summary of the different Knoevenagel type reactions and purification 
attempts. 
 
The reaction was successful and went to completion but the product degraded during 
purification by flash chromatography on silica (Table 2.3 Experiment 1). The 
purification by flash chromatography was next carried out on silica previously 
neutralised with a little triethylamine in the solvent mixture. This was also unsuccessful 
as most of the compound degraded (Table 2.3 Experiment 2). The TLC indicated that 
the crude mixture had one main impurity and the 1H NMR spectrum of the crude 
mixture indicated it was aromatic. By dissolving the mixture in various solvents it was 
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observed that most of the impurity could be removed dissolving the crude compound in 
cold diethyl ether in which only the desired compound was soluble. The impurity was 
removed by filtration and the organic solution was evaporated to yield the almost pure 
compound as a mixture of cis and trans compound with a 45 : 55 ratio as suggested by 
the proton ratio of the hydrogen adjacent to the carboxylic acid from the 1H NMR 
spectrum (Table 2.3 Experiment 3). Finally, the nitrile group was hydrolysed to yield 
the 4-fluorocyclohexanecarboxylic acids 2.1. 
 
1.1.4 Hydrolysis of the nitrile into the acid.74 
2.9                                                      2.1
F
CN
F
COOH
1) EtOH/H2O,OH- reflux
2) H+/ extraction
 
Scheme 2.10: Hydrolysis of the nitrile group into the carboxylic acid. 
This reaction was carried out five times in order to optimise the yield. In each case all 
the starting material was consumed. The factors examined were the quality of the 
starting material, the reaction time, the temperature, and the pH of the solution during 
extraction (Table 2.4). 
 
Table 2.4: Summary of the different hydrolysis reaction. 
 
Initially the starting material was not purified therefore the reaction was carried out on 
the crude starting material. It was believed that the impurities could be removed by 
extraction of the basic solution prior to the acidification of the solution in order to 
extract the acid. The longer the impure starting material was kept in the freezer before 
being reacted the worse the reaction yield. The starting material as an impure mixture 
Exp. 
Number 
T of oil     
bath in 
(°C) 
pH Time 
(h) 
Starting              
material in 
freezer 
Yield after 
purification 
(%) 
Pure 
mixture of 
both acids 
1 96 0.5 1.5  2 days crude 0  
2 88 1.5 2  2 days crude 35 No 
3 84 2 2.5  0 days crude 42 No 
4 85 2 3.5  9 days crude 0 No 
5 82 1.5 4  4 days pure 60 Yes 
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would start degrading in the freezer. It was also observed that no product was detected 
in experiment 1 compared to 2. The absence of product in experiment 1 could be 
explained by degradation possibly due to the higher temperature of the reaction or the 
very low pH of the solution when acidified prior to extraction. The final product using 
the crude starting material contained impurities. The product could be purified using an 
exchange resin but due to the small quantity involved and the success of a partial 
purification of the starting material the experiment was repeated on the purified mixture. 
In experiment 5, the starting material was 4 days old but had been previously purified 
by filtration (with cold ether) as previously described and the 1H NMR spectrum on the 
day of the reaction showed that the starting material had not degraded. Experiment 5 
gave a pure mixture of both targeted isomers in a 60% yield. In order to optimise the 
reaction, the starting material should be purified, the oil bath temperature should be 
controlled, and so should the pH of the solution before extraction. Compound 2.1 was 
fed as the cis and trans mixture to S. hygroscopicus by Biotica Technology Ltd.  
 
1.1.5 Difluorination of the ketone 75       
 
Cyclohexane-1,4-dione 2.11 was also used as starting material in the first step of the 
synthesis toward 4,4-difluorocyclohexanecarboxylic acid 2.4. DAST as previously seen 
in Scheme 2.2 can also difluorinate ketones68 and was chosen as fluorinating agent in 
this synthesis. In the literature cyclohexanone had been difluorinated in that manner in 
DCM at room temperature by Dolbier and coworkers,75 but no yield was mentioned. 
Similar conditions were used in this step. In order to optimise the reaction, the reaction 
was repeated varying the number of DAST equivalents, the reaction temperature, the 
concentration of the reactants, and the purification method (Table 2.5). 
OO
O
      DAST
CH2Cl2
FF 24h
2.6                                         2.10
 
Scheme 2.11: Difluorination of the diketone 2.6 using DAST. 
 
 
 
 
 
 68
Exp. 
N° 
[2.6] 
(molL-1) 
  N° of 
equiv.           
of 
DAST 
T. 
(°C) 
 
Presence 
of [2.10] 
after 
work up  
Separation Yield 
(%) 
 
1 0.17 1 20 Yes Silica 0 
2 0.45 0.89 20 Yes Basified Silica 10 
3 0.45 1 20 Yes Filtration 6 
4 0.11 1 45  No None 0 
Table 2.5: Summary of the different fluorination attempts. 
 
The reaction was followed by TLC and GCMS. It was first carried out at 0°C and 10°C 
but no product formed. It was left to reach room temperature and was stirred under 
anhydrous conditions for 24 hours. After 24 hours the degradation of the product would 
increase faster than its production. Fluorination would not occur at lower than room 
temperature because of the lower nucleophilic potential of the oxygen of the ketone 
compared to the previous alcohol. 
The crude product was yielded as a mixture of cyclohexane-1,4-dione 2.6 and 4,4-
difluorocyclohexanone 2.10, no tetrafluorinated compound was detected but other 
unidentified impurities were also present. At these higher temperatures DAST degrades, 
and the unstable difluorinated compound generated can also start to break down. 
During purification, the product degraded on silica. On neutralised silica (neutralised 
with triethylamine) the compound was partially purified, but some new degradation 
spots appeared on the TLC. A partial purification was achieved by dissolving the crude 
mixture in cold hexane (some impurities would not dissolve).The partially purified 
product degraded after 10 days in the freezer under N2. The purification by filtration had 
the advantage of being very fast and allowed us to react the unstable product in the next 
step. The rest of the synthesis should be carried out in a short period of time because of 
the speed of product degradation. The compound was unstable at room temperature and 
no carbon NMR spectrum was obtained (product degraded in CDCl3).      
 
1.1.6 Knoevenagel type reaction on the difluorinated compound.         
 
In order to transform the ketone into the carboxylic acid the same method as previously 
used was applied.73         
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Scheme 2.12: Transformation of the ketone 2.10 into cyano product 2.11 
 
Experiment 
number 
[28] 
mmolL-1 
Starting 
material 
purified by  
Number of 
equivalents 
Time 
(h) 
Product 
detected 
1 28 column 1.1 4.5 No 
2 52 filtration 2.5 2.5 Yes 
3 69 filtration 2.2 12 Yes 
Table 2.6: Summary of the different Knoevenagel type reactions. 
 
In experiment 2 and 3 the starting material 2.10 was reacted straight after being worked 
up and purified by filtration (Table 2.6). The reaction was followed by GCMS and 
TLC. A mixture of 4,4-difluorocyclohexanecarbonitrile 2.11, an aromatic compound, 
and other unidentified impurities were obtained (Table 2.6). Purification with column 
chromatography on silica and neutralised silica resulted in total degradation of the 
product. Some impurities were removed, as described previously, dissolving the mixture 
in cold diethyl ether and filtering out the impurities. The product was still impure, but 
most of the aromatic impurity had been removed.  
 
1.1.7 Hydolysis attempt of the nitile group in the acid of the difluorinated 
compound. 
CN COOH
FF FF
NaOH/H2O, EtOH
2.11                                                    2.4
 
Scheme 2.13: Hydrolysis of the cyano group. 
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The impure compound was hydrolysed in similar conditions as previously used for the 
monofluorinated compound,74 but only traces of hydrolysed compound were detected 
by mass spectrometry. The final difluorinated acid was purchased by Biotica 
Technology Ltd (10 mg) from Matrix Scientific. No incorporation was observed in S. 
hygroscopicus MG-210. The feeding results led to abandoning the synthesis.  
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CN COOH
FF F F
36%
21%
10%
88%
i)
ii) iii) iv)
v)
vi) vii)
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i) NaBH4, MeOH, -10°C, 2,5h  ii) DAST, DCM, 0°C, 1h iii) TO SMIC, DME, t-BuOK,       
t-BuOH, 25°C, 3h iv) EtOH, NaOH/ H 2O v) DAST, DCM, 25°C, 24h vi) TOSMIC, DME, 
25°C, 3h vii) EtOH, NaOH/ H 2O
a
 impure compound  b traces detected
2.7                     2.8                     2.9                   2.1
2.6
2.10                  2.11a                   2.4b
 
Scheme 2.14: Summary of the synthesis of 4-fluorocyclohexanecarboxylic acid 2.1 and 
attempted synthesis of 4,4-difluorocyclohexanecarboxylic acid 2.4. 
 
4-Fluorocyclohexanecarboxylic acid was successfully synthesised in 4 steps (Scheme 
2.14), with an improved fluorination step compared to the previous literature procedure.  
Another method to access compound 2.1 is to synthesise 3-fluoro-cyclohex-1-
enecarboxylic acid 2.3, and to attempt a reduction of the double bond. 
 
1.2 Synthesis of 3-Fluoro-cyclohex-1-enecarboxylic Acid and 
Attempt to Reduce its Double Bond. 
1.2.1 Synthesis of 3-fluoro-cyclohex-1-enecarboxylic acid.66 
 
In order to synthesise 3-fluoro-cyclohex-1-enecarboxylic acid 2.3 all four steps of the 
synthesis were repeated from a literature procedure from Bridge, O’Hagan and 
coworkers.66 The fluorination step using DAST in DCM has a reported yield of 69% 
yield.66 Such a high yield compared to the previous fluorinations with DAST can be 
explained by the strongly flattened cyclohexene ring compared to a cyclohexane ring. 
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The cylohexene ring contains 2 sp2 carbons. There is relatively little steric hindrance for 
the fluorine to approach. 
CO2Me CO2Me
O
CO2Me
OH
CO2Me
F
CO2Me
F
COOH
F
COOH
F
49%  60% 96%
60%
CH2OH
F
CrO3
COOH
F
  2.14                        2.15                     2.16                         2.17                   2.3
2.18                       2.2
i) CrO3, Benzene, acetic acid and acetic anhydride, RT, 45 min ii) CeCl3, NaBH4, MeOH, RT, 15 min  
        
iii) DAST, DCM, 0°C, 3.5 h iv) NaOH, EtOH, RT, 3h.
      i)                           ii)                            iii) iv)
2.19 2.2
LiAlH4
 
Scheme 2.15: Synthetic route towards 3-fluorocyclohex-1-enecarboxylic and 
3-fluorocyclohex-1-anecarboxylic acid. 
 
Methyl cyclohex-1-enecarboxylate 2.14 was oxidised with CrO3 to methyl 3-
oxocyclohex-1-enecarboxylate 2.15 in a 49% yield.76 This was then reduced to methyl 
3-hydroxycyclohex-1-enecarboxylate 2.16 in a 60% yield,77 followed by fluorination 
using DAST in methyl 3-fluorocyclohex-1-enecarboxylate 2.17 with a 96% yield.66 
Finally the ester was hydrolysed to 3-fluoro-cyclohex-1-enecarboxylic acid 2.3, but the 
acid was slightly impure (purification with an exchange resin may improve this).66 The 
ester and the acid were fed by Biotica Technology Ltd to S. hygroscopicus MG-210.52 
 
1.2.2 Double bond reduction attempt. 
 
The reduction of the double bond was then attempted on the ester. The Goss group had 
previously tried hydrogenation using various catalysts Ru/C, Pd/C, Ru/Al, Ru/C, but 
these conditions led to no reduction or reduction with loss of the fluorine.  
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Hydrazine was then tested in order to reduce the double bond, forming a diimide 
intermediate.78 Traces of compound were detected by GCMS and optimisation of the 
reaction was attempted, changing various conditions: reaction time, temperature, 
solvents, number of equivalents of hydrazine, concentration of the starting material, 
adding various catalysts Cu(II) (CuSO4), acetic acid associated with sodium periodate 
(Table 2.7 ).78 
 
CO2Me
F
CO2Me
F
Hydrazine/solvent
H2O2
 2.17                                           2.18
 
Scheme 2.16: Reduction of the double bond using hydrazine78 
 
 
Exp. 
nº 
 
Time 
(h) 
 
NH2NH2 
(equiv.) 
 
[2.17] 
(mmolL-1) 
 
Solvent 
 
CuSO4 
solution 
 
 
CH3CO2H 
and  
NaIO4 
 
H2O2 
addition 
Time 
 
 
T 
(°C) 
 
Product 
detected  
by GCMS 
1 4 22 46.0 EtOH No No 5 min 0 Yes 
2 4 100 24.4 MeOH Yes Yes 5 min 25 No 
3 4 22 232 EtOH Yes No 10 s 25 No 
4 4 22 244 EtOH No No 10 s 0 No 
5 4 25 45 MeOH No No 5 min 0 No 
6 16 22 47 EtOH Yes No 1.5 h 0 Yes 
7 80 22 88 EtOH Yes No 1.5 h 0 Yes 
Table 2.7: Summary of the different reduction attempts using hydrazine 
 
In experiment 1, 6 and 7 the main product had a mass of 171, and the possible reduced 
product with a mass M+1 of 161 was detected as the minor product. Experiment 7 
according to the GCMS seems to be the most optimised. Ethanol seemed to be the best 
solvent; the addition of H2O2 should be performed slowly and at low temperature, over 
a long period of time, under nitrogen. The yields were very poor, and not enough 
product was present to observe it by 1H NMR, to confirm if it was the reduced product. 
A nucleophilic attack on the double bond was suspected by hydrazine. In order to avoid 
this problem azodicarboxylate as a source of diimide was tried next using protic and 
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aprotic solvents,78 but no reduction was observed. All these experiments were repeated 
on the acid instead of the ester but the reactivity did not change.    
Another way to reduce the double bond would be reduction of the double bond and the 
ester to the alcohol, using an excess of lithium aluminium hydride (LiAlH4) and then 
oxidation of the resulting alcohol in the acid. The reduction of the ester with LiAlH4 to 
the alcohol was carried out from -10°C to 0°C. At -10°C no reaction occurred, but 
carried out at 0°C the reaction resulted in the cleavage of the fluorine bond.  
As the reduction of the double bond failed a different synthesis was attempted to access 
3-fluorocyclohexanecarboxylic acid 2.2 using the same method to the prior synthesis of 
4-fluorocyclohexanecarboxylic acid 2.1 using as starting material cyclohexane-1,3-
dione. 
 
1.3 3-Fluorocyclohexanecarboxylic Acid Synthesis. 
3-Fluorocyclohanoic acid would be accessed using the same method as previously 
except that cyclohexane-1,3-dione was first protected before being reduced.79 Direct 
reduction using NaBH4 did not work because of the acidic protons between both 
ketones, NaBH4 acting as a base instead of a reducing agent (Figure 2.2).  
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Figure 2.2: Stabilisation of the deprotonated compound. 
O OH F F F
ii) iii) iv)
i) (CH2OH)2, p-TsOH, C6H6, relux, 3.5 h ii) NaBH4, MeOH, -10°C, 1h then HCl iii) DAST, 
DCM, 0°C, 4h iv) TOSMIC, DME,  t-BuOK, t-BuOH, 25°C, 1.5h v) EtOH, NaOH/ H 2O, 3h, 
reflux
O
O
O
O O O NC HOOC
v)
29%                      24%                15%                    32%                 52%
 2.20                   2.21                     2.22                   2.23                   2.24                  2.2
 
Scheme 2.17: Synthesis toward 3-fluorocyclohexanecarboxylic acid. 
 
Diketone 2.20 was protected with ethylene glycol to afford 1,4-dioxa-spiro[4.5]decan-7-
one 2.21 in a 29% yield.79 The ketone was then reduced using sodium borohydride and 
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the alcohol deprotected with HCl to give 3-hydroxycyclohexanone 2.22 in a 24% 
yield.67 2.22 was then fluorinated using DAST to give 3-fluorocyclohexanone 2.23 in a 
15% yield.68 The fluorination was followed by a Knoevenagel type reaction using tosyl 
methyl isocyanide to transform the ketone 2.23 in a mixture of cis and trans 3-
fluorocyclohexanecarbonitrile 2.24 in a 32% yield.73 Finally the cyano group was 
hydrolysed to a mixture of cis and trans 3-fluorocyclohexanecarboxylic acid 2.2 with a 
1 : 1 ratio in a 52% yield.74 
The fluorination step and the Knoevenagel type reaction had lower yields than observed 
for the previous procedure with the 1, 4 diketone 2.6. This is probably due to 
elimination occurring in the fluorination step and during the Knoevenagel type reaction. 
This is due to the acidic protons adjacent to the ketone and to the carbon linked to the 
hydroxyl group or the fluorine, facilitating the elimination of the the hydroxyl group or 
the fluorine (Scheme 2.18).  
 
O OR
O
H
O
F-
F
H
O-
O
R= H or SF2N(Et)2
 
Scheme 2.18: Possible elimination occurring during the synthesis 
Similar methods were used to produce 4 and 3 fluorocyclohexanecarboxylic acid. The 
same method was tested in regard to the synthesis of 2-fluorocyclohexanecarboxylic 
acid. 
1.4 Attempt to synthesise 2-fluorocyclohexanecarboxylic acid.  
In order to compare fluorination rates the synthesis of 2-hydroxycyclohexanone 2.26 
was first attempted using NaBH4 on the diketone 2.25 as previously described, but no 
reduction was observed even at room temperature. A monoprotection of 2.25 was then 
attempted as previously performed with 3-fluorocyclohexanecarboxylic acid, using 
ethylene glycol, but no protected product 2.27 was observed. The failure of both 
reactions must be due to fact that both ketones of 2.25 are conjugated and therefore non 
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reactive. The mono alcohol 2.26 was finally obtained following a literature procedure 
resulting from the oxidation of cyclohexene 2.28 using potassium permanganate and 
copper sulphate in tert-butanol in a 21% yield.80 
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Scheme 2.19: Synthesis attempted toward 2-fluorocyclohexanecarboxylic acid 2.33. 
 
The fluorination of 2-hydroxycyclohexanone 2.26 was next attempted using DAST in 
similar conditions as previously for 4- and 3-hydroxycyclohexanone, but no fluorination 
was observed. Although the sterics were more favourable to the approach of the DAST 
than for 3-hydroxycyclohexanone (15% yield for the fluorination step) and 4-
hydroxycyclohexanone (22% yield for the fluorination step; the flatter the 6 membered 
ring the better the yield of the fluorination as observed with 3-
fluorocyclohexenecarboxylic acid: 96% yield for the fluorination step), 2-
hydroxycyclohexanone didn’t react with DAST. The lack of reactivity of the alcohol as 
a nucleophile, not attacking the electrophilic sulphur of DAST must be due to the 
tautomeric equilibrium between the ketone and the hydroxyl (Figure 2.3), therefore no 
reaction is observed. HF pyridine in DCM, neat HF triethylamine were also tested but 
without any success.  
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Figure 2.3: Keto-enol tautomerism of 2-hydroxycyclohexanecarboxylic acid 2.26. 
 
2-Fluorocyclohexanone 2.30 was finally obtained following a literature procedure using 
Selectfluor® an electrophilic fluorinating agent, on cyclohexanone 2.29 in methanol, in 
a 78% yield.81 The product must not be kept for too long, as it is fairly unstable under 
nitrogen at -20ºC (degrades after 10 days). 
The Knoevenagel type reaction was attempted on the compound using the same method 
as previously,73 no product 2.31 was detected and the starting material degraded. A 
Wittig reaction was also attempted on 2.30 to obtain 2.31 but failed as previously. The 
method was not applicable in order to synthesise the 2-fluorocyclohexanecarboxylic 
acid 2.33. Different literature syntheses already exist to access the final compound 2.33. 
This compound was not considered for feeding as its equivalent hydroxyl 1.96 had not 
been incorporated. Therefore the synthesis was not pursued. 
 
2 SYNTHESIS TOWARDS FLUOROHYDRIN 
CYCLOHEXANOIC ESTERS. 
 
Fluorohydrins are structurally closer than fluoro cyclohexane acids to the original 
shikimic acid pathway starter unit containing 2 hydroxyl groups in position 3 and 4 
(Figure 2.4).  
HO
HO CO2H
HO
HO CO2H
1.70                                   1.71
 
Figure 2.4: Natural starter units 
Compound 2.35 has the same relative stereochemistry to compound 1.71. It should have 
the best chance of incorporation compared to compound 2.34 to produce fluorinated 
rapamycin (Figure 2.5).  
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Figure 2.5: New targeted starter units 
 
In order to access those compounds, the following synthesis was planned: 
  
O
O
O
I
ORO
O
ORO
OH
F
HOO ORO
OH
F
 
Scheme 2.20: Planned synthesis in order to obtain compound 2.34 and 2.35. 
 
Previous feedings of non fluorinated starter units by Biotica Technology Ltd suggested 
that incorporations were similar between the methyl and ethyl esters, and the acid of the 
same molecule (unpublished results). The fluorinated starter units will be fed as esters 
avoiding a hydrolysis step.  
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2.1 Synthesis towards 4-Hydoxy, 3-Fluorocyclohexanoic Methyl 
Ester. 
2.1.1 Synthesis towards (1R*, 3S*, 4S*)-methyl 3-fluoro-4-
hydroxycyclohexanecarboxylate. 
O
O
O
I
OO
O
OO
OH
F
HOO
iii)
83 % 96 % 40 %
13% isolated    not isolated
2.36                        2.37                       2.38                             2.39
OO
OH
F2.40 2.41
i) ii)
iv)
78 : 22
 
 i) Ag2O/ H2O, NaOH/ H2O, 1h, RT ii) NaHCO3/ H2O, I2, KI /H2O 16h, RT iii) THF, MeONa/ MeOH, 16 
h, RT iV) (HF)3 NEt3 24h, RT 
Scheme 2.21: Synthetic route toward (1R*, 3S*, 4S*)-methyl 3-fluoro-4-
hydroxycyclohexanecarboxylate. 
 
Cyclohex-3-enecarbaldehyde 2.36 was oxidised with silver oxide to cyclohex-3-
enecarboxylic acid82 2.37 (literature procedure) in a 80% yield, then reacted with 
potassium iodide and iodine
 
to give (1R*, 4R*, 5R*)-4-iodo-6-oxa-bicyclo[3.2.1]octan-
7-one 2.38 (literature procedure) in a 96% yield.83 The product was next reacted with 
sodium methoxide in methanol to form the epoxide (1R*, 3R*, 6S*)-methyl 7-oxa-
bicyclo[4.1.0]heptane-3-carboxylate 2.39 in a 40% yield.83 The epoxide was opened 
using HF triethylamine84 creating a mixture of fluorohydrins (1R*, 3S*, 4S*)-methyl 3-
fluoro-4-hydroxycyclohexanecarboxylate 2.40 and (1R*, 3R*, 4R*)-methyl 4-fluoro-3-
hydroxycyclohexanecarboxylate 2.41 in a 76% yield. After integration of the hydrogen 
adjacent to the fluorine in the 1H NMR spectrum a ratio of 78 : 22 of 2.40 : 2.41 was 
found. Both compounds had very similar Rf on TLC, a slight separation was apparent 
after multiple developments (4 times) in DCM and ethyl acetate (95 : 5). The mixture 
was purified by flash chromatography on silica eluting with DCM (100%) to start and 
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an increasing gradient of ethyl acetate(1%, 2%, 3%, 4%, 5%max). Three columns were 
necessary to isolate 2.40 in a 13% yield, most of the compound remaining trapped as a 
mixture. The 1H, 13C, COSY and accurate mass confirmed that the isolated product was 
3-fluoro-4-hydroxy-cyclohexanecarboxylic acid methyl ester 2.40. The coupling 
constants of the hydrogen adjacent to the fluorine dddd, J = 49.1, 8.3, 6.9, 3.9 suggest 
that the fluorine occupies the equatorial position, deducing from the expected relative 
stereochemistry that the hydroxyl group also occupies the equatorial position and that 
the ester group occupies the axial position. This was confirmed later with the synthesis, 
isolation and characterisation of the ethyl ester equivalent.  
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Scheme 2.22: Possible opening of the epoxide 
 
Compound 2.40, the major product, originates from the expected diaxial opening of the 
epoxide by the fluorine (see Scheme 2.22). The coupling constants of the hydrogen 
adjacent to the fluorine, in the 1H NMR spectrum (Table 2.13) suggest that the fluorine 
group occupies the equatorial position, indicating that a chair flip occurred after 
formation of the fluorohydrin. This could be explained by hydrogen bonding between 
the hydrogen of the hydroxyl group and the fluorine, stabilising those groups in 
equatorial positions and lowering the global energy of the molecule. Similar bonding 
has been observed in cyclohexane fluorohydrins in the past.84  
In the 1H NMR spectrum of the mixture, the coupling constants of the hydrogen 
adjacent to the fluorine belonging to the minor compound 2.41 (dddd, J = 50.85, 10.38, 
8.46, 5.12 Hz) suggest that the fluorine also lies in an equatorial position. Compound 
2.41 was assumed to be the all equatorial (1R*, 3R*, 4R*)-methyl 4-fluoro-3-
hydroxycyclohexanecarboxylate resulting from alternative opening of the epoxide. This 
would imply a twist boat intermediate conformation of high energy, flipping to the 
thermodynamically more stable all equatorial minor compound (Scheme 2.22). The 
structure of the minor compound 2.41 would later be confirmed in later experiments 
synthesising and isolating the ethyl ester equivalent of 2.41 2.47.  
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As both compounds were very difficult to separate alternative methods for the opening 
of the epoxides were investigated. 
In order to selectively get 2.40, and therefore avoiding a separation from 2.41, different 
fluorinating agents (HF pyridine and HF triethylamine) were tested at different 
temperatures (Table 2.8).68 
 
OO
O
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F
  2.39                      2.40                        2.41
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Scheme 2.23: Opening of the epoxide using fluorine as a nucleophile 
 
Table 2.8: Summary of the different attempts to open the epoxide selectively  
 
Using HF pyridine at -78°C and at 0°C resulted in fluorination. The ratio of kinetic 
product 2.40 was more favourable at -78°C compared to 0°C. This result was not an 
improvement on the HF triethylamine fluorinating ratio. Using HF triethylamine at 5°C 
a slightly improved ratio of 82 : 18 between 2.40 : 2.41 was obtained. As a consequence 
of the lower temperature the reaction time tripled. No reaction occurred at 0°C and 
under. No major improvement was found towards the synthesis of compound 2.40 
varying the reaction temperature and the fluorinating agent. Compound 2.41’s ratio was 
best using HF pyridine as a fluorinating agent. Compound 2.41 is still present and 
difficult to separate, but if isolated will be fed as a new precursor. Using HF pyridine as 
a fluorinating agent would divert the synthesis toward production of 2.41 if necessary 
for a large scale feeding experiments. 
 
Fluorinating 
agent 
Temperature 
 
 
Time of 
completion  
Yield as pure 
mixture of 
2.40 and 2.41 
Ratio of 
isomers 
2.40/2.41 by 
1H NMR 
HF pyridine -78°C 2.5 h 73% 75 : 25 
HF pyridine 0°C        0.5 h 36% 50 : 50 
(HF)3NEt3 20°C 20 h 76% 78 : 22 
(HF)3NEt3 5°C 72 h 73% 82 : 18  
(HF)3NEt3 -10°C to 0°C None No reaction None 
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2.1.2 Epimerisation attempt on the methyl ester. 
OO
OH
F
OO
OH
F
2.40                                2.42
 
Scheme 2.24: Epimerisation of the methyl ester 
 
The epimerisation of the methyl ester compound using sodium methoxide will maintain 
the methyl ester. More than 1 equivalent of sodium methoxide was used because the 
hydroxyl proton had a lower pKa than the targeted proton adjacent to the ester group. 
The reaction was quenched with saturated ammonium chloride solution, then pH 7 
phosphate buffer. No epimerisation was observed by TLC and NMR for either 
temperature (Table 2.9). 
 
Reaction 
number 
NaOMe 
equivalents 
Temperature 
Quenching 
temperature 
Time Result 
1 4 0 ºC 0 ºC 6 h No reaction 
2 11 0 ºC to RT RT 4 h No reaction 
Table 2.9: Epimerisation attempt using sodium ethoxide. 
 
At that point the only proof of relative stereochemistry was deduced from the 
mechanism and the coupling constants on the fluorine, no NOESY interactions were 
observed between the methyl group of the ester and the hydrogen adjacent to the 
fluorine.  
Better NOESY interaction might be observed between the hydrogens on the methyl 
group of the ethyl ester and the hydrogen adjacent to the fluorine (Figure 2.6). The 
epimerisation could be facilitated with the ethyl group that is slightly more hindered 
than the methyl group and could more easily flip and stabilise itself in the equatorial 
position during the epimerisation. So it was decided to target the ethyl ester 
fluorohydrins instead and stop the investigations on the epimerisation of the methyl 
ester.  
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Figure 2.6: Possible NOESY interaction between CHF and H of ester group 
  
2.2 Fluorohydrin Ethyl Ester Synthesis. 
2.2.1 Synthesis towards (1R*, 3S*, 4S*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate. 
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i) NaOH, H2O, RT, 3h ii) H2SO4 ,EtOH, RT, 22h
2.40                                                     2.44
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Scheme 2.25: Conversion of the methyl ester in the methyl ester 
 
The remaining methyl ester 2.40 was converted to the ethyl ester 2.44. It was 
hydrolysed to the acid 2.43 in a sodium hydroxide aqueous solution, and esterified to 
the ethyl ester 2.44 using ethanol and sulphuric acid. This was performed with an 
overall yield of 44% over both steps (Scheme 2.25). This method could not be used 
reliably to produce gramme quantities of compound because of the difficulty to separate 
the mixture of both compounds 2.40 and 2.41, and the addition of two extra steps. 
Therefore it was decided to redirect the synthesis towards the ethyl ester 2.44, by 
opening the iodolactone 2.38 using sodium ethoxide instead of methoxide in order to 
access the ethyl ester epoxide 2.45, followed by the opening of the epoxide in a similar 
way to that which we had previously utilised with HF triethylamine.84  
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Scheme 2.26: Opening of the iodolactone  
 
Two ethyl ester epoxides 2.45 and 2.46 were isolated from the opening of the 
iodolactone: the expected major compound (1R*, 3R*, 6S*)-ethyl-7-oxa-
bicyclo[4.1.0]heptane-3-carboxylate 2.45 (in a 48% yield) and the minor one (1R*, 3S*, 
6S*)-ethyl-7-oxa-bicyclo[4.1.0]heptane-3-carboxylate 2.46 (in a 7% yield) (Scheme 
2.26). On the TLC using an 80 : 20 petroleum ether : ethyl acetate system the minor 
epoxide 2.46 had an Rf of 0.42 and the major one 2.45 of 0.34. The stereochemistry of 
the major epoxide 2.45 and the minor epoxide 2.46 was confirmed by NOESY NMR. 
For the minor epoxide a lack of interaction between the proton adjacent to the ester and 
the proton adjacent to the epoxide was observed (see Figure 2.7). This was in contrast 
to the interactions observed for the major epoxide.  
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Figure 2.7: Stereochemistry of both epoxides minor and major showing characteristic 
observed and non observed NOESY interactions. 
 
The formation of the major epoxide can easily be explained (Scheme 2.27), but the 
formation of the minor epoxide is surprising. As sodium ethoxide is present in the 
reaction one plausible explanation for the formation of the minor epoxide is 
epimerisation on the carbon adjacent to the ester of part of the main epoxide. In order to 
confirm this epimerisation, the major epoxide was placed in ethanol with sodium 
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ethoxide, and after a few hours minor epoxide formed, confirming the origin of the 
minor epoxide. 
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Scheme 2.27: Stereochemistry of the major epoxide formation step of one of the 
enantiomers. 
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Scheme 2.28: Opening of the ethyl ester 
 
Epoxide (1R*, 3R*, 6S*)-ethyl 7-oxa-bicyclo[4.1.0]heptane-3-carboxylate 2.45 was 
opened with HF triethylamine84 to yield a mixture of both isomers (1R*, 3S*, 4S*)-ethyl 
3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 and (1S*, 3S*, 4S*)-ethyl 4-fluoro-3-
hydroxycyclohexanecarboxylate 2.47 in a 4 : 1 mixture. This mix of both compounds 
was isolated after a first fast flash chromatography on silica column in a 76% yield. At 
first TLC revealed both compounds only as one same spot. After using multiple 
developments TLC (after 3 developments) 2 spots running very close could be 
identified. The separation using flash chromatography only resulted in very partial 
separation, most of the compound staying as a mixture. The major fluorohydrin 2.44 
was only isolated in a 10% yield after multiple columns, the rest of the compound 
staying as a mixture of 2.44 and 2.47 like the previous methyl ester compounds 2.40 
and 2.41. In order to obtain a crystal structure to confirm the relative stereochemistry of 
compound 2.44, a p-nitro benzoyl ester derivative 2.48 of the alcohol was synthesised. 
The PNB derivative 2.48 was obtained in a 63% yield, by reacting the original 
fluorohydrin 2.44 with 4-nitro-benzoyl chloride in pyridine.85 The crystal structure of 
2.48 demonstrates relative orientations of the fluorine, hydroxyl group and ester group 
on the ring and confirms the relative stereochemistry of 2.44 (Figure 2.8). 
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Figure 2.8: X-ray structure of (1S*, 2S*, 4R*)-4-(ethoxycarbonyl)-2-fluorocyclohexyl 
4-nitrobenzoate 2.48 
 
In the 1H NMR spectrum of the original fluorohydrin 2.44, the coupling constants of the 
hydrogen adjacent to the fluorine and the NOESY interactions suggested that the 
fluorine and the hydroxyl group are in equatorial positions, and the ethyl ester in the 
axial position (see Table 2.13). This conformation is possibly stabilised by hydrogen 
bonding between the hydrogen of the hydroxyl group and the fluorine as previously 
mentioned. 
The NOESY interaction between the hydrogen of the CH3 in the ethyl group and the 
hydrogen adjacent to the fluorine, confirmed that the ethyl ester compound 2.44 was 
easier to work with than the methyl ester equivalent 2.40 that had no NOESY 
interaction to confirm the stereochemistry. 
 
OO OO
OH
F
OO
F
OH
Sole product
O
2.46                         2.49                      2.50
 
Scheme 2.29: Opening of the alternative epoxide 
 
The alternative epoxide was opened in a similar way using HF triethylamine.84 The 
opening of the epoxide resulted in the formation and isolation of the expected 
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fluorohydrin (1R*, 3S*, 4S*)-ethyl 4-fluoro-3-hydroxycyclohexanecarboxylate 2.49 
resulting from the diaxial opening of the epoxide. Sufficient quantities of fluorohydrin 
2.49 were synthesised to enable feeding studies with S. hygroscopicus MG-210 in order 
to produce another fluorinated prerapamycin analogue.  
In order to obtain a crystal structure to confirm the relative stereochemistry of the 
compound a p-nitro benzoyl ester derivative of the alcohol was synthesised. The PNB 
derivative 2.51 was obtained in a 59% yield, reacting the original fluorohydrin with 4-
nitro-benzoyl chloride in pyridine.85 The relative stereochemistry of the compound was 
confirmed (Figure 2.9). 
.  
Figure 2.9: X-ray structure of (1S*, 2S*, 5R*)-5-(ethoxycarbonyl)-2-fluorocyclohexyl 
4-nitrobenzoate 2.51 
 
In the 1H NMR spectrum of the original fluorohydrin the coupling constants of the 
hydrogen adjacent to the fluorine and the NOESY interactions, suggested that the 
fluorine occupies the equatorial position, the hydroxyl group occupies also the 
equatorial position, and the ethyl ester the axial position (see Table 2.13). This 
conformation is probably stabilised by hydrogen bonding between the hydrogen of the 
hydroxyl group and the fluorine as previously discussed. 
 
Alternative opening 
In order to form the unfavourable all equatorial fluorohydrin 2.50, the product has to go 
through the very high energy double twisted boat transition state. Therefore an 
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alternative fluorinating agent was tested: HF pyridine at various temperatures from -78 
ºC to room temperature but only compound 2.49 was obtained.  
2.2.2 THP protection and optimisation of the separation between both 
isomers.  
 
In order to improve the separation between both isomers 2.44 and 2.47, it was decided 
to explore the introduction of a THP protecting group on the alcohol. By adding a THP 
group, an extra stereocenter is created, forming two diastereoisomers for each original 
molecule (Figure 2.10). 
* O
OR
O
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Figure 2.10: THP protecting group 
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24%4       :        1     mixture
100%
OHF
2.44              2.47                       2.52            2.53                  2.47+2.44
DHP
NH2SO3H
 
Scheme 2.30: THP protection.86 
The purified mixture of 2.44 and 2.47 was stirred in 3, 4-dihydro-2H-pyran (DHP) with 
a sulfamic acid catalyst for 4 days
.
86
 The reaction did not go to completion, 24% of the 
starting material was recovered (DCM : Ethyl acetate 95 : 5 solvent system Rf 0.30). 
The mixture of diastereoisomers THP derived from the protection of the major 
compound 2.52 was isolated after 3 long separations using column chromatography in a 
52% yield and the diastereoisomeric mixture of the THP protected minor compound 
2.53 was isolated in a 15% yield (Scheme 2.30). Both diastereoisomers of the main 
derived isomer were isolated in very small quantities and were characterised separately 
(DCM : Ethyl acetate 95 : 5 solvent system Rf 0.51 and 0.48), the main part of the 
mixture was inseparable. The minor mixture was only characterised as a mixture (DCM 
: Ethyl acetate 95 : 5 solvent system Rf 0.37).  
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COOEt
iii)
76% as a purified mixture
COOEt
HO
2.45                            2.47            2.44
   2.52                       2.44
  2.53                       2.47
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Scheme 2.31: Protection, separation and deprotection using a THP group 
 
The major mixture was hydrolysed with p-TsOH in ethanol in a 99% yield, and the 
minor mixture in a 76% yield.87  
The overall yield from the epoxide 2.45 to the isolated compound 2.44 over the 
fluorination, THP protection, and deprotection is equivalent to 39%. This compares 
favourably to the previous 10% yield obtained (fluorination followed by a very difficult 
and incomplete separation). The THP protection of the alcohol allowed a better 
separation quadrupling the amount of isolated (1S*, 3R*, 4R*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate 2.44 and isolating for the first time the all equatorial 
(1S*, 3S*, 4S*)-ethyl 4-fluoro-3-hydroxycyclohexanecarboxylate 2.47 that can directly 
be fed to S. hygroscopicus as an all equatorial shikimic acid fluorinated analogue 
(Figure 2.11).   
HO
HO CO2H COOEtHO
F
1.71                                                    2.47
 
Figure 2.11: Shikimic acid derivative 1.71 and fluorinated analogue 2.47. 
 
Following the successful isolation of the minor fluorohydrin 2.47, a p-nitro benzoyl 
ester derivative of the alcohol was synthesised in order to obtain a crystal structure to 
confirm the relative stereochemistry. The fluorohydrin 2.47 was reacted with 4-nitro-
benzoyl chloride in pyridine.85 The PNB derivative 2.54 was obtained in a 63% yield. 
The compound would not crystallize and therefore no X-ray structure was available. In 
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the 1H NMR spectrum of the original fluorohydrin 2.47 the coupling constants of the 
hydrogen adjacent to the fluorine, the hydroxyl group and ethyl ester and the NOESY 
interactions suggest that the fluorine, the hydroxyl group and the ethyl ester are all in 
equatorial positions (see Table 2.13). This conformation is the most stable, 
thermodynamically. 
 
2.2 Epimerisation of the Ethyl Ester 
 
As the first attempt of epimerisation on the methyl ester was unsuccessful, it was 
decided to try the epimerisation on the ethyl ester as well as a range of derivatives of the 
alcohol. The THP alcohol derivative 2.52 and the PNB derivative 2.48 had already been 
synthesised. A pivalic ester derivative of the alcohol 2.55 was also synthesised. It was 
believed that the bulky substituent would preferentially occupy the equatorial position 
thus forcing the ethyl ester to occupy the axial position. This could add selectivity 
towards the formation of the epimerised compound 
The pivalic ester 2.55 was prepared in one pot by combining pivalic acid and thionyl 
chloride in DCM yielding pivaloyl chloride. This was reacted with compound 2.44 to 
form (1R*, 3S*, 4S*)-ethyl 3-fluoro-4-(pivaloyloxy)cyclohexanecarboxylate 2.55 in a 
35% It was believed that such a bulky substituent would position itself in equatorial. 
 
OH
EtO O
F
OTHP
EtO O
F
O
EtO O
F
O
NO2
O
EtO O
F
O
2.44            2.52              2.48                                   2.55
 
Scheme 2.32: Range of compounds tested for epimerisation. 
 
The epimerisation was first attempted, using one equivalent of sodium ethoxide for the 
THP, PNB and pivalic acid derivatives and two equivalents for the free alcohol 
compound, because of the deprotonation of the alcohol in the alkoxide. The reactions 
were attempted at -20°C and room temperature. The reactions were quenched using pH 
7 phosphate buffer. No epimerised compound was detected.  
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2.2.1 Epimerisation kinetic conditions 
 
Previously sodium methoxide was used unsuccessfully in order to epimerise the methyl 
fluorohydrins. Sodium hydride a stronger base was used next for deprotonation 
purposes in THF at -20ºC. The reaction was quenched with sterically hindered proton 
donors also introduced at -20ºC. Phthalamide and tert-butanol were used. No 
epimerisation was observed using tert-butanol introduced at -20 ºC in diethyl ether 
possibly because of solubility problems, but using phthalamide some epimerisation 
occurred on the non protected molecule (Table 2.10). After a scale up of the reaction 
and separation using two successive columns, 63% of the starting material was 
recovered and the epimerised compound was isolated in a 23% yield.  
 
Compound  
OR
EtO
O
F
 
1H Coupling 
constants of H 
adjacent to the 
fluorine 
Suggested 
stereochemistry of 
the OR, fluorine 
and ester group in 
the starting material 
Epimerisation 
Ratio (%) 
R: H 49.1, 8.1, 6.8, 3.9 e, e, a 23 
R: THP mixture of 
2 Diastereoisomers 
47.9, 6.0, 6.0, 3.4 
47.2, 4.8, 4.8, 2.7 
a, a, e 
a, a, e 
0 
R: PNB 47.4, 6.4, 6.1, 3.5 
a, a, e(confirmed by 
X-ray structure) 
0 
R: COC(CH3)3 47.0, 4.6, 4.3, 4.3 a, a, e 0 
Table 2.10: Correlation between conformation of the starting material and 
epimerisation in kinetic conditions. 
 
Surprisingly the epimerisation was only successful on the non protected alcohol. In the 
1H NMR spectrum of the THP derivative the coupling constants of the proton adjacent 
to the fluorine, and X-ray structure of the PNB derivative suggest that both compounds 
have their fluorine group in the axial position, resulting in axial derivatised alcohols and 
equatorial ethyl esters. The proton NMR spectrum of the pivalic derivative was then 
investigated. It was expected that the sterically hindered pivalic ester would occupy the 
equatorial position, leaving the ethyl ester in the axial position. However the coupling 
constants of the proton adjacent to the fluorine indicate that the fluorine occupies the 
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axial position, therefore indicating that the pivalic ester occupies the axial position and 
the ethyl ester the equatorial position as with both previous derivatised compounds.  
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Scheme 2.33: Possible mechanisms explaining the epimerisation or non epimerisation 
in kinetic conditions with the ethyl ester occupying the equatorial position in the starting 
material. 
 
The sterically hindered OR group and fluorine group in an axial position are not 
favourable to the epimerisation (Scheme 2.33). Both axial hydrogens of the 
cyclohexane ring adjacent to the desired epimeric centre, and the axial sterically 
hindered OR group in the case of the PNB, THP and pivalic ester derivative sterically 
hinder the approach of the bulky proton donor in equatorial (see Scheme 2.33 and 2.34). 
The favourable axial approach leads to the non epimerised starting material (Scheme 
2.33). A ring flip, putting the fluorine and the hindered OR group into the equatorial 
position, would be the only way the epimerised product would be favoured. It is 
unlikely but the low temperature kinetic conditions might be unfavourable to this ring 
flip, and could explain the lack of epimerised compound. To investigate this possibility 
the reactions were repeated at a higher temperature of 0 ºC, but the starting material 
degraded (cleavage of the fluorine). The most probable explanation would be that the 
deprotonation on the epimeric carbon did not occur at -20°C. 
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Scheme 2.34: Mechanism of the epimerisation of 2.44 under kinetic conditions. 
 
In the case of the free alcohol, the ethyl ester occupies the axial position. This 
conformation is favourable due to the approach of the sterically hindered proton donor 
phthalamide, to give the epimerised compound (Scheme 2.34). The approach on the 
opposite side resulting in the starting material is unfavourable. Both protons in the axial 
position adjacent to the desired epimeric centre hinder the approach of the bulky proton 
donor (Scheme 2.34). A majority of epimerised compound was expected, but the 
epimerisation only appeared in a 23% yield. 70% of starting material was recovered 
with traces of phthalamide. However separating the phtalamide was very difficult and 
the yields were not reproducible. The fact that over 70% of starting material did not 
epimerise could be rationalised from the first deprotonation of the alcohol group. This 
would have stopped the stabilising hydrogen bonding between the alcohol group and the 
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fluorine. Without this bonding, the ethyl ester would want to position itself in equatorial 
(Scheme 2.34). Even at -20°C it is possible that part of the product ring flipped before 
the deprotonation of the carbon in alpha of the ester. Another explanation would be that 
only part of the starting material was deprotonated on the epimeric centre. 
As the epimerisation using sodium hydride in kinetic conditions was unsuccessful 
another base, n-BuLi in THF, was used in similar kinetic conditions from -78°C to -
20°C. No epimerised compound was detected but some degradation was observed. As 
the kinetic conditions were not satisfactory (the yield being fairly low and not always 
repeatable), it was decided to test different bases and an acid in thermodynamic 
conditions: t-BuOK, EtONa, pyridine and p-TsOH. The all equatorial epimerised 
compound is the more thermodynamically stable. All experiments were followed by 
TLC to track the formation of the epimerised compound. The temperature was increased 
every 20 minutes by 10°C (Table 2.11).  
 
Reagent Number of 
equivalents 
Solvent Temperature 
range of 
reactions 
(ºC) 
Identified 
Side 
products 
Degradation 
 
Presence 
of 
epimerised 
compound 
p-TsOH Catalytical Toluene 20-110 No Yes 0 
Pyridine 1.3 
1.3 
Ethanol 
Toluene 
20-79 
20-110 
No 
No 
Yes 
Yes 
0 
0 
EtONa 1.2-1.4 Ethanol 20-79 Epoxides 
acids 
Yes Traces on 
TLC 
t-BuOK 1.3 Toluene 20-110 Epoxides 
acids 
Yes Yes 
None 0 Toluene 110 No No 0 
Table 2.11: Range of epimerisation attempts of 2.44 using various reagents with 
thermodynamic conditions. 
 
Epimerised compound 2.50 was observed with ethoxide in ethanol by TLC in very low 
concentration, but after work up, a mixture of mainly both epoxides 2.45 and 2.46 
obtained previously (opening of the iodolactone), and starting material was isolated. 
The epimerised compound seems to be relatively volatile and during the work up traces 
of epimerised compound might have evaporated with the ethanol as an azeotrope.   
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Epimerisation of 2.44 only started occurring in thermodynamic conditions using 
potassium tert-butoxide between 70 and 110 ºC (reflux). The highest epimerisation rate 
was observed at reflux. However some degradation and side products formed even at 
lower temperatures. Both epoxides 2.45 and 2.46 that had formed as expected products 
in the opening of the iodolactone previously (Scheme 2.35) were also identified as side 
products. 
EtOOC
F
O-
EtOOC
O
F-COOEt
O-
F
COOEt
O
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  Alcoxyde of 2.44                                                                    2.45                                        2.46
 
Scheme 2.35: Side reaction formation of the epoxides. 
 
The formation of the epoxide can only proceed if the alkoxide and the fluorine are in the 
axial position. This suggests that part of the molecules as an alkoxide ringed flip to the 
diaxial fluorine alkoxide, due to the breaking of the hydrogen bond.  
The reaction was left to cool down then exposed to the moisture in the air, when 
quenched a small dark solid formed. This solid was not soluble in CDCl3, but was 
solubilised in CD3OD and analysed by NMR. The 1H NMR spectrum identified a 
mixture of acids resulting in the hydrolysis of the ethyl ester of both epoxides and 
starting material. This hydrolysis could be due to hydroxide formed from the 1.2 
equivalents of tert-butoxide coming into contact with moisture in the air.  
 
2.2.2 Thermodynamic epimerisation using potassium tert-butoxide. 
 
As the pKa values of tert-butanol (29.4 in DMSO) and the hydrogen on the desired 
epimeric centre are very close (approximatively 29.5 in DMSO), the deprotonation will 
become reversible if the reaction is carried out at a high temperature (toluene reflux, 
thermodynamic conditions) and the equilibrium between non epimerised compound 
2.44 and epimerised compound 2.50 should displace itself strongly toward the 
thermodynamically more stable compound, accumulating the epimerised compound 
2.50.  
In order to epimerise the fluorohydrin 2.44, one equivalent of base is necessary to 
deprotonate the hydroxyl group (lower pKa than the protons on the desired epimeric 
centre and tert-butanol) and a catalytic amount of base is necessary for the 
epimerisation (0.1-0.2 equivalents).  
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Scheme 2.36: Deprotonation of the hydroxyl to the alkoxide. 
 
The thermodynamic conditions can be compared to a catalytic cycle using 0.1 to 0.2 
equivalents of base (Scheme 2.37). 
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Scheme 2.37: Catalytical mechanism of the thermodynamic epimerisation. 
 
The reaction was repeated on fluorohydrin 2.44 using different temperatures (between 
70 and 110ºC), different amounts of potassium (tert-butoxide between 1.1 and 1.5 
equivalents) and different reaction times (between 10 and 60 minutes). The best yield 
was obtained at reflux for 30 minutes, with 1.2 equivalents of potassium tert-butoxide 
with a yield of 34%. After 30 minutes at reflux the amount of degradation products 
increases very quickly (after 50 minutes most of the starting material and the product 
would have degraded). This makes the reaction quite difficult to reproduce in a 
reasonable yield due to the starting material and the product degrading during the 
reaction. 
Previously the opening of the epoxide gave a 4 to 1 mixture of two isomers 2.44 and 
2.47 that were very difficult to separate and had to be protected with a THP group in 
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order to facilitate the separation, followed by a deprotection. The unwanted isomer is 
already all equatorial and should not epimerise (thermodynamically more stable than if 
epimerised).   
COOEt
OH
F
COOEt
OH
F
COOEt
F
OH
COOEt
F
OH
2.44                 2.47                         2.50                  2.47
4           :          1
100% 24%              not isolated
 
Schemes 2.38: Epimerisation of the mixture. 
 
The mixture was epimerised and after optimisation a total yield of 24% was obtained 
avoiding the protection and deprotection step. As the starting mixture had a ratio of 4 to 
1 this means that 30% of product 2.44 epimerised. 
There are limits to this method, however as part of the product degrades and conditions 
for this reaction are not easy to reproduce. Just a few minutes extra reaction time 
reduces the yield considerably, and the entire product and the starting material could 
degrade if the time is doubled. This reaction is also difficult to follow by TLC as both 
compounds of the original mixture have very similar Rf, only multiple development can 
separate them.  
The epimerisation on the free alcohol has 3 major disadvantages:  
1- The formation of the epoxides as side products.  
2- Using more than 1 equivalent of t-BuOK per molecule due to the presence of the 
proton on the hydroxyl group. This excess base in contact with water produces 
hydroxides potentially responsible for some of the hydrolysis of the esters and acids and 
other degradation. Boiling the compound in dry toluene without presence of base 
showed no degradation. 
3- The direct production of the more volatile epimerised compound in a high boiling 
point solvent toluene. The evaporation of the solvent in vacuo has to be done very 
carefully at a low temperature, and controlled reduce pressure. 
Kinetic conditions (low temperature) had failed previously because of the conformation 
of the protected molecules (the ethyl ester standing in the equatorial position). In 
thermodynamic conditions the ring could flip and epimerisation could occur. The 
thermodynamic conditions were tried on the THP protected diastereoisomeric mixture, 
which was originally produced for separation purposes. As a result of using 0.2 
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equivalents of t-BuOK in toluene at reflux for 40 minutes the compound epimerised in a 
53% yield, and 46% of starting material was recovered. Little degradation was observed 
on TLC, only appearing after an hour reflux. The deprotection was performed with p-
TsOH in methanol, instead of ethanol because of the volatility issues with the 
deprotected product; this resulted in a 93% yield.87 When ethanol was used as a solvent 
in the deprotection and removed in vacuo some compound was lost, because of its 
volatility.  
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2.44             2.47                       2.52                           2.56                              2.50
 
Scheme 2.39: Epimerisation of the THP mixture. 
 
Compared to the previous epimerisation, the reaction results are easily reproducible. 
Nearly all the remaining starting material was recovered. The overall yield is slightly 
improved, 26% over 3 steps instead of 24% yield previously achieved. This method 
compared to the previous one is fully reproducible, the starting materials are recovered 
and the product does not degrade under the conditions used. The starting material can 
also be recycled. The THP protection is not an added step as it is necessary for the 
separations of both isomers (compounds have to be fed as a pure racemic mixture). 
This method was chosen for the gramme scale synthesis for quantitative feeding of the 
all equatorial compound.  
A PNB derivative of 2.50 was synthesised as previously described. The relative 
stereochemistry of epimerised fluorohydrin 2.50 was confirmed by X-ray structure of 
the PNB derivative 2.57, all 3 groups positioned in equatorial (Figure 2.12). 
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Figure 2.12: X-ray structure of (1S*, 2S*, 4S*)-4-(ethoxycarbonyl)-2-fluorocyclohexyl 
4-nitrobenzoate 2.57 
 
At that point in time four fluorohydrins had been synthesised (Figure 2.13). 
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Figure 2.13: Range of fluorohydrins synthesised. 
 
Qualitative feeding indicated that only the epimerised compound 2.50 was well 
incorporated. For a better understanding about the incorporation of the fluorohydrins by 
S. hygroscopicus, two more molecules were targeted 2.58 and 2.59 (Figure 2.14). 
COOEt
OH
F
COOEt
OH
F
  2.58          2.59
 
Figure 2.14: New targets. 
 
In order to access compounds 2.58 and 2.59, the hydroxyl group of the non epimerised 
2.44 and the epimerised compound 2.50 need to be inverted. 
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2.3 Alcohol Inversion 
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2.50                      2.58
2.44                       2.59
 
Scheme 2.40: Inversion of the hydroxyl group. 
 
The Mitsunobu reaction is a classic method for inverting a hydroxyl group. However it 
is generally not very successful on alcohols in a sterically hindered environment. The 
inversion was attempted on the less sterically hindered all equatorial fluorohydrin 2.50 
without any success, since no reaction occurred, and the starting material was 
recovered.88 
Alternatively in order to invert the hydroxyl group, the hydroxyl needs to be 
transformed into a good leaving group, allowing it next to be displaced through an SN2 
mechanism by a hydroxyl group or a group that can be hydrolysed to a hydroxyl group. 
Mesyl chloride was first used in order to transform the hydroxyl group into a good 
leaving group (-OMs).   
COOEt
OH
F
COOEt
OMs
F
i
i) MsCl, DMAP, Hunig's base, DCM, -10ºC, 60%
2.50                        2.60
 
Scheme 2.41: Mesylation step of the alcohol. 
 
Fluorohydrin 2.50 was transformed using mesyl chloride to (1S*, 3S*, 4S*)-ethyl 3-
fluoro-4-(mesityloxy)cyclohexanecarboxylate 2.60 in a 60% yield.89  
In order to displace the mesylate group, cesium acetate,89-91 sodium acetate,92 were tried 
at various temperatures, and in some cases under microwave conditions (Table 2.12). In 
order to displace the hydroxyl group, formic acid93 was tried on the free alcohol 2.50 
(Table 2.12)  
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Reactive Solvent 
mixture 
T  
(ºC) 
Problems 
occurring 
time Product 
detected 
Predicted 
group in 
product 
CsOAca 18-Crown-6 
Toluene 
Reflux  
110 
No reaction 24h None Acetate 
CsOAca 18-Crown-6 
Toluene 
Microwave 
250  
Explosion or 
degradation 
10 min. 2.61 traces Acetate 
NaOAca DMF 
H2O 
Reflux 
120 
Does not go 
to completion 
3 days 2.61 12% 
isolated 
Acetate 
NaOAca DMF Microwave 
250 
Explosion   2.61 traces Acetate 
HCOOHb 
DCC CuCl 
DMAP 
DCM Reflux 
40 
 3 days None formate or 
OH. 
a: inversion on mesylate 2.60, b: inversion on free alcohol 2.50. 
Table 2.12: Main inversion attempts on the mesylate 2.60 and the free alcohol 2.50. 
 
The microwave reactions would lead some times to unpredictable explosions due to a 
sudden rise in pressure in the vial, whilst using acetate salts, this possibly due to 
decarboxylation. The best result was obtained when the mesylate 2.60 was heated at 
reflux with sodium acetate in an 80 :20 mixture of DMF and water.92 However the best 
yield observed for the isolated acetate compound was limited to 12% after optimisation.  
COOEt
OMs
F
i) NaOAc,  DMF : H2O 8 : 2 , reflux, 12%
COOEt
O
F
O
2.60                       2.61
 
Scheme 2.42: Displacement of the mesylate with sodium acetate 
 
The reflux temperature and the solubility of sodium acetate are a limiting factor. A 
better leaving group is needed than the mesylate. 
In sugar chemistry the most activated leaving group used for inverting alcohol groups is 
the triflate. The lipophilic tetrabutylammonium benzoate would be a very good 
nucleophile in an aprotic solvent such as toluene. Benzoate also has the advantage to be 
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UV active (easily followed by TLC) and a solvent like toluene can be heated at reflux 
(110ºC) if necessary. 
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i) ii) iii)
(i)Triflic Anhydride, Pyridine, DCM, 0ºC, 2 h, 67% (ii) Bu4N+BzO-, toluene, RT, 16 h, 61 % 
(iii)  Na, EtOH, RT, 16 h,  88 % 2.58, 4 % 2.59.
2.50                        2.62                       2.63                        2.58             2.59
 
Scheme 2.43: Alcohol inversion of 2.50 through a triflates 
 
(1S*, 3S*, 4S*)-Ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.50 was transformed 
using triflic anhydride to (1S*, 3S*, 4S*)-ethyl 3-fluoro-4-
(trifluoromethylsulfonyloxy)cyclohexanecarboxylate 2.62 in a 67% crude yield. The 
compound was not purified at that stage because of stability issues with the triflate. The 
triflate was then displaced and inverted using tetrabutyl ammonium benzoate to (1R*, 
2S*, 4S*)-4-(ethoxycarbonyl)-2-fluorocyclohexyl benzoate 2.63 in a 61% yield. Finally 
the alcohol was deprotected using ethoxide to (1S*, 3S*, 4R*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate 2.58 in an 88% yield. Some epimerised compound 
(1R*, 3S*, 4R*)-ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.59 was isolated in a 
4% yield. 
The same method was applied toward the synthesis of (1R*, 3S*, 4R*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate. 
COOEt
OTf
F
COOEt
OBz
F
COOEt
OH
F
COOEt
OH
F
COOEt
OH
F
i) ii) iii)
(i)Triflic Anhydride, Pyridine, DCM, 0ºC, 2 h, 76 % (ii) Bu4N+BzO-, toluene, RT, 16 h, 65 % 
(iii) Na, EtOH, RT, 16 h,  57 % 2.59, 33 % 2.58
2.44                        2.64                         2.65                       2.59             2.58
 
Scheme 2.44: Alcohol inversion of 2.44 through a triflate 
 
(1R*, 3S*, 4S*)-Ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 was transformed 
to (1R*, 3S*, 4S*)-ethyl 3-fluoro-4-(trifluoromethylsulfonyloxy)cyclohexane 
carboxylate 2.64 in a 76% crude yield (not purified for stability issues as previously), 
then was inverted using to (1R*, 2S*, 4R*)-4-(ethoxycarbonyl)-2-fluorocyclohexyl 
benzoate 2.65 in a 65% yield. Finally the alcohol was deprotected to (1R*, 3S*, 4R*)-
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ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.59 in a 57% yield, and a large 
amount of epimerised compound (1R*, 3S*, 4R*)-ethyl 3-fluoro-4-
hydroxycyclohexanecarboxylate 2.58 was isolated in a 33% yield.    
 
2.4 Confirmation of the Stereochemistry of Fluorohydrin 
cyclohexane Methyl and Ethyl Esters. 
 
All the fluorohydrins were assigned using 1H, 13C, DEPT, COSY, HSQC and NOESY 
NMR. Table 2.13 shows the coupling constants found in the 1H NMR spectrum of 
hydrogens situated on the stereocenters, when available, and the NOESY NMR 
interactions, also when available (Table 2.13). This allows us to deduce the relative 
stereochemistry of the racemic mixtures in CDCl3. Only one of the enantiomers is 
represented in the final column. 
Molecule Coupling constants of 
H adjacent to the  
F 
OH 
COOR 
All NOESY 
Interaction 
Between H adjacent 
to F, OR, COOEt 
and CH3  
Deduced 
stereochemistry 
with observed 
NOESY 
interactions 
OO
OH
F
 
2.40 
 CHF: dddd, J = 49.1, 
8.3, 6.9, 3.9 Hz 
CHOH: m 
CHCOOMe: m 
No interaction 
 
 
HO
F
OO
 
OO
OH
F
 
2.44 
CHF: dddd, J = 49.1, 
8.1, 6.8, 3.9 Hz 
CHOH: m 
CHCOOEt: m 
COOCH2CH3-CHF  
HO
F
H
OOH3C
 
OO
OH
F
 
2.47 
CHF: dddd, J = 50.9, 
10.4, 8.4, 5.0 Hz 
CHOH: dddd, J = 
11.1, 11.1, 8.3, 4.9 Hz 
CHCOOEt dddd, J = 
11.7, 11.7, 3.8, 3.8 Hz 
CHCO2Et-CHOH  
 
F CO2Et
HO
H
H
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OO
OH
F
 
2.49 
CHF: dddd, J = 49.7, 
8.2, 6.9, 3.9 Hz 
CHOH: m 
CHCOOEt: m 
COOCH2CH3-CHOH  
F
HO
H
OOH3C
 
 
OH
F
OO
 
2.59 
CHF: dddd, J = 50.2, 
4.5, 2.2, 2.2 Hz 
CHOH: dddd, J = 
26.4, 10.9, 4.7, 2.3 Hz 
CHCOOEt: dddd, J = 
11.5, 11.5, 3.9, 3.9 Hz 
 
CHF-CHOH  
 
CO2Et
F
H
HO H
 
OH
F
O O
 
2.50 
CHF: dddd, J = 50.7, 
11.2, 8.6, 4.7 Hz 
CHOH: m 
CHCOOEt: m 
CHF- CHCO2Et  
HO CO2Et
F
H
H
 
OH
F
O O
 
2.58 
CHF: dddd, J = 47.0, 
10.5, 4.8, 2.8 Hz 
CHOH: m 
CHCOOEt: m 
CHF-CHOH 
CHF-CHCOOEt 
 
CO2Et
F
HO
H
H
H
 
Table 2.13: Stereochemistry of the different fluorohydrins confirmed by proton NMR 
and NOESY.  
All the stereochemistries of the ethyl ester fluorohydrins were confirmed by NOESY 
NMR. In the case of the isolated methyl ester fluorohydrin 2.40, no NOESY 
interactions were observed, but the large coupling constants of the proton adjacent to the 
fluorine suggest that the fluorine stands in equatorial. Those coupling constants are 
nearly identical to the ethyl ester equivalent 2.44. The relative stereochemistry of the 
methyl ester 2.40 should be identical to the ethyl ester 2.44, as they were synthesised 
using identical fluorination steps on epoxides with identical stereochemistry (Scheme 
2.20). The conformation of both molecules should be identical as they have similar 
coupling constants for the hydrogen adjacent to the fluorine (Table 2.13). Moreover 
2.40 was converted in 2.44 after the methyl ester 2.40 was hydrolysed and the resulting 
acid was esterified to the ethyl ester 2.44 (Scheme 2.25). 
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2.5 Global Synthesis of 6 Different Ethyl Ester Cyclohexane 
Fluorohydrins.   
O OH
I
O
O
O
CO2Et
H
TfO CO2Et
i ii
O
CO2Et
+
7:1
F
+4:1
F
F
2.37 2.38 2.45 2.46
2.53
2.47
2.49
CO2Et
CO2Et
CO2EtHO
2.44
HO CO2Et
CO2Et
TfO
CO2Et
F
BzO
CO2Et
F
HO
2.64
2.65
2.59
2.56
2.50
2.62
2.63
iii, iv
CO2Et
OH
v
vi
vii
viii
ix
x
xi
xii
xiii
xiv
xv
+
HO
CO2Et
F
F
THPO
F
F
THPO
F
OBz
F
CO2Et
HO
CO2Et
F
CO2Et
OTHP
F
2.52
2.58
 
                    (i) I2, KI, NaHCO3, H2O, RT, 16 h, 96% (ii) EtONa, EtOH, THF, 0ºC, 16 h, 48% 2.45, 7% 2.46 (iii) Et3N 
3HF, RT, 16 h, 76% as a mixture of 2.52 and 2.53 (iv) DHP, H2NSO3H, 4 days, 52% 2.52, 15% 2.53; (v) p-
TsOH, EtOH, RT, 2 h, 76% (vi) Et3N:3HF, RT 76% (vii) p-TsOH, EtOH, RT, 2 h, 99% (viii)Triflic 
Anhydride, Pyridine, DCM, 0ºC, 2 h, 76% (ix) Bu4N+BzO-, toluene, RT, 16 h, 65% (x) Na, EtOH, RT, 16 h, 
57% 2.59, 33% 2.58 (xi) t-BuOK, toluene, reflux, 40 minutes, 53% (xii) p-TsOH, MeOH, RT, 2 h, 92% 
(xiii)Triflic Anhydride, Pyridine, DCM, 0ºC, 2 h, 67% (xiv) Bu4N+BzO-, toluene, RT, 16 h, 61% (xv) Na, 
EtOH, RT, 16 h, 88% 2.58, 4% 2.59. 
Scheme 2.45: Global optimised synthesis accessing 6 different fluorohydrins. 
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This synthesis allowed us to access 6 different ethyl ester fluorohydrins, which were fed 
to S. hygroscopicus in order to produce incorporation data. The optimisation of the 
epimerisation allowed us to obtain a gramme scale synthesis of (1S*, 3S*, 4S*)-ethyl 3-
fluoro-4-hydroxycyclohexanecarboxylate 2.50. A large scale feeding was prepared in 
order to isolate a quantitative amount of prerapamycin.  
 
3 FEEDING OF THE MOLECULES TO S. 
HYGROSCOPICUS MG-210. 
 
All the feedings were done at a final concentration of 2 mmolL-1. The incorporation 
rates were quantified by the presence of the characteristic rapamycin triene detected by 
UV at 278 nm and quantified by HPLC. Samples were quantified based on a rapamycin 
calibration curve of absorbance peak area. 
 
3.1 Previous Feedings of 6 Carbon Membered Ring Starter 
Units. 
OH
OH
CO2H CO2HCO2H
1.71             1.89             1.90
 
Figure 2.15: Non fluorinated 6 membered rings including a carboxylic acid starter units 
previously fed. 
 
A series of feeding experiments were attempted by Biotica Technology Ltd to S. 
hygroscopicus MG-210 using a broad range of starter units, of these three were 6 carbon 
membered rings with a carboxylic acid.44 One of these was the natural occurring starter 
unit 3,4-dihydroxycyclohexanecarboxylic acid 1.71 fed as a racemic mixture.44 The 
second was cyclohexanecarboxylic acid 1.89 and the third was cyclohex-1-
enecarboxylic acid 1.90.44 All three were successfully incorporated. The corresponding 
prerapamycins were isolated and characterised by Biotica Technology Ltd by mass 
spectrometry and multidimensional NMR spectroscopy experiments. This allowed them 
to resolve the structure and stereochemistry of these prerapamycin analogues.44 The 
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calculated incorporation values from the whole broth of the natural occurring starter unit 
3,4-dihydroxycyclohexanecarboxylic acid 1.71 and the cyclohexanecarboxylic acid 1.89 
were very similar to the naturally occurring production without inhibition of the 
shikimic acid pathway (20 - 25 mgL-1)94. Incorporation of the cyclohex-1-enecarboxylic 
acid was about 2 times less (10±4 mgL-1). All 3 compounds yielded different 
prerapamycin analogues (Table 2.14). The feeding of the natural occurring starter unit 
1.71 yielded the original prerapamycin. The feeding of the cyclohexanecarboxylic acid 
1.89 yielded a similar analogue without the presence of the hydroxyl group on carbon 
39 of the cyclohexyl ring (39-deshydroxyprerapamycin), and the feeding of cyclohex-1-
enecarboxylic acid yielded a similar analogue as the first without the hydroxyl group on 
carbon 40 (40-deshydroxyprerapamycin)(Table 2.14). 
O
O
O
O
O O
OH
HO
HOH
A
B
N
R
39
40
 
Figure 2.16: Prerapamycin analogues   
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.14: Previously fed 6 membered ring starter units by Biotica Technology Ltd.44 
 
Starter acid analogue 
 
Prerapamycin 
analogue 
(Scheme 1) 
Rapamycin analogue 
produced 
(mgL-1) 
CO2HHO
HO 1.71
 
R=
HO
HO isolated 
20-25 94  
 
CO2H
1.89
 
  R=
HO
isolated
 
20-25   
CO2H
1.90
 
R= HO isolated
 
10±4 94  
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These results suggest that hydroxylation can occur on position 3 or 4 of the cyclohexyl 
moiety depending on the substrate and that the double bond of cyclohex-1-
enecarboxylic acid was reduced (Table 2.14). Biotica Technology Ltd resolved the 
structures and their stereochemistry using The relative conformation of the cyclohexyl 
moiety in all 3 isolated prerapamycins suggests that all the groups stand in equatorial 
positions as a chair conformation (Table 2.14). In order to resolve this conformational 
matter and to synthesise new fluorinated analogues, a range of three 
monohydroxycyclohexanecarboxylic acid with the hydroxyl group in position 2-, 3- and 
4- were fed in parallel with 3-hydroxycyclohex-1-enecarboxylic acid, and the three 
previously synthesised fluorinated analogues 2.1, 2.2 and 2.3 (Table 2.15). 
 
3.2 Feeding of the Hydroxycyclohexanecarboxylic Acids and 
Fluorinated Cyclohexanecarboxylic Acids. 
Fluorinated compounds synthesised previously (racemic mixtures of both cis and trans 
diastereoisomers of 3-fluorocyclohexanecarboxylic acid 2.2 in a 48 : 52 ratio, both cis 
and trans isomers of 4-fluorocyclohexanecarboxylic acid 2.1 in a 55 : 45 ratio and 3-
fluorocyclohex-1-enecarboxylic acid 2.3 and its methyl ester equivalent 2.17 were fed 
in parallel with compounds provided by Biotica Technology Ltd (cyclohexanecarboxylic 
acid 1.89, 4-hydroxycyclohexanecarboxylic acid 1.94, 3-hydroxycyclohexanecarboxylic 
acid 1.95, 2-hydroxycyclohexanecarboxylic acid 1.96, 3-hydroxycyclohex-1-
enecarboxylic acid 1.97, cyclohex-1-enecarboxylic acid 1.90 and 4,4-
difluorocyclohexanecarboxylic acid 2.4 (Figure 2.17 and table 2.15).52 
 
 
O
O
O
O
O O
OH
HO
HOH
A
B
N
R
39
40
 
Figure 2.17: Prerapamycin analogues   
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Table 2.15: Incorporation results of all 6 membered ring cyclohexanoic and 
cyclohexenoic acids fed to MG-210. 
 
Out of the three hydroxycyclohexanecarboxylic acids 1.94, 1.95, 1.96, 4-hydroxy 1.94 
was incorporated in relatively high quantities to yield 39-deshydroxyprerapamycin 
(Table 2.15), 3-hydroxy 1.95 was incorporated 10 fold less than the previous to yield 
the 40-deshydroxyprerapamycin analogue, and 2 hydroxy 1.96 was not incorporated. 3-
Hydroxycyclohex-1-enecarboxylic acid 1.97 was incorporated in relatively higher 
Starter acid analogue 
 
Prerapamycin analogue 
(Figure 2.17) 
Rapamycin analogue 
produced  
(mgL-1) 
CO2H
OH 1.96
 
 
0  
    
CO2H
HO 1.95
 
R=    HO
 
3±1 
 
CO2HHO
1.94
 
R=HO
 
33±3 
CO2H
F 2.2
 
 0  
CO2HF
2.1
 
 
0 
CO2H
F
F
2.4
 
 0 
CO2H
1.90
 
 
R= HO
 
10±4  94 
CO2H
HO 1.97
 
R= HO  
18±3 
CO2R
F
R= H and OMe
2.3       2.17
 
 0 
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quantities (Table 2.15). These results seem to indicate that the starter unit with the 
hydroxyl group in position 4 1.94 has a 10 fold incorporation compared to the starter 
unit with the hydroxyl group in position 3 1.95 (Table 2.15).  
Biotica Technology Ltd discovered that the structure and stereochemistry of the 
prerapamycin analogues obtained for the feeding of 1.95 and 1.97 were both identical to 
the prerapamycin obtained previously for the feeding of 1.90 (Table 2.15). The feeding 
of 1.94 produced the same prerapamycin analogue as the previous feeding of 1.89 
(Table 2.14 and 2.15). The structure of isolated prerapamycins44 from the feeding of 
both 3- and 4-hydroxycyclohexanecarboxylic acids suggest that only the all equatorial 
products in both cases were incorporated (Table 2.15).52 Those all equatorial molecules 
are the trans 4-hydroxycyclohexanecarboxylic acid and the cis 3-
hydroxycyclohexanecarboxylic acid (Figure 2.18). 
 
HO CO2H HO CO2H
1.94                                                     1.95
 
Figure 2.18: Suggested all equatorial hydroxycyclohexanecarboxylic acid incorporated 
 
Surprisingly none of the 3 synthesised fluorinated analogues were incorporated, nor was 
4,4-difluorocyclohexanecarboxylic acid despite the fact that their hydroxyl equivalents 
were incorporated. Although the length of the C-F bond is very similar to the C-OH 
bond, none of the fluorinated analogues were incorporated, suggesting that the hydroxyl 
group may act as a hydrogen bond acceptor and is required to initiate the biosynthesis 
on the starter unit.  
Hydroxylation that occurred on cyclohex-1-enecarboxylic acid and cyclohex-1-
enecarboxylic acid suggest that the presence of the fluorine in position 3 or 4 of the 
starter unit, or the presence of the hydroxyl group in position 2 seems to obstruct a 
possible hydroxylation that could occur on the carbon adjacent to the carbon bonded to 
the fluorine and would allow incorporation and initiation of the biosynthesis. 
In order to incorporate a fluorinated starter unit, it seems that a hydroxyl group is 
necessary in position 3 or 4 and justifies the synthesis and feeding of a series of 
fluorohydrins instead of monofluorinated compounds. These fluorohydrins, structurally 
closer to the original starter unit, could give us a better understanding of the 
stereochemical criteria necessary for a good incorporation. 
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3.3 Feeding of the 6 fluorohydrins   
 
CO2Et
OH
F
CO2Et
OH
F
CO2Et
F
OH
CO2Et
F
OH
CO2Et
F
OH
CO2Et
F
OH
2.49              2.47            2.44              2.50             2.58            2.59
 
Figure 2.19: Fluorohydrins fed to S. hygroscopicus. 
 
Previous feedings of the hydroxycyclohexanecarboxylic acid suggest that the best 
incorporation is observed for an all equatorial molecule, with the hydroxyl group in 
position 4. In order to confirm this theory and produce the first fluoroprerapamycins, a 
range of 6 fluorohydrins were fed as racemic mixtures. Those molecules are all isomers 
with the fluorine and hydroxyl group in position 3- and 4- and vice versa with various 
relative stereochemistries. The 6 compounds were all fed in parallel with trans 4-
hydroxycyclohexanecarboxylic acid 1.94, cyclohexanecarboxylic acid 1.89 and an 
unfed control. All the feedings were done in quadruplet, except for compound 2.59 that 
was fed in triplicate and 4 unfed control tubes were added. 
 
Starter acid 
analogue  
 
Rapamycin 
analogue 
(Scheme 1.) 
Corresponding 
fluorinated 
prerapamycin 
MS peaks detected 
Rapamycin 
analogue production 
(mgL-1) 
None (control) 
 
 
None 
 
 
[M+Na]+ 847.7 
[M+formate]- 870.5 
 
0  
 
     
CO2H
 
 
1.89 
 
 
R=   
HO
 
 
 
[M+Na]+ 847.7 
[M+formate]- 870.5 
 
27±2  
 
 
 
HO CO2H
 
 
1.94 
 
 
R=    
HO
 
 
[M+Na]+ 866.7 
 
29±2 
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FHO CO2Et
 
 
2.47 
 
 
R=  
F
HO
 
[M+Na]+ 866.7 
[M+formate]- 888.4 5±1
 
CO2Et
OH
F
 
 
   2.49 
 
 
R=     
F
HO
 
[M+Na]+ 866.7 
 
7±1 
 
CO2Et
F
HO
 
   2.44 R=  
HO
F
 
[M+Na]+ 866.7 
[M+formate]- 888.4 
 
10±1 
 
CO2Et
F
HO
 
2.59 R=  F
HO
 
[M+Na]+ 866.7 
[M+formate]- 888.5 
 
26±2 
 
CO2EtF
HO
 
2.50 
 
R=  
HO
F
 
[M+Na]+ 866.7 
[M+formate]- 888.6 
 
28±1 
 
CO2EtF
OH
       
2.58 
 
R=   F
HO
 
 
 
[M+Na]+ 866.7 
 
4±1 
 
Table 2.16: Incorporation results of the fluorohydrin feeding. 
 
Surprisingly all 6 fluorohydrins were incorporated, producing the fluorinated analogues 
(Table 2.16). The fluoroprerapamycins were all detected on the LCMS as the [M+Na]+ 
ion (866.7) and in most cases as the [M+formate]- ion (888.4 to 888.6) (See table). 
 The best incorporations were observed for compound 18 and 2.59, in which the alcohol 
group is in position 4, situated in the equatorial position with the ethyl ester group. The 
best incorporation out of the two being observed for the all equatorial 2.59 compound 
with the fluorine positioned in the equatorial position 3. This incorporation is similar to 
the natural starter unit. The worst incorporation was observed when the alcohol group is 
positioned in axial. Incorporation was fairly low when the fluorine was in position 4.  
It was also observed that the incorporations of trans 4-hydroxycyclohexanecarboxylic 
acid and cyclohexanecarboxylic acid were similar to the earlier feedings. Although 
previously 4-hydroxycyclohexanecarboxylic acid was fed as a 50 : 50 mixture of cis and 
trans compound (2 mmolL-1) and therefore half as much trans compound (1 mmolL-1) 
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was fed, the incorporation results were similar. The incorporation of trans 4-
hydroxycyclohexanecarboxylic acid is very good, and it seems that the production 
reaches a maximum around 30 mgL-1. The all equatorial compound 2.50 has a very high 
incorporation close to those 30 mgL-1, and slightly higher than the natural starter unit. It 
is structurally the closest fluorinated analogue to this starter unit, differing by having a 
fluorine instead of the hydroxyl group and an ester instead of the acid. 
CO2Et
F
OH
CO2H
OH
OH
2.50                      1.71
 
Figure 2.20: Best incorporated fluorohydrin and natural starter unit 
 
The hydroxyl group in the equatorial position is essential to the high incorporation and 
initiation of the PKS. 
As the best incorporated fluorinated starter unit is structurally and conformationally the 
closest to the natural starter unit, the fluorinated prerapamycin should only differ with 
the hydroxyl group in position 3 replaced by a fluorine.  
In order to isolate and to confirm the structure of the fluorinated prerapamycin a scale 
up of the feeding was performed. 
 
3.4 Scale up Feeding  
 
912 mg of compound 2.50 in 15 mL of methanol were fed to S. hygroscopicus, leading 
to 16 mg of isolated fluorinated prerapamycin. It appeared clearly as a mixture of two 
fluorinated prerapamycins that can interconvert. The proton NMR spectrum suggests a 
ratio of 48:52 for PRERAP1/PRERAP2. The prerapamycins were partially separable 
(preparative HPLC), but would start interconverting very quickly becoming a mixture 
again. It is believed that these two compounds are due to the cis-trans isomerism on the 
amide bond (Figure 2.21). This phenomenon was observed by for the original 
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O
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R
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O
R
R
 
     Trans                                                                                                             Cis 
Figure 2.21:  Cis-trans isomerism on the amide bond. 
 
From the 1H, 13C, COSY, DEPT, 2D NMR spectra: HMBC, HSQC, COSY and 
comparing the data from the previous NMR data of non-fluorinated prerapamycin,49 the 
mixture of both isomers was resolved. Both compounds are presented in separate tables 
(table 2.17 and 2.18). The tables show the assignment for each proton of the 
corresponding carbon according to the HSQC, the proton-proton correlations of the 
COSY and the 3 bond hydrogen carbons correlations observed from the HMBC.  
The chloroform peak was calibrated on 7.26 ppm in the 1H NMR spectrum and on 77.0 
ppm in the 13C NMR spectrum.  
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Figure 2.22: Numbered fluorinated prerapamycin analogue. 
 
Position 1H-NMR 13C 
NMR 
HMBC 
δH / ppm 
 
Multiplicity    
(Hz) 
COSY 
1    171.5  
2 5.38   3a, 3b 52.6 C1, C3, C4 
3a 
3b 
1.78 
2.19 
 2, 4a 
2, 4b 
26.2 C5 
4a 
4b 
1.25 
1.75 
 3a, 5a 
3b, 5b 
20.9 C2, C6 
5a 
5b 
1.49 
1.74 
 4a, 6a, 6b 
4b, 6a, 6b 
25.1 C4 
6a 
6b 
3.25 
3.84 
 
br.d (13.1)  
5a, 5b 
5a, 5b 
44.4 C2, C4, C5 
8    172.4  
9a 
9b 
2.57 
2.89 
d (13.8) 
d (13.7) 
none 40.2 C8, C10, C11 
10 none  none 98.6 none 
10-OH      
11 1.49  12a, 12b, 
43 
38.6 C9, C10, C12, C43 
12a 
12b 
1.47 
1.62 
 11, 13a  
11, 13a 
27.6 C10, C11, C13, 
C14 
13a 
13b 
1.34 
1.52 
 13a, 14 
13a, 14 
31.9 C14 
14 3.89 dddd (11.4, 
11.4, 2.0, 
2.0) 
13a,13b, 
15a, 15b  
69.6 C15, C16 
15a 
15b 
1.53 
1.68 
 14, 16 
14, 16 
40.6 C14, C16, C17 
16 4.08 dd (6.2, 6.2) 15a, 15b 75.6 C14, C15, C17, 
C18, C44 
17 none  None 138.4  
18 6.23 d (12.2) 19 125.1 C16, C17, C19, 
C20, C44 
19 6.33 dd (14.6, 18, 20 127.7 C17, C18, C20, 
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11.2) C21 
20 6.19 dd (14.7, 
10.7) 
19, 21 132.2 C18, C19, C21, 
C22 
21 6.05 dd (14.9, 
10.4) 
20, 22 130.5 C19, C20, C22, 
C23 
22 5.31 dd (14.9, 
9.4 Hz) 
21, 23 139.0 C20, C21, C23, 
C24 
23 2.16  22, 24a, 
24b, 45 
37.3 (C24,C45) 
24a 
24b 
1.30 
1.69 
 23, 25 
23, 25 
40.3 C22, C23, C25, 
C26, C45 
25 2.43  24a, 24b, 
46 
45.6 C23, C24, C26, 
C46 
26    215.5  
27a 
27b 
2.54 
 
2.65 
dd (16.7, 
3.3) 
dd(16.7, 
2.7) 
28 
 
28 
46.4 C26, C28, C29 
28 4.34  27a, 27b 72.0 C26, C27, C29, 
C30, C47 
29    139.6  
30 5.37 d (9.8 Hz) 31 123.7 C28, C31, C32, 
C47, C48 
31 3.25  30, 48 46.4 C28, C29, C31, 
C32, C47, C48 
32    208.8  
33a 
33b 
2.61 
2.63 
dd(9.7,18.3)  
m 
34 
34 
40.6 C32, C34, C35 
34 5.13 ddd (6.5, 
6.3, 3.8 Hz) 
33a, 33b, 
35 
75.9 C32, C33, C35, 
C36, C1, C49 
35 1.94  34, 36a, 
36b, 49 
32.6 C49 
36a 
36b 
1.09 
1.20 
dd (3.4, 3.4) 35, 37 
35 
37.5 C34, C35, C37, 
C49 
37 1.41  36a, 38a, 
38b, 42a, 
42b 
32.9 C35, C36, C41 
38a 
38b 
1.46 
1.68 
 37, 39 
37, 39 
40.7 C36, C40, C42 
39 4.26 
 
dddd (51.3, 
10.2, 8.7, 
5.0 Hz) 
38a, 38b, 
40 
96.2  d 
173.8 
Hz                
C38, C40 
40 3.59  39, 41a, 
41b 
73.6 C39, C41 
41a 
 
41b 
1.28 
 
1.96 
 37, 42a, 
42b 
37, 42a, 
42b 
30.7 C37, C39, C40, 
C42 
42a 
 
42b 
1.68 
 
0.84 
 37, 41a, 
41b 
37, 41a, 
29.2 C36, C37, C40 
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 41b 
43 0.95 d (6.5 Hz) 11 16.8 C10, C11, C12 
44 1.65 s  12.7 C17, C18 
45 1.02 d (6.3 Hz) 23 21.7 C22, C23, C24 
46 1.01 d (6.1 Hz) 25 16.6 C24, C25, C26 
47 1.59 d (1.0 Hz)  13.1 C28, C29, C30 
48 1.08 d (6.8 Hz) 31 16.2 C30, C31, C32 
49 0.89 d (6.1 Hz) 35 16.0 C34, C35, C36 
Table 2.17: Table presenting 1H, 13C and 2D correlations from COSY, HSQC, HMBC 
of PRERAP1. 
 
Position 1H-NMR 13C NMR HMBC 
δH / ppm 
 
Multiplicity 
(Hz) 
COSY 
1    169.0  
2 4.37  3a, 3b 55.7 C1, C3, C4, C8 
3a 
3b 
1.53 
2.41 
 2, 4a, 4b  
2, 4a, 4b 
26.7 C1, C5 
4a 
 
4b 
1.51 
 
1.71 
 3a, 3b, 
5a, 5b 
3a, 3b, 5a 
20.5  
5a 
5b 
1.29 
1.63 
 4a, 4b, 
6a, 6b 
24.4 C6 
6a 
6b 
2.15 
4.47 
 
br.d (13.4) 
5a, 5b 
5a, 5b 
39.1 C2 
8    171.7  
  9a 
9b 
2.41 
2.69 
 d (16.1 ) 
 d (16.3 ) 
 38.8 C8, C10, C11 
10    98.4  
10-OH 6.66 br. s   C10, C11 
11 1.54  12a, 12b, 
43 
38.6 C10, C12 
12a 
 
12b 
1.49 
 
1.69 
 11, 13a, 
13b 
11, 13a, 
13b 
27.3 C10, C11, C13, 
C14, C43 
13a 
 
13b 
1.26 
 
1.57 
 12a, 12b, 
14 
idem 
32.3 C14 
14 4.22  13a, 13b, 
15a, 15b 
71.3 C12, C15, C16 
15a 
15b 
1.46 
1.69 
 14, 16 
14, 16 
40.6  
16 4.22  15a, 15b 76.0 C14, C15, C17, 
C18, C44 
17 none   141.6  
18 6.09 d (10.5) 19 122.6 C16, C17, C19, 
C20, C44 
19 6.39 dd (14.2, 
11.2) 
18, 20 128.6 C17, C18, C21 
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20 6.00 dd (14.2, 
10.8) 
19, 21 131.2 C18, C21, C22 
21 6.06 dd (14.5, 
10.6) 
20, 22 130.2 C19, C20, C22, 
C23 
22 5.19 dd (14.6, 
9.9) 
21, 23 139.4 C20, C23, C24, 
C45 
23 2.12  22, 24a, 
24b, 45 
39.8 C21, C22, C45 
24a 
24b 
1.37 
1.98 
dd (13.2, 
4.0) 
23, 25 
23, 25 
39.7 C22, C23, C25, 
C26, C46 
25 2.44  24a, 24b, 
46 
46.3 C23, C24, C26, 
C46 
26 none   216.2  
27a 
 
27b 
2.45 
 
2.60 
dd (17.7,2.1 
Hz) 
28 
 
28 
48.0 C26, C28, C29 
28 4.40  27a, 27b 72.1 C26, C27, C29, 
C30, C47 
29 none   139.7  
30 5.44 d (9.8) 31 125.4 C28, 31, C32, 
C48 
31 3.39 dq (10, 6.8) 30, 48 45.6 C29, C30, C32, 
C48 
32 none   209.0  
33 2.65 
2.95 
m 
ddd (18.6, 
9.9, 2.5) 
34 
34 
39.7 C32, C34, C35 
34 5.36  33a, 33b, 
35 
74.4 C32, C33, C36 
35 1.96  34, 36a, 
36b, 49 
32.8 C33, C34, C49 
36a 
36b 
1.05 
1.16 
m 
dd (7.5, 5.7)  
35, 37 
35, 37 
37.5 C34, C35, C37, 
37 1.45  36a, 36b, 
38a, 38b, 
42a, 42b 
33.0 none 
38a 
38b 
1.48 
1.66 
 37, 39 
37, 39 
40.6 C36, C37, C40 
39 4.37-4.22  38a, 38b, 
40 
96.2 d 
(173.8Hz) 
C40 
40 3.61  39, 41a, 
41b 
73.4 C39, C41 
41a 
41b 
1.29 
2.00 
 40, 42a 
40, 42b 
30.9 C39, C42 
42a 
42b 
1.73 
0.90 
 37, 41a 
37, 41b 
29.9 C36, C37, C40, 
C41, 
43 0.95 d (6.5 Hz) 11 16.9 C10, C11, C12 
44 1.79 s  15.7 C16 
45 1.00 d (  6.0 Hz) 23 21.7 C22, C23, C24 
46 1.03 d (7.2 Hz) 25 19.1 C24, C25, C26 
47 1.49 d (1.1 Hz)  11.8 C28, C29, C30 
 118
48 1.01 d (7.1 Hz) 31 14.6 C30, C31, C32 
49 0.90 d (6.5 Hz) 35 15.0 C34, C35, C36 
Table 2.18: Table presenting 1H, 13C and 2D correlations from COSY, HSQC, HMBC 
of PRERAP2. 
 
There is a big difference in chemical shifts observed from one molecule to another in 
the 1H NMR spectrum for proton 2 and 6, also observed on the 13C NMR spectrum. 
This is due to the cis-trans isomerism on the amide bond (C8-N7). As carbon 2 and 6 
are directly connected to the nitrogen of the amide bond (N7), their chemical 
environment is directly modified by the cis-trans isomerism and so is their chemical 
shift. The fluorine NMR spectrum confirmed the presence of two fluorinated 
compounds with two peaks at δF (282 MHz, CDCl3) -74.96, -75.85 integrating similar 
ratios to the 1H NMR spectrum.  
The HRMS also confirms the presence of fluorinated prerapamycins 
The calculated exact mass of fluorinated prerapamycin C48H74FNO10 is 843.5297 
 
 
 
Figure 2.23 HRMS of the mixture of both fluorinated prerapamycin 
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Mass of main 
peaks  
Mass of added or 
missing fragment 
Corresponding 
fragments 
Calculated Mass 
866.5234 
867.5269 
868.5278 
+22.9937: Na+ C48H74FNO10+ Na+ 866.5189 
861.5664 
861.5664 + 1 
861.5664 + 2 
+18.0367: H2O C48H74FNO10+H2O 861.5402 
 
826.5308 
827.5317 
828.5392 
-16.9989: -H2O + 
H+ 
C48H74FNO10–H2O 
+H+ 
826.5264 
808.5201 
809.5250 
808.5201 + 2 
-35.0096: -2H2O + 
H+ 
C48H74FNO10-
2H2O +H+ 
808.5158 
 
790.5093 
790.5093 + 1 
790.5093 + 2 
-53.0204: -3H2O + 
H+ 
C48H74FNO10–
3H2O +H+ 
790.5053 
Table 2.19: Interpretation of the HRMS. 
 
The HRMS showed corresponding masses of C48H74FNO10+Na+, C48H74FNO10+ H2O, 
C48H74FNO10–H2O+H+, C48H74FNO10–2H2O+H+, C48H74FNO10–3H2O+H+ in the form 
of 3 main isotopes of decreasing intensity (measured peak intensity for C48H74FNO10+ 
Na+ +0: 100%, +1: 53%, +2: 17%, calculated abundance 100%, 53.5%, 16.1%). The 
first one of higher intensity only contains the most common isotopes 1H, 12C, 14N, 16O 
and 19F. The second peak M+1 is a mixture of fluoroprerapamycins containing the most 
common isotopes (1H, 12C, 14N, 16O and 19F) and one 13C or one 2H or one 17O or one 
15N. 19F is the only stable isotope of fluorine. The M+2 peak is a mixture of 
fluoroprerapamycins containing the most common isotopes and two of the previous 
isotopes (13C, 2H, 17O, 15N ) or one 18O or one 3H or one 14C.  
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CONCLUSION 
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4-Fluorocyclohexanecarboxylic acid and 3-fluorocyclohexanecarboxylic acid were 
synthesised using the same methodology (Scheme 3.1). By fluorinating the flattened 
hydroxyl cyclohexanone intermediate, containing one sp2 carbon in its 6-membered ring 
the steric hindrance and dehydration is limited. The yield of the fluorination step was 
increased in the synthesis toward 4-fluorocyclohexanecarboxylic acid compared to the 
previous literature method (fluorination of a saturated ring.52, 64). 
COOH
F
CN
F
O
F
O
OH
i) DAST, DCM, 0°C ii) TOSMIC, DME,  t-BuOK, t-BuOH, 25°C 
iii) EtOH, NaOH/ H2O, reflux
i) ii) iii)
 
Scheme 3.1: Common synthetic method used to synthesise 4- and 3- 
fluorocyclohexanecarboxylic acid 
 
3-Fluorocyclohex-1-enecarboxylic acid was synthesised following the literature 
procedure of Bridge and O’Hagan (Scheme 3.2).66  
i) CrO3, Benzene, acetic acid and acetic anhydride, RT, 45 min ii) CeCl3, NaBH4, MeOH, RT, 15 min
iii) DAST, DCM, 0°C, 3.5 h iv) NaOH, EtOH, RT, 3h
CO2Me CO2Me
O
CO2Me
OH
CO2Me
F
COOH
F
      i)                           ii)                            iii) iv)
 
Scheme 3.2: Synthesis of starter unit 3-fluorocyclohexenecarboxylic acid  
 
All three fluorinated compounds: 3-fluorocyclohex-1-enecarboxylic acid, 4 and 3- 
fluorocyclohexanecarboxylic acid when fed to S. hygroscopicus MG-210 were not 
incorporated to the contrary of the hydroxylated equivalents fed previously by Biotica 
Technology Ltd and fed in parallel with the three fluorinated compounds (Scheme 3.4).   
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R
O
O
O
O
O O
OH
HO
HOH
N
F COOH
COOH
F
HO COOH
No incorporation
No incorporation
Starter unit                                          R                        incorporation levels
                                                                                              (mgL-1)
0
0
3±1
MG-210
starter unit
COOHHO
18±3
HO
COOH
HO
F COOH
No incorporation
33±3
0
HO
HO
 
Scheme 3.4: Non incorporated monofluorinated starter units and incorporated hydroxyl 
equivalents. 
 
Previous incorporation experiments by Biotica Technology Ltd had shown that starter 
units without a hydroxyl group present had been hydroxylated first by S. hygroscopicus 
MG-210 before being incorporated, with the exception of tetrahydro-2Hpyran-4-
carboxylic acid that already contained a hydrogen bond acceptor and was incorporated at 
very low levels (Scheme 3.5). They had also showed that 2-
hydroxycyclohexanecarboxylic acid had not been incorporated.  
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COOHHO
HO
COOH
COOH
O
COOH
O
O
N
O
O
O
OH
OOH
HO
Starter units cyclohexyl moiety of prerapamyicn analogue
HO
HO
R
HO
HO
O
low levels of incorporation
COOH
OH
No incorporation
 
Scheme 3.5: Other 6 membered ring starter units that were fed to S. hygroscopicus  
MG-210 by Biotica Technology Ltd.44, 52  
 
Those results suggest that the presence of a hydrogen bond acceptor and more 
specifically a hydroxyl group in position 3 or 4 is necessary for incorporation. The 
presence of fluorine on the ring in position 3 or 4 seems to block any possible 
enzymatic oxidation in position 3 or 4 necessary for incorporation of a cyclohexane or 
cyclohexene carboxylic acid derivative. Although the fluorine carbon bond is isosteric 
to a carbon hydroxyl bond it is not recognised and accepted by the PKS. This could be 
due to fluorine’s different electronic and hydrogen bonding properties compared to a 
hydroxyl group.52  
In order to obtain fluorinated analogues and a better understanding of the rules of 
incorporations, a range of fluorohydrins containing a hydroxyl group in position 3 or 4 
prerequisite for incorporation were synthesised (Scheme 3.6).  
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O OH
I
O
O
O
CO2Et
H
TfO CO2Et
O
CO2Et
+
7:1
F
+4:1
F
F
2.37 2.38 2.45 2.46
2.53
2.47
2.49
CO2Et
CO2Et
CO2EtHO
2.44
HO CO2Et
CO2Et
TfO
CO2Et
F
BzO
CO2Et
F
HO
2.64
2.65
2.59
2.56
2.50
2.62
2.63
CO2Et
OH
+
HO
CO2Et
F
F
THPO
F
F
THPO
F
OBz
F
CO2Et
HO
CO2Et
F
CO2Et
OTHP
F
2.52
2.58
 
Scheme 3.6: Synthesis accessing to 6 different fluorohydrins. 
 
The relative stereochemistry of all 6 fluorohydrins was confirmed using NOESY NMR 
experiments. All 6 fluorohydrins were fed and incorporated by S. hygroscopicus MG-
210 at various incorporation levels. The highest incoporations were observed for 2.50 
and 2.59 when the ethyl ester group and hydroxyl in position 4 were in an equatorial 
position. The all equatorial product 2.50 had the best incorporation levels out of the two 
(Scheme 3.7).  
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HO CO2Et
F
=
=
CO2Et
OH
F
CO2EtHO
F
Only onee of the two
enantiomers
=
2.50 2.50
2.59 2.59
 
Scheme 3.7: Synthesised fluorinated starter units, incorporation levels and 
corresponding prerapamycin analogues 
 
The feeding of 2.50 was scaled up and the structure of the corresponding prerapamycin 
analogue resulting from the incorporation of 2.50 was confirmed using 1H, 13C, DEPT, 
COSY, HSQC, HMBC, NOESY NMR experiments.  
Rapamycin analogues could be produced in a similar way using a strain lacking the Rap 
K gene responsible for the synthesis of the starter unit. The activity of the new 
fluorinated rapamycin analogues could be evaluated and could also give us a better 
understanding on the importance of the hydrogen bond of the hydroxyl group on carbon 
40 with FKBP12, measuring the binding to FKBP12 and FRAP in the ternary complex, 
and its impact on the biological activity of rapamycin. 
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General Information and Materials 
 
Reaction glassware was dried in an oven at 120ºC and cooled in a dry atmosphere of 
nitrogen. The solvents used in reactions were dried and distilled prior to use: 
tetrahydrofuran (THF) and diethyl ether (sodium, benzophenone, under nitrogen), ethyl 
acetate (calcium chloride, under nitrogen), dichloromethane and diisopropylamine 
(calcium hydride). Petroleum ether refers to the 40-60°C boiling fraction. Non-aqueous 
reactions were carried out under an atmosphere of dry nitrogen unless otherwise stated. 
Air-sensitive reagents and solutions were transferred via syringe or cannula and were 
introduced to the apparatus through rubber septa. Thin layer chromatography was 
carried out on Merck, Kieselgel 60, F254 glass backed plates. Flash chromatography 
was carried out using Fluka silica gel-60 (35-70 mm). NMR spectra were recorded on 
Varian Unity 300 MHz (1H at 299.908 MHz, 13C at 75.45 MHz), Varian Unity 400 
MHz (1H at 299.956 MHz, 13C at 100.57 MHz) and Bruker Avance BB ATM 500 MHz 
(1H at 499.779 MHz, 13C at 125.669 MHz) machines. Samples were run in 
deuterochloroform, unless stated otherwise, with chemical shifts reported in parts per 
million quoted relative to CDCl3 at δH= 7.26, δC= 77.0. The deuterated solvent was used 
as a lock. Coupling constants are reported in hertz. Accurate electrospray ionisation 
mass spectra (HR ESI-MS) were obtained on a Finnigan MAT 900 XLT mass 
spectrometer at the EPSRC National Mass Spectrometry Service Centre, Swansea. 
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1 SYNTHESIS TOWARDS 
MONOFLUOROCYCLOHEXANECARBOXYLIC ACIDS 
4,4-DIFLUOROCYCLOHEXANECARBOXYLIC ACID AND 
3-FLUOROCYCLOHEXENECARBOXYLIC ACID. 
 
1.1 Synthesis towards 4-Fluorocyclohexanecarboxylic Acid. 
 
General procedure towards the synthesis of 4-hydroxycyclohexanone 
(2.7)(literature compound)67 
OHO
1
23
4
65
 
NaBH4 (438mg, 11.5 mmol) was added in small portions over a 5 minute period to a 
solution of 1,4-cyclohexanedione 2.6 (4 g, 35.7 mmol) in methanol (80 mL), stirred 
under nitrogen at -10°C. The solution was left to stir a further 2.5 hours at -10°C, then 
slowly neutralised with an aqueous HCl solution (15 mL, 1M). The methanol was 
evaporated in vacuo, and the remaining aqueous solution was extracted in 
dichloromethane (3×50 mL). The organic extracts were combined and washed with 
saturated NaCl solution (10 mL), dried over MgSO4, filtered and evaporated in vacuo. 
The mixture was purified by flash chromatography on silica, eluting with a mixture of 
Petroleum ether and ethyl acetate (1 : 9), to give the title compound 2.7 as a colourless 
oil (1.45 g; 12.7 mmol, 36%): δH (300MHz, CDCl3) 1.84-2.10 (m, 5H, OH, 2H3, 2H5), 
2.26-2.65 (m, 4H, 2H2, 2H6), 4.19 (tt, J = 3.2, 6.4 Hz, 1H, H4); δC (75 MHz, CDCl3) 
34.1 (C3, C5), 37.6 (C2, C6), 66.7 (C4), 211.6 (C1); MS (CI) m/z 115.1 [M+H]+; IR 
(neat film): νmax(cm-1) 3421(OH), 2942 (CH), 1716 (C=O); Rf = 0.26 (100% ethyl 
acetate)  
 
General procedure for the synthesis of 4-fluorocyclohexanone (2.8)69                                  
OF
1
23
4
65
 
Diethylaminosulphur trifluoride (DAST) (1.05 mL, 7.95 mmol) in dichloromethane 
(300 mL), cooled to –78°C was added via cannula to a solution of 4-
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hydroxycyclohexanone 2.7 (900 mg, 7.89 mmol) in dichloromethane (100 mL) 
previously cooled to -78°C and stirred under nitrogen. The solution was then placed in 
an ice bath and left to stir at 0 °C. The reaction went to completion after one hour, 
before water (100 mL) was added. The organic phase was separated, dried over MgSO4, 
filtered and the solvent removed in vacuo. The product was purified by flash 
chromatography on silica, eluting with a mixture of petroleum ether and ethyl acetate 
(9:1) to give the title compound 2.8 as a yellow transparent oil (195 mg, 1.68 mmol, 
21%): δH (300 MHz, CDCl3) 1.85-2.10 (m, 2H, H3eq, H5eq), 2.26-2.37 (m, 4H, H2ax, 
H6ax H3eq, H5eq), 2.59-2.71 (m, 2H, H2eq, H6eq) 4.99 (ttd, J = 48.5, 5.0, 2.4 Hz, 1H, 
H4); δc (75 MHz, CDCl3) 31.0 (d, J = 21.1 Hz, C3, C5), 36.2 (d, J = 4.6 Hz, C2, C6), 
87.2 (d, J = 169.6 Hz, C4), 210.0 (C1); δF (282 MHz, CDCl3) -187.0; HRMS (EI) m/z 
116.0630 (Calcd. 116.0632 for C6H9FO); IR (neat film): νmax(cm-1) 1716 (C=O); Rf = 
0.41 (60: 40 Petrol/ethyl acetate) 
 
General procedure for the synthesis of 4-fluorocyclohexancarbonitrile (2.9)73 
 
 
 
 
Tosyl methyl isocyanide (55.5 mg, 0.28 mmol) in 1, 1-dimethoxyethane (DME) (0.7 
mL) was added to 4-fluorocyclohexanone 2.8 (30 mg, 0.26 mmol) in DME (0.7 mL) 
stirring under nitrogen before cooling to 0°C. Potassium tert-butoxide (58.1 mg, 0.52 
mmol) in tert-butanol (0.8 mL) and DME (0.4 mL) was added via cannula to the 
previous cooled mixture. The reaction was left to stir for 3.5 hours at room temperature 
until completion and ether (30 mL) added. The organic phase was washed with aqueous 
NaHCO3 solution (10%, 2×10 mL), saturated aqueous NaCl solution (2×10 mL), dried 
on MgSO4, and filtered. The solvents were removed in vacuo. The crude product was 
dissolved in ether (1 mL), filtered through cotton wool and the filtrate evaporated in 
vacuo to give the partially pure title compound 2.9 (29.5 mg, 0.23 mmol, 88%) as a light 
brown oil: δH (300 MHz, CDCl3), 1.73-1.85 (m, 4H, CH2-CF-CH2), 1.90-2.05 (m, 4H, 
2H2, 2H6), 2.54-2.65 (m, 0.55 H, H1 trans, 2.72-2.82 (m, 0.45 H, H1 cis), 4.69 (dm(o), 
J = 47.9 Hz), 4.74 (dm(o), 47.9 Hz) ; δC (75 MHz, CDCl3) 24.2 (d, J = 5.3 Hz, C2, C6 
cis), 24.6 (d, J = 5.3 Hz, C2, C6 trans), 26.5 (C1 cis), 26.7 (C1 trans), 28.3 (d, J = 21.0 
Hz, C3, C5 cis), 29.1 (d, J = 21.0 Hz, C3, C5 trans), 87.6 (d, J = 171.3 Hz, C4 trans), 
88.1 (d, J = 170.5 Hz, C4 cis), 141.8 (C7 cis), 152.2 (C7, trans); δF (282 MHz, CDCl3) -
CNF
1
23
4
65
7
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182.4 (2s); MS (CI) m / z 128.0 [M+H]+; IR (neat film): νmax(cm-1) 2233 (-CN); Rf = 
0.32 (60: 40 Petrol/ethyl acetate) 
 
General procedure for the synthesis of 4-fluorocyclohexane carboxylic acid (2.1)74 
(literature compound using a different method) 
CO2HF
1
23
4
65
7
 
A solution of aqueous sodium hydroxide (1M, 3.5 mL), and ethanol (0.35 mL) were 
added to 4-fluorocyclohexancarbonitrile 2.9 (40.5 mg, 0.32 mmol) in ethanol (0.36 mL), 
and heated for 4 hours in an oil bath at 82°C. The ethanol was evaporated in vacuo. The 
aqueous phase was washed with diethyl ether (10 mL), acidified between pH 1 and 2 
using concentrated hydrochloric acid, then extracted with diethyl ether (3×10 mL). The 
organic extracts were combined, dried on sodium sulphate, filtered and evaporated to 
give a 55:45 mixture of the trans and cis isomer 2.1 (28 mg, 0.192 mmol, 60%) as a 
light brown resin: δH (300MHz, CDCl3) 1.46-2.18 (m, 8H, 2H2, 2H3, 2H5, 2H6), 2.33-
2.345 (m, 1H, H1), 4.54 (ttd, J = 48.0, 9.5, 3.8 Hz, 0.55H, H4ax), 4.78 (ttd, J = 48.0, 
4.6, 2.3 Hz, 0.45, H4eq); δC (75 MHz, CDCl3) 22.9 (d, J = 2.9 Hz, C2, C6 trans) 25.5 
(d, J
 
= 10.4 Hz, C2, C6 cis), 29.8 (d, J
 
= 21.1, Hz, C3, C5 trans), 30.9 (d, J
 
= 19.7 Hz, 
C3, C5 cis), 41.1 (C1 trans), 41.3 (C1 cis), 88.5 (d, J
 
= 169.2 Hz, C4 cis), 90.7 (d, J
 
= 
171.8 Hz, C4 trans), 181.1 (C7 cis), 181.2 (C7 trans), δF (282 MHz, CDCl3) -174.7, -
183.3; MS (ESI) m / z = 147.0 [M+H]+; IR (KBr pellet): νmax(cm-1) 2945 (OH), 1701 
(C=O). 
 
1.2 Synthesis towards 4,4-Difluorocyclohexanecarboxylic Acid. 
 
General procedure for the synthesis of 4,4-difluorocyclohexanone (2.10)75 
O
F
F 1
23
4
5 6
                                     
 
Diethyl amino sulphur trifluoride (0.1 mL, 0.76 mmol) was added to a solution of 1,4-
cyclohexanedione 2.6 (95mg, 0.85 mmol) in dichloromethane (5 mL), cooled at -78°C, 
and stirred under nitrogen. The mixture was left to warm to room temperature and 
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stirred for 24 hours. The solution was then washed with aqueous saturated NaHCO3 
solution (3×3 mL). The organic extract was dried on MgSO4, filtered, evaporated in 
vacuo and purified by flash chromatography on neutralised silica eluting with a mixture 
of petroleum ether and ethyl acetate (8 : 2), to give the title compound 2.10 as a yellow 
oil, with slight impurities (11 mg, 0.08 mmol, 10%): Rf = 0.48 (60: 40 Petrol/ethyl 
acetate); δH (300MHz, CDCl3) 2.31 (tt, J = 13.3, 7.2 Hz, 4H, H), 2.55 (t, J = 7.2 Hz, 
4H); δF (300MHz, CDCl3): -100.5 (s); m / z (relative intensity) 135.1 (M+1). 
 
General procedure for the synthesis of 4,4-difluorocyclohexancarbonitrile 2.1173                                                 
                                                       
CN
F
F 1
23
5 6
4
 
Tosyl methyl isocyanide (902 mg, 4.6 mmol) in 1, 1-dimethoxyethane (12 mL) was 
added to a solution of partially purified 4,4-difluorocyclohexanone 2.10 (902 mg, 4.6 
mmol ) in DME (12 mL) stirred under nitrogen. The mixture was then cooled at 0°C. 
Potassium tert-butoxide (1.014 g, 9 mmol) in tert-butanol (6 mL) and DME (6 mL) was 
added via cannula to the previous cooled mixture. The reaction was left to stir for 
3.5hours at room temperature and was followed by TLC (60:40 Petrol: Ethyl acetate) 
until completion. Ether (30 mL) was added. The organic extracts were combined and 
washed successively with NaHCO3 solution (10%, 2×10 mL), and with saturated NaCl 
aqueous solution (2×10 mL), then dried on MgSO4, and filtered. The solvents were 
removed under reduced pressure. The crude product was dissolved in ether (1 mL), 
filtered through cotton wool and the filtrate evaporated in vacuo to give the partially 
purified title compound 2.11 (29.5 mg, 0.23 mmol). δH (300MHz, CDCl3) 2.21-1.90 (m, 
8H, H2,3,5,6), 2.83-2.68 (m, 1H, H1) 
m / z (relative intensity) 146.2 (M+1).  
 
General procedure for the synthesis of 4,4-difluorocyclohexanecarboxylic acid 
(2.4)74                                                 
                                                     
F
F O
OH
  
A solution of aqueous sodium hydroxide (1M, 3 mL), and ethanol (0.5 mL) was added 
to a stirred solution of partially purified 4-fluorocyclohexancarbonitrile 2.11 (41.5 mg, 
0.286 mmol) in ethanol (0.5 mL) and refluxed for 3 hours in an oil bath at 88°C. The 
ethanol was removed in vacuo. The aqueous phase was washed with diethyl ether and 
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was acidified at 0°C down to pH 2 using concentrated hydrochloric acid, extracted with 
diethyl ether (3×10 mL), dried over sodium sulphate, filtered and evaporated in vacuo. 
A trace of product 2.4 was detected by GCMS. m / z (relative intensity) 163.2 (M+1). 
 
1.3 Synthesis towards 3-Fluorocyclohexenecarboxylic Acid.  
  
General procedure for the synthesis of methyl- 3-oxo-1-cyclohexene-1-carboxylate 
(2.15) (literature compound).76 
CO2Me
O
1
2
3
4
5
6
7 8
 
CrO3 (8.48 g, 84.8 mmol) was added to a stirring solution of acetic anhydride (21.2 mL) 
and glacial acetic acid (42.4 mL) at 0°C. The previous cooled mixture was added drop 
wise over a 30 minute period to a stirred solution of methyl-1-cyclohexene-1-
carboxylate 2.14 (3.9g, 3.8 mL, 27.8 mmol) in benzene (43 mL), cooled in a water bath. 
The solution was left to stir another 15 minutes. Benzene was added (50 mL), and the 
solution was neutralised with a KOH solution (5 molL-1, 85 mL). The solution was the 
poured in water (180 mL), extracted with diethyl ether (4×300 mL), the organic extracts 
combined, washed consecutively with a NaHCO3 solution (3×70 mL) and with a NaCl 
solution (70 mL), dried over MgSO4, filtered, and removed in vacuo. The product was 
purified by distillation (0.5 Tor, 55°C) to give the title compound 2.15 (2.88g, 18.6 
mmol, 67%) as a colourless oil: δH (300MHz, CDCl3) 2.01-2.10 (m, 2H, H5), 2.43-2.47 
(m, 2H, H4), 2.56-2.61 (m, 2H, H6), 3.83 (s, 3H, H8), 6.73 (bs, 1H, H2); δC (300MHz, 
CDCl3) 22.1 (C5), 24.8 (C6), 37.7 (C4), 52.6 (C8), 133.1 (C2), 148.7 (C1), 167.0 (C7), 
200.1 (C3); MS (CI) m / z 155.1 [M+H]+; IR (neat film): νmax(cm-1) 2951.32 (-OMe), 
1713.2 (C=O). 
 
General procedure for the synthesis of methyl- 3-hydroxy-1-cyclohexene-1-
carboxylate (2.16)(literature compound).77 
 
CO2Me
OH
1
2
3
4
5
6
7 8
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NaBH4 (332.5 mg, 8.8 mmol) was added to a stirred solution of methyl-3-oxo-1-
cyclohexene-1-carboxylate 2.15 (1.34g, 8.7 mmol) and CeCl3 (H2O) (3.25g, 8.7 mmol) 
in methanol (22 mL), and left to stir for 15 minutes. The solution was neutralised to pH 
7 with HCl (1molL-1), extracted with diethyl ether (3×50 mL), dried over MgSO4, 
filtered, and removed in vacuo to give the title compound 2.16 (815.5 mg, 5.2 mmol, 
60%) as a colourless oil: δH (300MHz, CDCl3) 1.61-2.88 ( m, 6H, H6, 4, 5), 3.74 (s, 3H, 
H8) 4.30-4.40 (m, 1H, H3), 6.86-6.88 (m, 1H, H2); δC (300MHz, CDCl3) 19.0 (C5), 
24.2 (C6), 31.1 (C4), 51.8 (C8), 66.0 (C3), 132.4 (C2), 139.7 (C1), 167.7 (C7); MS (CI) 
m / z 157.1 [M+H]+; IR (neat film): νmax(cm-1) 3417 (-OH), 2945.5 (-OMe), 1716.52 
(C=O)     
 
General procedure for the synthesis of methyl-3-fluoro-1-cyclohexene-1-
carboxylate (2.17)(literature compound).66 
CO2Me
F
1
2
34
5
6
7 8
 
DAST (1.15 mL, 1.4g, 8.7 mmol) was added to a solution of Methyl- 3-hydroxy-1-
cyclohexene-1-carboxylate 2.16 (1.17 g, 7.49 mmol) in DCM (220 mL) at 0°C stirring 
under nitrogen. The solution was left to stir for 3.5 hours at room temperature. Water 
(70 mL) was added to the solution, and the organic phase separated, dried over MgSO4, 
filtered, and removed in vacuo. The product was purified by flash chromatography on 
silica, eluting with DCM to give the title compound to give the title compound 2.17 
(1.13 g, 7.15 mmol, 96%) as yellow oil: δH (300MHz, CDCl3) 1.61-2.43 (m, 6H, 2H4, 
2H5, 2H6) 3.75 (s, 1H, H8), 5.13 (dm, JHF = 48 Hz, 1H, H3), 6.87-6.93 (m, 1H, H2); δC 
(300MHz, CDCl3) 164.8 (C7), 134.5 (d, J = 19.5 Hz, C1), 85.7 (d, J = 164.3 Hz, C3), 
52.0 (C8), 28.3 (d, J = 19.5 Hz, C4), 24.1 (d, J= 3.0 Hz, C6), 18.1 (d, J
 
= 4.5 Hz, C5); 
δF (282MHz, CDCl3): -168.0, -152.1; m / z 159.2 [M+H]+; IR (neat film): νmax(cm-1) 
2952 (-OMe), 1720 (C=O).     
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General procedure for the synthesis of 3-fluoro-1-cyclohexene-1-carboxylic acid 
2.3 (literature compound).66 
                                               
CO2H
F
1
2
34
5
6
7 8
          
Methyl-3-fluoro-1-cyclohexene-1-carboxylate 2.17 (65 mg, 0.41 mmol) was dissolved 
in ethanol (1 mL) and aquous NaOH solution (2 mL, 1 molL-1). The mixture was left to 
stir at room temperature for 3 hours. The aqueous phase was washed with DCM (2×10 
mL), then was acidified with an HCl solution (2 molL-1) down to pH 1, extracted with 
DCM (4×10 mL), the organic extracts were combined and dried over MgSO4, filtered, 
and removed in vacuo, to give the title compound 2.3 (47.4 mg, 0.33 mmol, 80%) as a 
yellow gel: δH (300MHz, CDCl3) 1.45-2.40 (m, 6H, H 6,4,5), 5.15 (dm, JHF = 48 Hz, 
1H, H3), 7.03 (d, J = 9 Hz, 1H, H2), 8.70 (bs, OH); δC (75 MHz, CDCl3 18.1 (d, J= 5.2 
Hz, 1C, C5), 23.8 (C6), 28.2 (d, J= 18.8 Hz, 1C, C4), 86.1 (d, JHF = 165 Hz, 1C, C3), 
136.8 (d, J= 19.5 Hz, 1C, C1), 142.0 (s, 1C, C2), 172.1 (C7); δF (282 MHz, CDCl3) -
172.5; m / z 143.1 (M-1); IR (neat film): νmax(cm-1) 2951.2 (-OH), 1695.9 (C=O). 
 
1.4 Synthesis toward 3-Fluorocyclohexanecarboxylic Acid. 
 
General procedure for the synthesis of methyl-3-fluorocyclohexanecarboxylate 
(2.18).78  
CO2Me
F
 
Hydrogen peroxide (0.4 mL, 27.5%) was added drop by drop to a solution of Methyl-3-
fluoro-1-cyclohexene-1-carboxylate 2.17 (58 mg, 0.37 mmol) in ethanol (7 mL) and 
hydrazine (0.4g, 8 mmol) monohydrate at 0°C.78 The solution was left to stir for 4 hours 
at room temperature. Water was added (2 mL). Then the product was extracted with 
diethyl ether (3×20 mL) and the organic extracts were combined and dried over 
Na2SO4, filtered, and evaporated in vacuo. Some mixture was recovered (30 mg), and a 
minor peak on the GCMS seemed to indicate the presence of product, but the 1H NMR 
spectrum did not confirm that result. 
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The experiment was repeated with methanol instead of ethanol. No title compound was 
detected, but starting material was recovered. 
It was also repeated by adding 2 drops of saturated copper sulphate solution, no title 
compound and no starting material were detected. 
 
Hydrazine (330.2 mg, 6.596 mmol) acetic acid (1 drop) and saturated copper sulphate 
solution (1 drop) were added to Methyl-3-fluoro-1-cyclohexene-1-carboxylate 2.17 
(10.4mg, 0.066 mmol) in methanol (2.7 mL). Sodium periodate solution (281.0 mg, 1.3 
mmol ) in water (2.1 mL) was added to the previous solution, drop wise over one hour, 
maintaining the temperature of the reaction at room temperature.78 The solution was 
then left to stir for 48 hours at room temperature. The methanol was evaporated in 
vacuo. The solution was extracted with ether (3×10 mL), the organic extracts were 
combined, washed with saturated NaCl solution, and dried over Na2SO4, filtered, and 
evaporated in vacuo. No title compound was detected.       
  
Acetic acid (0.14 mL) was added drop wise to a solution of methyl-3-fluoro-1-
cyclohexene-1-carboxylate 2.17 (20mg, 126.5 µmol) in DMSO (0.85 mL), and 
dipotassium azodicarboxylate (52 mg, 268 µmol) and was left to stir over night.78 The 
solution was diluted in brine (2 mL), then solution was extracted with pentane (3×5 
mL), the organic extracts were combined, dried over Na2SO4, filtered, and evaporated in 
vacuo. No title compound was detected. 
        
Acetic acid (0.04 mL, 0.715 mmol) in methanol (0.08 mL) was added drop wise over a 
period of 30 minutes to a stirred solution of methyl-3-fluoro-1-cyclohexene-1-
carboxylate 2.17 (21 mg, 0.132 mmol), and dipotassium azodicarboxylate (77 mg, 0.396 
mmol) in methanol (0.9 mL) previously cooled to 0°C.78 The reaction was left to stir 
over night. The solution was evaporated, and the residue taken up in water (2 mL) and 
extracted with DCM (3×10 mL). The organic extracts were combined, washed with 
saturated bicarbonate solution, dried over Na2SO4 and evaporated in vacuo. No title 
compound was detected.      
All four unsuccessful experiments in order to reduce the double bond were carried out 
in parallel on 3-fluoro-1-cyclohexene-1-carboxylic acid. No title compound was 
detected. 
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General procedure for the synthesis of 3-fluorocyclohexanecarboxylic acid (2.2).78  
CO2H
F
1
2
3
6
4
5
 
Hydrogen peroxide (0.2 mL, 27.5%) was added drop by drop to a solution of 3-fluoro-
1-cyclohexene-1-carboxylic acid 2.3 (27.4 mg, 0.19 mmol) in ethanol (2 mL), hydrazine 
(165.1 mg, 3.3 mmol) monohydrate and 2 drops of CuSO4 stirred at 0°C. The solution 
was left to stir for 6 hours at room temperature. Water was added (1 mL). The aquous 
phase was washed with diethyl ether (10 mL), extracted and acidified to pH 1 with HCl 
solution (2molL-1). Then the product was extracted with diethyl ether (3×10 mL) and 
the organic extracts were combined and dried over Na2SO4, filtered, and evaporated in 
vacuo. No title compound was detected 
 
Acetic acid (0.13 mL) was added drop by drop to a solution of 3-fluoro-1-cyclohexene-
1-carboxylic acid 2.3 (17 mg, 0.118 mmol) and dipotassium azodicarboxylate (50 mg, 
0.258 mmol) in DMSO (0.7 mL). The solution was left to stir for 6 hours. The solution 
was diluted in brine (2 mL), and extracted with pentane (3×5 mL), the organic extracts 
were combined, dried over Na2SO4, filtered, and evaporated in vacuo. No title 
compound was detected. 
 
Acetic acid (0.07 mL, 1.251 mmol) in methanol (0.2 mL) was added drop wise over a 
period of 30 minutes to a stirred solution of 3-fluoro-1-cyclohexene-1-carboxylic acid 
2.3 (25 mg, 0.173 mmol), and dipotassium azodicarboxylate ( 0.101 mg, 0.521 mmol) 
in methanol (0.5 mL) previously cooled to 0°C. The reaction was left to stir over night. 
The solution was evaporated, and the residue taken up in water (2 mL), and extracted 
with DCM (3×5 mL). The organic extracts were combined, washed with saturated 
bicarbonate solution, dried and evaporated in vacuo. No title compound was detected.    
 
General procedure for the synthesis of (3-fluoro-cyclohexyl)-methanol (2.19)  
F
HO
 
Methyl-3-fluoro-1-cyclohexene-1-carboxylate 2.17 (96 mg, 0.600 mmol) in THF (0.8 
mL) was added to a solution of AlLiH4 (34 mg, 0.897 mmol) in THF (1.5 mL) at 0°C 
stirred under nitrogen. The reaction was left to stir for 4.5 hours at 0°C. Water (34µL), 
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sodium hydroxide solution (34 µL, 15%), and extra water (102 µL) were added 
successively. The mixture was passed through a filtering funnel, and was washed with 
ether. The filtered solution was then evaporated in vacuo, and purified by flash 
chromatography on silica, eluting with DCM. No title compound was detected.    
 
General procedure for the synthesis of 1,4-dioxa-spiro[4.5]decan-7-one 
(2.21)(literature compound).79 
 
 
 
 
 
p-Toluene sulfonic acid (150 mg, ) was added to a solution of ethylene glycol (8.8g, 142 
mmol) and cyclohexane-1,3-dione 2.20 (15g, 134 mmol) in benzene(134 mL). The 
solution was stirred and refluxed for 3.5 hours. The organic solution was left to cool 
down, and was washed with NaHCO3 solution (8%, 40 mL). The NaHCO3 solution was 
then extracted with benzene (3×40 mL). The organic extracts were combined and added 
to the previous, and dried over MgSO4, filtered, evaporated in vacuo and purified by 
flash chromatography on silica eluting with a mixture of petrol and ethyl acetate (70:30) 
to give the title compound 2.21 as a yellow oil (6.1g, 39.1 mmol, 29%). δH (300MHz, 
CDCl3 ) 1.83-1.97 (m, 4H, H9, H10), 2.31-2.35 (m, 2H, H8), 2.59 (s, 2H, H6), 3.93-
3.99 (m, 4H, H2, H3); MS (CI) m/z 157.1 (M+1);  
 
General procedure for the synthesis of 3-hydroxy-cyclohexanone (2.22)(literature 
compound).67 
O
3
4
5
6
OH
1
2
 
NaBH4 (400mg, 10.6 mmol) was added in 4 portions during 5 minutes to 1,4-dioxa-
spiro[4.5]decan-7-one 2.21 (5.9g, 37.8 mmol) in MeOH (82 mL), cooled at –10°C 
stirred under nitrogen and was left to stir 1 hour at 0 °C. HCl solution (1 molL-1, 10 mL) 
was then slowly added to the mixture, to neutralise the solution. The solution was then 
evaporated in vacuo, until all the methanol was evaporated, water was added (10 mL) 
and was extracted with ethyl acetate (3× 30 mL). The organic extracts were combined, 
washed with saturated NaCl solution (2× 30 mL), dried over MgSO4, filtered, 
O
O
O
2
3
4
5
6
1
78
9
10
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evaporated in vacuo and purified by flash chromatography on silica eluting with a 
mixture of petroleum ether and ethyl acetate (55:45) to give the title compound 2.22 as a 
colourless oil (1.05g, 9.2 mmol, 24%): δH (300MHz, CDCl3 ) 1.63-1.83 (m, 3H, H4, 
2H5), 1.98-2.13 (m, 2H, H4, OH), 2.32 (t, J= 6.5 Hz, 2H, H6), 2.41 (dd, J= 14.2, 7.7 
Hz, 1H, H2), 2.67 (dd, J = 14.5, 4.2 Hz, 1H, H2), 4.19 (tt, J = 7.5, 3.6 Hz, 1H, H3); MS 
(CI) m/z 114.1 [M]; 
 
 
General procedure for the synthesis of 3-fluoro-cyclohexanone (2.23).69 
O
F
1
2
3
4
5
6
 
Diethyl amino sulphur trifluoride (0.12 mL, 0.91 mmol) was added to a solution of 3-
hydroxycyclohexanone 2.22 (100mg, 0.88 mmol) in dichloromethane (35 mL) cooled at 
-78°C stirred under nitrogen. The mixture was then stirred at 0°C for 4 hours. Water (20 
mL) was carefully added. The organic phase was extracted, washed with water (20 mL), 
dried over MgSO4, filtered, evaporated in vacuo, and purified by flash chromatography 
on silica eluting with a mixture of petrol and ethyl acetate (95:5) to give the title 
compound 2.23 as a colourless oil (15 mg, 0.13 mmol, 15%); δH (300MHz, CDCl3 ) 
1.76-1.88 (m, 1H, H5), 1.91-2.14 (m, 3H, 2H4, H5), 2.28-2.47 (m, 2H, H6), 2.54-2.74 
(m, 2H, H2), 5.06 (dm, J = 49.7 Hz, 1H, H3); HRMS (EI) m/z 116.0630 (Calcd. 
116.0632 for C6H9FO);  
 
General procedure for the synthesis of 3-fluorocyclohexanecarbonitrile (2.24).73 
CN
F
1 2
3
4
5
6
7
 
Tosyl methyl isocyanide (392 mg, 1.98 mmol) in 1, 1-dimethoxyethane (DME) (3.3 
mL) was added to 3-fluorocyclohexanone 2.23 (205 mg, 1.77 mmol) in DME (3.3 mL) 
stirring under nitrogen before cooling to 0°C. Potassium tert-butoxide (410 mg, 3.67 
mmol) in tert-butanol (2.9 mL) and DME (2.9 mL) was added via cannula to the 
previous cooled mixture. The reaction was left to stir for 1.5 hours at room temperature 
until completion and ether (200 mL) added. The organic phase was washed with 
aqueous NaHCO3 solution (10%, 2×50 mL), saturated aqueous NaCl solution (2×50 
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mL), dried over MgSO4, and filtered. The solvents were removed in vacuo. The crude 
product was dissolved in petroleum ether (1 mL), filtered through cotton wool and the 
filtrate evaporated in vacuo to give the partially purified mixture of the cis and trans 
title compound 2.24 (73 mg, 0.57 mmol, 32%) as a light brown oil: 
δH (400MHz, CD3OD) 1.77-1.98 (m, 7H, H2, 2H4, 2H5, 2H6), 2.10-2.30 (m, 1H, H2), 
2.81 (tt, J = 9.44, 3.65 Hz, 0.52 H, H1trans), 2.99 (tt, J = 9.59, 3.71 Hz, 1H, 0.48 
H 1cis), 4.56 (ttd, J = 47.7, 7.70, 3.82 Hz, 0.48H, H3cis), 4.84 (ttd, J = 47.3, 5.2, 2.6 Hz, 
0.52 H, H3trans); δC (75 MHz, CD3OD) 20.4 (d, J = 4.2 Hz, C5trans), 21.6 (d, J = 9.2 
Hz, C1trans), 25.1 (d, J = 4.6 Hz, C5cis), 26.3 (d, J = 10.0 Hz, C1cis), 29.5 (d, J = 1.4 
Hz, C6cis), 29.6 (C6trans), 30.9 (d, J = 20.6 Hz, C2trans), 32.1 (d, J = 19.4 Hz, C2cis), 
34.9 (d, J = 21.4 Hz, C4trans), 35.5 (d, J = 21.5 Hz, C4cis), 88.7 (d, J = 170.2 Hz, 
C3trans), 90.0 (d, J = 172.6 Hz, C3cis), 123.0 (C7cis), 123.4 (C7trans); δF (282 MHz, 
CDCl3) -183.9, -173.3; HRMS (ESI) m / z 145.1137 [M+NH4]+ (Calcd. 145.1136 for 
C7H10FN+NH4+); IR (neat film): νmax(cm-1) 2241 (-CN).   
 
General procedure for the synthesis of 3-fluorocyclohexanecarboxylic acid (2.2).74  
COOH
F
1 2
3
4
5
6
7
 
A solution of aqueous sodium hydroxide (1M, 5.2 mL), and ethanol (0.52 mL) was 
added to 3-fluorocyclohexancarbonitrile 2.24 (73 mg, 0.57 mmol) in ethanol (0.64 mL), 
and heated for 3 hours in an oil bath at 82°C. The ethanol was evaporated in vacuo. The 
aqueous phase was washed with diethyl ether (10 mL), acidified to between pH 1 and 2 
using concentrated hydrochloric acid, extracted with diethyl ether (3×10 mL), the 
organic extracts combined, dried on sodium sulphate, filtered and evaporated to give a 6 
to 4 mixture of the trans and cis isomer of the title compound 2.2 (43 mg, 0.29 mmol, 
52%) as a yellow oil: δH (400MHz, CD3OD) 1.27-1.42 (m, 2H, H5), 1.44-1.55 (m, 1H, 
H4), 1.56-1.81 (m, 1H, H6), 1.83-1.96 (m, 2H, H2, H4), 1.99-2.17 (m, 1H, H6), 2.24-
2.40 (m, 1.52H, H2, 0.52H1), 2.65 (tt, J = 11.4, 3.7 Hz, 0.48 H, H1cis), 4.49 (ttd, J = 
48.2, 10.4, 4.8 Hz, 0.48 H, H3cis), 4.87 (dm, J = 48.0 Hz, 0.52 H, H3trans); δC (75 
MHz, CDCl3) 19.4 (s, J = 10.1 Hz, C5trans), 22.2 (d, J = 11.4 Hz, C5cis), 27.4 
(C6trans), 27.8 (C6cis), 30.1 (d, J = 21.3 Hz, C2trans), 31.9 (d, J = 18.3 Hz, C2cis), 
32.7 (d, J = 20.9 Hz, C4cis), 34.5 (d, J = 20.9 Hz, C4trans), 37.5 (d, J = 11.1 Hz, 
C1cis), 40.8 (d, J = 11.0 Hz, C1trans), 88.3 (d, J = 168.8 Hz, C3cis), 90.9 (d, J = 173.3 
Hz, C3trans), 180.3 (C7cis), 181.5 (C7trans); δF (282 MHz, CDCl3) -183.6, -170.4 (d, J 
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= 47.9 Hz); HRMS (CI)(negative) m / z 145.0668 [M-H]- (Calcd. 145.0670 for 
C7H11O2F-H); IR (neat film): νmax(cm-1) 2943 (OH), 1703 (C=O).  
 
1.5 Synthesis toward 2-Fluorocyclohexanecarboxylic Acid. 
 
General procedure for the synthesis of 2-hydroxycyclohexanone (2.26)(literature 
procedure).80  
O
3
4
5
6 1 2
OH
 
A mixture of potassium permanganate (8 g, 50.6 mmol), copper sulphate pentahydrate 
(4 g, 9.2 mmol), tert-butanol (2 mL) cyclohexene 2.28 (493 mg, 6 mmol) was stirred for 
16 hours. The solution was filtered, removed in vacuo to give the title compound 2.26 as 
a colourless oil (146 mg, 1.28 mmol, 21%): δH(400 MHz, CD3OD) 1.66-2.15 (m, 6H), 
2.31-2.40 (m, 2H), 2.79 (d, J = 1.1 Hz), 4.36 (ddd, 1H, J = 8.7, 5.2, 1.1 Hz); δC (75 
MHz, CD3OD) 25.5 (C4), 29.5 (C5), 38.7 (C3), 41.8 (C5), 77.4 (C2), 213.9 (C1). 
 
 
 
General procedure for the synthesis of 2-fluorocyclohexanone (2.30)(literature 
compound)81 
O
3
4
5
6 1 2
F
 
Selectfluor (1.895g, 5.35 mmol) was added to cyclohexanone 2.29 (500 mg, 5.1 mmol) 
in methanol (50 mL) and refluxed for 3.5 hours. The methanol was removed in vacuo, 
DCM (20 mL) was added, filtered, removed in vacuo to give the title compound 2.30 as 
a transparent oil (465 mg, 4.01 mmol, 78%): δH (400 MHz, CDCl3)1.28-2.03 (m, 8H), 
4.63 (dm, J = 49.0 Hz, 1H, H2) 
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2 SYNTHESIS OF THE FLUOROHYDRIN 
CYCLOHEXANECARBOXYLIC METHYL AND ETHYL 
ESTERS.  
 
2.1 Synthesis towards 3-Hydroxy-4-fluorocyclohexane 
carboxylic Methyl Ester. 
 
General procedure for the synthesis of cyclohex-3-enecarboxylic acid 
(2.37)(literature compound).82 
OHO
1
2
  3
 4
5
 6
7
 
NaOH (3.9 g, 97.5 mmol) was added to a solution of Ag2O (4.6 g, 19.9 mmol) in water 
(23 mL). Cyclohex-3-enecarbaldehyde 2.36 (2.16 g, 19.6 mmol) was added in 2 
portions, to the previous solution maintained at room temperature, in a water bath and 
left to stir for 80 minutes. The solution was then filtered through a Buckner funnel. The 
aqueous solution was washed with ether (2×30 mL), then was acidified with an HCl 
solution (2 molL-1) down to pH 1 and extracted with diethyl ether (3×50 mL). The 
organic extracts were combined and dried over MgSO4, filtered and evaporated in 
vacuo. The product was purified by distillation to give the title compound 2.37 (2.06 g, 
16.34 mmol, 83%) as a transparent oil: δH (300MHz, CDCl3) 1.64-1.77 ( m, 1H, H6), 
1.99-2.15 (m, 3H, 2H5, H6), 2.25-2.30 (m, 2H, 2H2), 2.55-2.65 (m, 1H, H1), 5.64-5.73 
(m, 2H, H3, H4), 10.76 (bs, 1H, OH); δC (300MHz, CDCl3) 24.3 (C5), 24.8 (C6), 27.1 
(C2), 39.1 (C1), 124.9 (C4), 126.7 (C3), 182.6 (C7); MS(EI) m / z 127.1 (M+1); IR 
(neat film): νmax(cm-1) 2953.5 (-OH), 1713.6 (C=O). 
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General procedure for the synthesis of (1R*, 4R*, 5R*)-4-iodo-6-oxa-
bicyclo[3.2.1]octan-7-one (2.38)(literature procedure).83  
O
O
I
1
2
3
4
5
6
7
 
Cyclohex-3-enecarboxylic acid 2.37 (10 g, 79.3 mmol) was added to a solution of 
NaHCO3 in water (425 mL, 0.5molL-1). A solution of iodine (37 g, 145.7 mmol) and 
potassium iodide (71g, 427.7 mmol) in water (995 mL) was then added to the previous 
solution and left to stir over night at room temperature. Water (400 mL) and saturated 
Na2S2O3 solution was added until the solution colour turned white and all the iodine was 
neutralised (500 mL), then extracted with DCM (4×1L). The organic extracts were 
combined and washed with NaHCO3 saturated solution, dried over Na2SO4, filtered, and 
evaporated in vacuo to give the title compound 2.38 (19.2g, 96%) as a light yellow 
powder: δH (300MHz, CDCl3) 1.79-1.96 (m, 2H, H6), 2.07-2.16 (m, 1H, H5), 2.34- 2.50 
(m, 2H, H3 and H5), 2.66-2.70 (m, 1H, H1), 2.77-2.81 (d, J = 12.3 Hz, 1H, H2), 4.48-
4.52 (m, 1H, H4), 4.80-4.84 (t, J = 5.7 Hz, 1H, H3); δC (75 MHz, CDCl3) 22.9 (C6), 
23.7 (C4), 29.5 (C5), 34.3 (C2), 38.4 (C1), 80.0 (C3), 177.7 (C7); MS (CI) m/z 253.1 
[M+H]+; IR (KBr pellet): νmax(cm-1) 2926 (-O-), 1706 (C=0). 
 
General procedure for the synthesis of 7-oxa-bicyclo[4.1.0]heptane-3-carboxylic 
acid methyl ester (2.39)(literature compound).83  
OO
O
1
24
5
6
7
8
3
 
8-Iodo-2-oxa-bicyclo[3.3.1]nonan-4-one 2.38 (4g, 15.9 mmol) in THF (179 mL) was 
added to a solution of NaOMe (1 g, 18.6 mmol) in Methanol (179 mL) at 0°C stirring 
under nitrogen, and was left to stir over night at room temperature. Phosphate ph 7 
buffer was added after evaporating the methanol and the THF in vacuo until the pH was 
close to 7 (300 mL), then extracted with diethyl ether. The organic extracts were 
combined and washed with water and NaCl saturated solution, dried over Na2SO4, 
filtered, and evaporated in vacuo and purified by flash chromatography on silica eluting 
with a mixture of petroleum ether and ethyl acetate (9 : 1), to give the title compound 
2.39 as a colourless oil ( 0.997g, 6.4 mmol, 40%): δH (300MHz, CDCl3) 1.52-1.63 (m, 
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2H, H4), 1.69-1.79 (m, 1H, H5), 2.12-2.25 (m, 4H, H3, 2H2, H5), 3.12 (bs, 2H, H1, 
H6), 3.62 (s, 3H, H8); δC (75MHz, CDCl3) 20.9 (C4), 23.9 (C2), 26.2 (C5), 37.7 (C3), 
50.6 (C6), 51.7 (C1), 51.7 (C8), 175.2 (C7); m / z (relative intensity) 157.2 (M+1); IR 
(neat film): νmax(cm-1) 2953.3 (C=O), 1732.4 (-OMe). 
 
General procedure for the synthesis of (1R*, 3S*, 4S*)-methyl 3-fluoro-4-
hydroxycyclohexanecarboxylate84 (2.40) 
OO
OH
F
1
2
3
4
5
6
OO
F
OH
   Major                             minor
7
8
2.40                                2.41
 
7-Oxa-bicyclo[4.1.0]heptane-3-carboxylic acid methyl ester 2.39 ( 470 mg, 3.01 mmol) 
was added to triethylamine trihydrofluoride (4 mL) and was left to stir for 20 hours 
under nitrogen. NaHCO3 saturated solution was added until all the HF was neutralised 
(10 mL) and extracted with ethyl acetate (3×20 mL). The organic extracts were 
combined and washed with NaHCO3 saturated solution (50 mL) and NaCl saturated 
solution (50 mL), dried over Na2SO4, filtered, and evaporated in vacuo, to give a 4 : 1 
mixture of the title compound 2.40, and the isomer 2.41 as a colourless oil ( 402 mg, 
2.28 mmol, 76%). The mixture was purified by flash chromatography on silica eluting 
with a mixture of DCM and ethyl acetate (95: 5), to give the title compound 2.40 as a 
colourless oil (70 mg, 0.40 mmol, 13%): δH (300MHz, CDCl3) 1.49-1.69 (m, 2H, H5, 
H6), 1.74-2.03 (m, 3H, H2, H5, H6), 2.09 (bs, 1H, OH), 2.24-2.40 ( m, 1H, H2), 2.72-
2.79 (m, 1H, H1), 3.73-3.83 (m, 1H, H4), 3.69 (s, 3H, H8), 4.59 ( dddd, J = 49.1, 8.3, 
6.9, 3.9, 1H, H3); δC (300MHz, CDCl3) 23.8 (d, J = 1.3 Hz, C6), 28.0 (d, J = 4.1 Hz, 
C5), 29.9 (d, J = 19.9 Hz, C2), 38.3 (d, J = 7.4 Hz, C1), 51.9 (C8), 70.1 (d, J = 21.8 Hz, 
C4), 92.1 (d, J = 172.0 Hz, C3), 174.7 (C7); δF (282 MHz, CDCl3) 186.5 (d, J = 48.3 
Hz); HRMS (CI) m / z 177.0927 [M+H]+ (Calcd. 177.0927 for C18H13FO3+H+ ); IR 
(neat film): νmax(cm-1) 3603.5(-OH), 2951.5(-OMe), 1731.06 (C=O).  
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2.2 Synthesis towards Fluorohydrincyclohexanecarboxylic 
Ethyl Esters and Derivatives. 
 
General procedure for the synthesis of (1R*, 3R*, 6S*)-ethyl-7-oxa-
bicyclo[4.1.0]heptane-3-carboxylate (2.45) and (1R*, 3S*, 6S*)-ethyl-7-oxa-
bicyclo[4.1.0]heptane-3-carboxylate (2.46)83 
(1R*, 4R*, 5R*)-4-iodo-6-oxa-bicyclo[3.2.1]octan-7-one 2.38 (20 g, 79.3 mmol) in 
THF (810 mL) was added via cannula to a solution of Na (2.3 g, 100 mmol) in ethanol 
(890 mL) at 0°C stirring under nitrogen, and was left to stir over night at room 
temperature. Phosphate buffer (pH 7) was added after evaporating the methanol in 
vacuo until the pH gets close to 7 and then extracted with diethyl ether. The organic 
extracts were combined and washed with water and NaCl saturated solution, dried over 
Na2SO4, filtered, and evaporated in vacuo and purified by flash chromatography on 
silica eluting with a mixture of petroleum ether and ethyl acetate (9 : 1), to give the title 
compound 2.45 as a colourless oil (6.5g, 48%), and the title compound 2.46 as a 
colourless oil (0.948 g, 7%).  
OO
O
1
2
3
4
5
6
789
 
          2.45 
2.45: δH (300 MHz, CDCl3) 1.24 (t, J = 7.1 Hz, 3H, H9), 1.53-1.67 (m, 2H, H4, H4), 
1.70-1.84 (m, 1H, H2), 2.11-2.25 (m, 4H, H3, H2, H5, H5), 3.15-3.18 (m, 2H, H1, H6), 
4.11 (q, J = 7.1 Hz, 2H, H8); δC (75 MHz, CDCl3) 14.1 (C9), 20.9 (C4), 24.0 (C2), 26.1 
(C5), 37.9 (C3), 50.7 (C6), 51.7 (C1), 60.4 (C8), 175.0 (C7); MS (CI) m/z 171.2 
[M+H]+; IR (neat film): νmax(cm-1) 2987 (-OEt), 1727 (C=O). 
OO
1
2
3
4
5
6
789
O
 
          2.46 
2.46: δH (400 MHz, CDCl3) 1.24 (t, J = 7.1 Hz, 3H, H9), 1.36-1.46 (m, 1H, H4), 1.72-
1.80 (m, 1H, H4), 1.90-1.99 (m, 3H, H5, H5, H2), 2.24-2.29 (m, 1H, H2), 2.45-2.54 (m, 
1H, H3), 3.13-3.15 (m, 1H, H6), 3.22-3.24 (m, 1H, H1), 4.12 (q, J = 7.1 Hz, 2H, H8); 
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δC (75 MHz, CDCl3) 14.1 (C9), 22.6 (C4), 22.7 (C5), 27.0 (C2), 35.7 (C3), 51.3 (C6), 
52.1 (C1), 60.3 (C8), 175.6 (C7); HRMS (EI) m/z 170.0936 [M]+. (Calcd. for C9H14O3 
170.0943); IR (neat film): νmax(cm-1) 2981 (-OEt), 1728 (C=O). 
 
General procedure for the synthesis of (1S*, 3R*, 4R*)-ethyl-3-fluoro-4-
(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate (2.52) and (1S*, 3S*, 4S*)-
ethyl-4-fluoro-3-(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate (2.53)84, 86 
(1R*, 3R*, 6S*)-ethyl-7-oxa-bicyclo[4.1.0]heptane-3-carboxylate 2.45 (6 g, 35.3 mmol) 
was added to triethylamine hydrofluoride (18 mL) and was stirring for 40 hours under 
nitrogen. NaHCO3 saturated solution was added until all the HF was neutralised then 
extracted in ethyl acetate.84 The organic extracts were combined and washed with 
NaHCO3 saturated solution and NaCl saturated solution, dried over Na2SO4, filtered, 
evaporated in vacuo, purified by flash chromatography on silica eluting with a mixture 
of DCM and ethyl acetate (90:10), to give a 4 : 1 mixture of the (1S*, 3R*, 4R*)-ethyl 
3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 and (1R*, 3R*, 4R*)-ethyl 4-fluoro-3-
hydroxycyclohexanecarboxylate 2.47 as a colourless oil (5.1 g, 26.8 mmol, 76% 
isolated).  
Sulfamic acid (731 mg, 7.5 mmol) was added to a solution of a 4:1 mixture of (1S*, 
3R*, 4R*)-ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 and (1R*, 3R*, 4R*)-
ethyl 4-fluoro-3-hydroxycyclohexanecarboxylate 2.47 (5.1 g, 26.8 mmol) in 3, 4-
dihydro-2H-pyran (9 mL, 8 g, 95.1 mmol), and left to stir under nitrogen for 4 days. The 
excess 3,4-dihydro-2H-pyran was evaporated in vacuo, diethyl ether was added and the 
solution was filtered, evaporated in vacuo and purified by flash chromatography on 
silica eluting to start with a 100% DCM and then a mixture of DCM and ethyl acetate 
(98:2) to give (1S*, 3R*, 4R*)-ethyl 3-fluoro-4-(tetrahydro-2H-pyran-2-
yloxy)cyclohexanecarboxylate 2.52 as the major product, as a yellow oil (3.81 g, 13.9 
mmol, 52%), and (1S*, 3S*, 4S*)-ethyl 4-fluoro-3-(tetrahydro-2H-pyran-2-
yloxy)cyclohexanecarboxylate 2.53 as the minor product as a yellow oil (1.07 g, 3.9 
mmol, 15% ) and starting material (1.23 g, 6.5 mmol, 24%) was recovered. 
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General procedure for the synthesis of (1S*, 3R*, 4R*)-ethyl-3-fluoro-4-
(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate (2.52): Reported as two 
diastereomeric compounds 2.52a and 2.52b. 
O
F
O
1
2
34
5
6
7 8
9
10
11
12
13
14O O
 
2.52 
2.52a: δH (400 MHz, CDCl3) 1.19 (t, J = 7.1, 3H, H8), 1.42-1.54 (m, 4H, H5, H10, H10, 
H12), 1.61-1.69 (m, 3H, H5, H6, H11), 1.70-1.90 (m, 4H, H2, H2, H6, H12), 2.03- 2.18 
(m, 1H, H2), 2.57-2.64 (m, H1), 3.41-3.46 (m, 1H, H13), 3.60-3.76 (m, 1H, H4), 3.80- 
3.85 (m, 1H, H13), 4.10 (q, J = 7.1 Hz, 2H, H7), 4.58 (dddd, J = 47.9, 6.0, 6.0, 3.4 Hz, 
1H, H3), 4.66-4.68 (m, 1H, H9); δC (100 MHz, CDCl3) 14.1 (C8), 19.4 (C12), 23.7 
(C11), 25.3 (C10), 27.1 (C6), 29.7 (d, J = 19.9 Hz, 1C, C2), 30.9 (C5), 37.6 (C1), 60.4 
(C7), 62.5 (C13), 73.2 (d, J = 22.9 Hz, 1C, C4), 89.9 (d, J = 173.3 Hz, 1C, C3), 99.1 
(C9), 174.6 (C14): δF (282 MHz, CDCl3) -186.83 (d, J = 50.8 Hz).  
2.52b: δH (400 MHz, CDCl3) 1.24 (t, J = 7.1, 3H, H8), 1.47-1.59 (m, 4H, H5, H10, 
H10, H12), 1.66-1.76 (m, 6H, H5, H6, H6, H11, H11, H12), 2.10-2.16 (m, 2H, H2), 
2.60-2.67 (m, 1H, H1), 3.45-3.50 (m, 1H, H13), 3.81- 3.88 (m, 2H, H13, H4), 4.11 (q, J 
= 7.1 Hz, 2H, H7), 4.67-4.70 (m(o), 1H, H9), 4.76 (dddd(o), J = 47.2, 4.8, 4.8, 2.7 Hz, 
1H, H3); δC (100 MHz, CDCl3) 14.2 (C8), 19.4 (C12), 22.8 (C11), 24.4 (C6), 25.3 
(C10), 29.3 (d, J = 19.9 Hz, 1C, C2), 30.9 (C5), 37.3 (C1), 60.4 (C7), 62.4 (C13), 70.8 
(d, J = 26.4 Hz, 1C, C4), 89.3 (d, J = 171.4 Hz, 1C, C3), 96.6 (C9),175.0 (C14); δF (282 
MHz, CDCl3) -186.45 (t, J = 46.0 Hz,1C); HRMS (CI) m/z 275.1658 [M+H]+ (Calcd. 
for C14H23FO4+H+ 275.1659); IR (neat film): νmax(cm-1) 2943 (-OEt), 1732 (C=O). 
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General procedure for the synthesis of (1S*, 3S*, 4S*)-ethyl-4-fluoro-3-
(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate (2.53).  
F
O
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2.53 
2.53: δH (300MHz, CDCl3) 1.23-1.29 (t(o), J = 7.1 Hz, 3H, H8), 1.44-1.63 (m, 7H), 
1.72-1.87 (m, 2H), 1.96-2.04 (m, 1H) 2.13-2.44 (m, 3H), 3.47-3.54 (m, 1H), 3.64-4.03 
(m, 2H), 4.12 (q, J = 7.1 Hz, 2H), 4.54-4.24 (m, 1H), 4.80-4.96 (m, 1H); δC (100 MHz, 
CDCl3) 14.0, 19.4, 19.5, 22.1, 23.6, 25.3, 25.8, 29.6 (d, J = 18.9 Hz), 30.0, 30.5, 30.6, 
33.9 (d, J = 8.4 Hz), 41.1(d, J = 1.8 Hz), 60.5, 61.5, 62.6, 62.8, 73.8 (d, J = 18.2 Hz), 
77.1 (d, J = 16.4 Hz), 95.1 (d, J = 177.7 Hz), 100.0 (d, J = 3.1 Hz), 174.1; δF (282 MHz, 
CDCl3) -182.1 (d, J = 50.9 Hz), -182.6 (d, J = 50.8 Hz); HRMS (CI) m/z 275.1658 
[M+H]+ (Calcd. for C14H23FO4+H+ 275.1659); IR (neat film): νmax(cm-1) 2944 (-OEt), 
1732 (C=O). 
 
General procedure for the synthesis of (1R*, 3R*, 4R*)-ethyl-4-fluoro-3-
hydroxycyclohexanecarboxylate (2.47)87 
OO
OH
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2
34
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     2.47 
p-Tosyl sulfonic acid was added in catalytic amount to the solution of (1S*, 3S*, 4S*)-
ethyl-4-fluoro-3-(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate 2.53 (280 mg, 
1.02 mmol) in ethanol (6 mL) and was left to stir for 2 hours. NaHCO3 saturated 
solution was added (10 mL) to quench the ethanol was then evaporated in vacuo. The 
solution was extracted with ethyl acetate (3×20 mL) and the organic extracts were 
combined and washed with NaHCO3 saturated solution and NaCl saturated solution, 
dried over Na2SO4, filtered, evaporated in vacuo and purified by flash chromatography 
on silica eluting with a mixture of DCM and ethyl acetate (90: 10) to give 2.47 as a 
colourless oil (147 mg, 0.77 mmol, 76%).  
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δH (400MHz, CDCl3) 1.25 (t, 3H, J = 7.1, H9), 1.49-1.61 (m, 3H, H2, H5, H6), 1.99-
2.10 (m, 1H, H6), 2.10-2.20 (m, 1H, H5), 2.22-2.28 (m, 1H, H2), 2.42 (dddd, 1H, H1, J 
= 11.7, 11.7, 3.8, 3.8 Hz), 3.71 (dddd, J = 11.1, 11.1, 8.3, 4.9 Hz, 1H, H3), 4.13 (q, J = 
7.1 Hz, 2H, H8), 4.31 (dddd, J = 50.9, 10.4, 8.3, 5.0 Hz 1 H, H4); δC (75 MHz, CDCl3) 
14.0 (C9), 25.8 (d, J = 11.2 Hz, 1C, C6), 28.5 (d, J = 18.7 Hz, 1C, C5), 33.5 (d, J = 7.2 
Hz, 1C, C2), 40.7 (C1), 60.7 (C8), 71.9 (d, J = 19.2 Hz, 1C, C3), 95.6 (d, J = 174.6 Hz, 
1C, C4), 174.3 (C9); δF (282 MHz, CDCl3) -186.55; HRMS (ESI) m/z 191.1080 
[M+H]+ (Calcd. For C9H15FO3+H+ 191.1083); IR (neat film): νmax(cm-1) 3446.9 (-
OH), 2943.1 (-OEt), 1734.2 (C=O). 
 
General procedure for the synthesis of (1R*, 2R*, 5R*)-5-(ethoxycarbonyl)-2-
fluorocyclohexyl 4-nitrobenzoate (2.54)85 
F
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4-Nitro-benzoyl chloride (67 mg, 0.36 mmol) was added to 4-fluoro-3-hydroxy-
cyclohexanecarboxylic acid ethyl ester 2.47 (46 mg, 0.24 mmol) in pyridine (3 mL) 
under nitrogen and left to stir for 2 days. Water (15 mL) was added, and the solution 
was extracted with ethyl acetate (3×20 mL). The organic extracts were combined and 
successively washed with oxalic acid solution (10%, 20 mL), cold NaHCO3 solution 
(10%, 20 mL), and water (3× 20 mL) and dried over MgSO4, filtered, evaporated in 
vacuo and purified by flash chromatography on silica eluting with a mixture of petrol 
and ethyl acetate ( 95:5) to give the title compound 2.54 as a colourless oil (52 mg, 0.15 
mmol, 63%): δH (400MHz, CDCl3) 1.22 (t, J = 7.1 Hz, 3H, H9), 1.60-1.79 (m, 3H, H3, 
H4, H6), 2.10-2.18 (m, 1H, H3), 2.30-2.36 (m, 1H, H4), 2.43-2.59 (m, 2H, H5, H6), 
4.10 (q, J = 7.11 Hz, 1H, H8), 4.67 (dddd, J = 50.4, 10.4, 8.9, 5.0 Hz, 1H, H2), 5.20 
(dddd, J = 19.6, 11.0, 5.0, 2.2 Hz, 1H, H1), 8.23 (d, J = 9.2 Hz, 2H, H13, H15), 8.30 (d, 
J = 8.4 Hz, 2H, H12, H16); δc (75 MHz, CDCl3) 14.0 (C9), 25.6 (d, J = 10.8 Hz, C3), 
29.3 (s, 1C, C4), 31.5 (s, J = 6.3 Hz, 1C, C6), 40.3 (d, 1C, C5), 60.8 (s, 1C, C8), 74.7 (d, 
J = 18.7 Hz, C1), 91.4 (d, J = 179.9 Hz, 1C, C2), 123.6 (s, 2C, C13, C15), 130.9 (s, 2C, 
C12, C16), 135.4 (C11), 150.8 (C14), 164.1 (C10), 173.5 (C7); δF (300MHz, CDCl3) 
184.9 (d, J = 53.6 Hz); HRMS (ESI) m / z 357.1452 [M+NH4]+ (Calcd. 357.1456 for 
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C16H18FO6+NH4+); IR (neat film): νmax(cm-1) 2955.6 (-OEt), 2874.4 (-OR), 1722.1 
(C=O), 1526.0 (C-NO2), 1347.6 (C-NO2), 1607.5, 1526.0, 872.4 (aromatic). 
 
 
General procedure for the synthesis of (1R*, 3S*, 4S*)-ethyl-4-fluoro-3-
hydroxycyclohexanecarboxylate (2.49)84 
OO
OH
F
1
2
34
5
6
789
 
     
(1R*, 3S*, 6S*)-ethyl-7-oxa-bicyclo[4.1.0]heptane-3-carboxylate 2.46 (175 mg, 1.03 
mmol) was added to triethylamine trihydrofluoride84 (1.5 mL) and was left to stir for 16 
hours under nitrogen. NaHCO3 saturated solution was added until all the HF was 
neutralised and extracted in ethyl acetate. The organic extracts were combined and 
washed with NaHCO3 saturated solution and NaCl saturated solution, dried over 
Na2SO4, filtered, and evaporated in vacuo. The mixture was purified by flash 
chromatography on silica eluting with a mixture of DCM and ethyl acetate (90:10), to 
give the title compound 2.49 as a colourless oil (148 mg, 76%). 
δH (400 MHz, CDCl3 ) 1.26 (t, J = 7.2 Hz, 3H, H9), 1.60-1.76 (m, 3H, H2, H5, H6), 
1.90-2.08 (m, 2H, H5, H6), 2.18-2.30 (m(o), 2H, H2, -OH), 2.69-2.72 (m, 1H, H1), 
3.91-4.00 (m, 1H, H3), 4.15 (q, J = 7.1 Hz, 2H, H8), 4.38 (dddd, J = 49.7, 8.2, 6.9, 3.9 
Hz, 1H, H4); δC (75 MHz, CDCl3 ) 14.1 (C9), 23.8 (d, J = 7.4 Hz, 1C, C6), 26.3 (d, J = 
19.1 Hz, 1C, C5), 31.7 (d, J = 3.8 Hz, 1C, C2), 37.6 (C1), 60.6 (C8), 68.8 (d, J = 22.5 
Hz, 1C, C3), 93.4 (d, J = 173.5 Hz, 1C, C4), 174.6 (C7); δF (282 MHz, CDCl3) -186.3; 
HRMS (ESI) m/z 208.1345 [M+NH4]+ (Calcd. for C9H15FO3+NH4+ 208.1343); IR (neat 
film): νmax(cm-1) 3439.3 (-OH), 2940.4 (-OEt), 1727.2 (C=O). 
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General procedure for the synthesis of (1S*,2S*,5R*)-5-(ethoxycarbonyl)-2-
fluorocyclohexyl 4-nitrobenzoate (2.51)85 
O O
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4-Nitro-benzoyl chloride (135 mg, 0.73 mmol) was added to 3-fluoro-4-hydroxy-
cyclohexanecarboxylic acid ethyl ester 2.49 (70 mg, 0.37 mmol) in pyridine (2 mL) 
under nitrogen and and was left to stir over night. Water (6 mL) was added, and the 
solution was extracted with ethyl acetate (3×20 mL). The organic extracts were 
combined and successively washed with oxalic acid solution (10%, 20 mL), cold 
NaHCO3 solution (10%, 20 mL), and water (2× 20 mL) and dried over Na2SO4, filtered, 
evaporated in vacuo and purified by flash chromatography on silica eluting with a 
mixture of petrol and ethyl acetate ( 95:5) to give the title compound 2.51 as white 
crystals ( 76 mg, 0.22 mmol, 59%) δH (300 MHz, CDCl3) 1.26 (t, J = 7.1 Hz, 3H, H9), 
1.76-2.02 (m, 5H, 2H3, 2H4, H6), 2.23-2.34 (m, 1H, H6), 2.67-2.77 (m, 1H, H5), 4.16 
(q, J = 7.1 Hz, 2H, H8), 4.70 (dddd, J = 47.9, 5.6, 5.3, 2.9 Hz, 1H, H2), 5.36-5.44 (m, 
1H, H1), 8.18 (d, J = 9.1 Hz, 2H, H13, H15), 8.29 (d, J = 9.1 Hz, 2H, H12, H16); δc (75 
MHz, CDCl3) 14.1 (C9), 23.0 (d, J = 4.5 Hz, C4), 26.6 (d, J = 20.0 Hz, C3), 28.7 (C6), 
37.7 (C5), 60.8 (C8), 70.9 (d, J = 27.4 Hz, C1), 87.9 (d, J = 174.7 Hz, 1C, C2), 123.7 (s, 
2C, C13, C15), 130.9 (s, 2C, C12, C16), 135.4 (C11), 150.9 (C14), 163.6 (C10), 174.1 
(C7); δF (282 MHz, CDCl3) -188.4; HRMS (ESI) m / z 357.1454 [M+NH4]+ (Calcd. 
357.1456 for C16H18FO6+NH4+); IR (neat film): νmax(cm-1) 2952.6 (-OEt), 2917.3 (-
OR), 1724.8 (C=O), 1522.6 (C-NO2), 1348.6 (C-NO2), 1607.6, 1522.6, 868.2 
(aromatic); X-ray structure available. 
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General procedure for the synthesis of (1S*, 3R*, 4R*)-ethyl-3-fluoro-4-
hydroxycyclohexanecarboxylate (2.44)84 
OO
OH
F
1
2
34
5
6
7
8
9
 
(1R*, 3R*, 6S*)-ethyl-7-oxa-bicyclo[4.1.0]heptane-3-carboxylate 2.45 (70 mg, 0.41 
mmol) was added to triethylamine trihydrofluoride (1 mL) and was left to stir for 40 
hours under nitrogen. NaHCO3 saturated solution was added until all the HF was 
neutralised then extracted in ethyl acetate. The organic extracts were combined and 
washed with NaHCO3 saturated solution and NaCl saturated solution, dried over 
MgSO4, filtered, evaporated in vacuo, purified by flash chromatography on silica 
eluting with a mixture of DCM and ethyl acetate (95:5), to give the title compound 2.44 
(8 mg, 0.042 mmol, 10%). 
A sodium hydroxide aqueous solution (2 mL, 1 molL-1) was added to (1R,3S,4S)-
methyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.40 (25.4 mg, 0.144 mmol), and 
was left to stir for 3 hours. The aqueous solution was washed with ethyl acetate (2 mL), 
extracted, acidified to pH 1 with dilute HCl aqueous solution (0.1 molL-1), extracted 
with ethyl acetate (3×10 mL). The organic extracts were combined and washed with 
NaCl saturated solution, dried over Na2SO4, filtered and evaporated in vacuo to the 
crude acid 2.43 (17.3 mg). Concentrated sulfuric acid (2 drops) was added to the crude 
acid in dry ethanol (3 mL) and was left to stir for 20 hours. The reaction was neutralised 
with NaHCO3 saturated solution (3 mL). The ethanol was evaporated in vacuo. The 
aqueous solution was extracted with ethyl acetate (4×10 mL). The organic extracts were 
combined, washed with NaHCO3 saturated solution and NaCl saturated solution, dried 
over Na2SO4, filtered, evaporated in vacuo, purified by flash chromatography on silica 
eluting with a mixture of petroleum ether and ethyl acetate (80 : 20), to give the title 
compound 2.44 (12 mg, 0.063 mmol, 44%). 
A catalytic amount of p-Toluene sulfonic acid was added to the solution of (1S*, 3R*, 
4R*)-ethyl 3-fluoro-4-(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate 2.52 (310 
mg, 1.13 mmol) in ethanol (8 mL) and was left to stir for 2 hours.87 NaHCO3 saturated 
solution was added (10 mL) to quench, the ethanol was then evaporated in vacuo. The 
solution was extracted with ethyl acetate (3×20 mL) and the organic extracts were 
combined and washed with NaHCO3 saturated solution and NaCl saturated solution, 
dried over Na2SO4, filtered, evaporated in vacuo and purified by flash chromatography 
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on silica eluting with a mixture of DCM and ethyl acetate (90: 10) to give 2.44 as a 
colourless oil (212 mg, 99%).  
δH (300MHz, CDCl3) 1.24 (t, J = 7.1 Hz, 3H, H9), 1.47-1.67 (m, 2H, H5, H6), 1.72-
2.02 (m, 3H, H2, H5, H6), 2.21-2.36 ( m, 2H, H2, -OH), 2.68-2.75 (m, 1H, H1), 3.71-
3.80 (m, 1H, H4), 4.12 (q, J = 7.1 Hz, 2H, H8), 4.58 (dddd, J = 49.1, 8.1, 6.8, 3.9 Hz, 
1H, H3); δC (75 MHz, CDCl3) 14.0 (C9), 23.7 (C6), 27.9 (d, J = 3.9 Hz, 1C, C5), 29.7 
(d, J = 20.0 Hz, 1C, C2), 38.2 (d, J = 7.3 Hz, 1C, C1), 60.6 (C8), 70.0 (d, J = 22.5 Hz, 
1C, C4), 92.2 (d, J = 172.3 Hz, 1C, C3), 174.5 (C7); δF (282 MHz, CDCl3) -186.5; 
HRMS (FI) m/z 191.1083 [M+H]+ (Calcd. for C9H15FO3+H+ 191.1083); IR (neat film): 
νmax(cm-1) 3424(-OH), 2940 (-OEt), 1727 (C=O). 
 
General procedure for the synthesis of (1S*, 2S*, 4R*)-4-(ethoxycarbonyl)-2-
fluorocyclohexyl 4-nitrobenzoate (2.48)85 
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4-Nitro-benzoyl chloride (187 mg, 1.01 mmol) was added to 3-fluoro-4-hydroxy-
cyclohexanecarboxylic acid ethyl ester 2.44 (156 mg, 0.82 mmol) in pyridine (1.2 mL) 
under nitrogen and and was left to stir over night. Water (6 mL) was added, and the 
solution was extracted with ethyl acetate (3×20 mL). The organic extracts were 
combined and successively washed with oxalic acid solution (10%, 20 mL), cold 
NaHCO3 solution (10%, 20 mL), and water (2× 20 mL) and dried over Na2SO4, filtered, 
evaporated in vacuo and purified by flash chromatography on silica eluting with a 
mixture of petrol and ethyl acetate ( 95:5) to give the title compound 2.48 as a 
colourless oil (174 mg, 0.39 mmol, 63%), that crystallised after 2 weeks at –20°C:  
δH (300 MHz, CDCl3) 1.29 (t, J = 7.1 Hz, 3H, H9), 1.82-2.36 (m, 6H, H3, H5, H6), 2.82 
(tt, J= 8.3, 4.3 Hz, 1H, H4), 4.18 (q, J= 7.1, 2H, H7), 4.90 (dddd, J = 47.4, 6.4, 6.1, 3.5 
Hz, 1H, H2), 5.20-5.28 (m, 1H, H1), 8.21 (d, J= 8.6 Hz, 2H, H13, H15), 8.30 (d, J= 8.6 
Hz, 2H, H12, H16); δc (75 MHz, CDCl3), 14.2 (C8) 23.7 (C5), 25.4 (C6), 30.2 (d, J = 
19.5 Hz, C3), 37.5 (d, J = 5.2 Hz, C4) 60.8 (C7), 71.9 (d, J = 26.3 Hz, C1), 87.8 (d, J = 
174.0 Hz, C2), 123.6 (s, 2C, C13, C15), 130.8 (s, 2C, C12, C16), 135.2 (s, 1C, C11), 
150.7 (s, 1C, C14), 163.7 (C10), 174.3 (C9); δF (282 MHz, CDCl3) -186.8 (d, J = 29.6 
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Hz); HRMS (FI) m / z 340.1196 [M+H]+ (Calcd. 340.1196 for C16H18FO6+H+); IR (neat 
film): νmax(cm-1) 2952.6 (-OEt), 1724.8 (C=O), 1522.6. (C-NO2), 1348.6 (C-NO2), 
1607.6, 1522.6, 868.1 (aromatic); X-ray data available.  
 
General procedure for the synthesis of (1R*, 3R*, 4R*)-ethyl-3-fluoro-4-
(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate (2.56)  
O
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Potassium tert-butoxide (186 mg, 1.65 mmol) was added to a racemic mixture of (1S*, 
3R*, 4R*)-ethyl-3-fluoro-4-(tetrahydro-2H-pyran-2-yloxy) cyclohexanecarboxylate 
2.52 (2.20g, 8.02 mmol) in freshly distilled toluene (104 mL) under nitrogen and 
refluxed for 40 minutes. The reaction vessel was then allowed to cool to room 
temperature under nitrogen. The solution was then purified by flash chromatography on 
silica eluting with hexane, then a mixture of hexane and ethyl acetate (95:5), to give the 
title compound 2.56 as a yellow oil (1.17g, 53%) and starting material (1.01g, 46% 
recovered).  
δH (300 MHz, CDCl3) 1.23 (t, J = 7.1 Hz, 3H), 1.33-1.86 (m, 9H), 1.94-1.98 (m, 1H), 
2.11-2.15 (m, 1H), 2.31-2.36 (m, 2H), 3.48-3.53 (m, 1H), 3.63-3.75 (m, 1H), 3.87-4.02 
(m, 1H), 4.12 (t, J = 7.1 Hz, 2H), 4.29-4.47 (m, 1H), 4.80-4.83 (m, 1H); δC (75 MHz, 
CDCl3) 14.1, 19.7, 25.3, 26.7 (d, J = 1.78 Hz), 30.3 (d, J = 8.17 Hz), 30.6, 30.8, 33.2 
(d, J = 20.30 Hz), 40.7 (d, J = 11.10 Hz), 60.6, 62.8, 77.7 (d, J = 15.9 Hz), 94.6 (d, J = 
177.95 Hz), 100.2 (d, J = 2.83 Hz), 173.8 (d, J = 2.08 Hz); δF (282 MHz, CDCl3) -
180.20 (d, J = 49.5 Hz), -181.03 (d, J = 49.5 Hz); HRMS (ESI) m/z 292.1921 
[M+NH4]+ (Calcd. for C14H23FO4+NH4+ 292.1924); IR (neat film): νmax(cm-1) 2939 (-
OEt), 1731 (C=O). 
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General procedure for the synthesis of (1R*, 3R*, 4R*)-ethyl-3-fluoro-4-
hydroxycyclohexanecarboxylate (2.50) 
OH
F
O O
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34
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A catalytic amount of p-Toluene sulfonic acid was added to a racemic mixture of (1R*, 
3R*, 4R*)-ethyl-3-fluoro-4-(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate 2.56 
(1.7 g, 6.2 mmol) in methanol (8 mL) and was left to stir for 2 hours.87 NaHCO3 
saturated solution was added (10 mL) to neutralise the acid. The methanol was 
evaporated in vacuo, and the solution was extracted with ethyl acetate (3×20 mL). The 
organic extracts were combined and washed with NaHCO3 saturated solution (30 mL) 
and NaCl saturated solution (30 mL), dried over MgSO4, filtered, evaporated in vacuo. 
The product was purified by flash chromatography on silica eluting with a mixture of 
dichloromethane and ethyl acetate (90: 10) to give the title compound 2.50 as a 
colourless oil (1.09 g, 5.74 mmol, 93%).  
(1S*, 3R*, 4R*)-ethyl-3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 (524 mg, 2.76 
mmol) in THF (5 mL) was slowly added over a period of 10 minutes to a solution of 
sodium hydride (138mg, 5.75 mmol) in THF (55 mL) at –20°C. The reaction was left to 
stir at for 18 hours. Phtalamide (1g ) was then added and left to stir for 1 hour at –20°C, 
then tert-butanol (4 mL) was added and left to stir for another hour at –20°C. The 
solution was left to heat up to room temperature. Then ether was added (100 mL), and 
the solution was extracted. The organic extract was washed with NaHCO3 saturated 
solution and NaCl saturated solution, then dried over MgSO4, filtered, evaporated in 
vacuo and purified by 2 successive flash chromatography on silica eluting with a 
mixture of petroleum ether and ethyl acetate (90/10) and then (85/15), to give the title 
compound 2.50 as a light orange oil (123 mg, 0.64 mmol, 23%) and recovered starting 
material (330 mg, 1.74 mmol, 63%).  
Potassium tert-butoxide (2.13 g, 18.9 mmol) was added to (1S*, 3R*, 4R*)-ethyl-3-
fluoro-4-hydroxycyclohexanecarboxylate 2.44 (3 g, 15.79 mmol) in freshly distilled 
toluene under nitrogen. The reaction vessel was heated under reflux (in an oil bath pre-
heated to 120°C) for 30 minutes. The reaction vessel was allowed to cool to room 
temperature, whilst stirring exposed to the atmosphere. After 10 minutes the reaction 
mixture was filtered through a cotton wool plug and washed with ethyl acetate (100 
mL). The solvent was removed in vacuo, ensuring that the water bath temperature did 
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not exceed 30°C to avoid loss of the volatile product (2.8g crude). The compound was 
purified by flash chromatography on silica eluting with a gradient mixture of petroleum 
ether and ethyl acetate (9:1) to (85:15) petroleum ether /ethyl acetate, to give the title 
compound as a light orange oil (1.01 g, 5.3 mmol, 34%). 
Potassium tert-butoxide (532 mg, 4.74 mmol) was added to a 4 : 1 mixture of (1S*, 
3R*, 4R*)-ethyl-3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 and (1R*, 3R*, 4R*)-
ethyl-4-fluoro-3-hydroxycyclohexanecarboxylate 2.47 (750 mg, 3.95 mmol) in freshly 
distilled toluene under nitrogen. The reaction vessel was then heated under reflux (in an 
oil bath pre-heated to 120°C) for 30 minutes. The reaction vessel was then allowed to 
cool to room temperature, whilst stirring exposed to the atmosphere. After 10 minutes 
the reaction mixture was filtered through a cotton wool plug and washed with ethyl 
acetate (100 mL). The solvent was removed in vacuo, ensuring that the water bath 
temperature did not exceed 30°C to avoid loss of the volatile product (2.8g crude). The 
compound was purified by flash chromatography on silica eluting with a gradient 
mixture of petroleum ether and ethyl acetate (9:1) to (85:15) petroleum ether /ethyl 
acetate, to give the title compound 2.50 as a light orange oil (178 mg, 0.937 mmol, 
24%). 
δH (400MHz, CDCl3) 1.25 (t, J = 7.1 Hz, 3H, H9), 1.35-1.50 (m, 2H, H5, H6), 1.63-
1.70 ( m, 1H, H2), 1.96-2.02 (m, 1H, H6), 2.06-2.12 (m, 1H, H5), 2.33-2.43 (m, 2H, 
H1, H2), 3.61-3.73 (m, 1H, H4), 4.13 (q, J = 7.1 Hz, 2H, H8), 4.35 (dddd, J = 50.7, 
11.2, 8.6, 4.7 Hz, 1H, H3); δC (75 MHz, CDCl3) 14.0 (C9), 26.4 (C6), 30.2 (d, J = 7.6 
Hz, 1C, C5), 32.4 (d, J = 19.9 Hz, 1C, C2), 40.9 (d, J = 11.1 Hz, 1C, C1), 60.7 (C8), 
72.7 (d, J = 18.0 Hz, C4), 95.5 (d, J = 175.3 Hz, C3), 173.9 (C7); IR 1731.4 (C=O), 
3438.8 (-OH), 2941.4 (-CH); δF (282 MHz, CDCl3) -186.2; HRMS (ESI) m/z 191.1080 
[M+H]+ (Calcd. for C9H15FO3+H+ 191.1083).  
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General procedure for the synthesis of (1R*, 3S*, 4S*)-ethyl 3-fluoro-4-
(pivaloyloxy)cyclohexanecarboxylate (2.55) 
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Pivalic acid (92 mg, 0.90 mmol) was added to thionyl chloride (106 mg, 0.89 mmol) in 
DCM (2 mL) and refluxed for 2 hours under nitrogen. The solution was left to cool 
down, then (1R*, 3S*, 4S*)-ethyl 3-fluoro-4-hydroxycyclohexanecarboxylate 2.44 (113 
mg, 0.59 mmol) in DCM (1 mL) was added and left to stir over night under nitrogen. 
DCM (10 mL) was added, the organic solution was washed with saturated NaHCO3 
solution (3×5 mL), dried over Na2SO4, filtered, evaporated in vacuo and purified by 
flash chromatography on silica eluting with a mixture of petrol and ethyl acetate ( 95:5) 
to give the title compound 2.55 as yellow crystals (47 mg, 0.17 mmol, 29%): δH 
(300MHz, CDCl3 ) 1.23 (s, 9H, H12), 1.27 (t, J = 7.1 Hz, 3H, H9), 1.67-2.13 (m, 6H, H 
2,6,5), 2.67-2.77 (m, 1H, H1), 4.15 (q, J= 7.1 Hz, 2H, H8), 4.71 (dddd, J= 47.0, 4.6, 
4.3, 4.3 Hz, 1H, H3), 4.91-5.00 (m, 1H, H4); δc (75 MHz, CDCl3) 14.2 (C9), 23.3 (C6), 
25.0 (C5), 27.1 (3C, C12), 29.4 (d, J = 18 Hz, C2), 37.2 (d, J = 3.8 Hz, C1), 38.8 (C11), 
60.6 (C8), 68.8 (d, J = 27.0 Hz, C4), 87.6 (d, J = 172.5 Hz, C3), 174.6 (C10), 177.3 
(C7); δF (282 MHz, CDCl3) -187.9; HRMS (CI) m / z 275.1658 [M+H]+ (Calcd. 
275.1659 For C14H23FO4+H+); IR (neat film): νmax(cm-1) 2917.2 (-OEt), 2849.0 (-
OR), 1719.4 (C=O) 
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General procedure for the synthesis of (1S*, 2S*, 4S*)-4-(ethoxycarbonyl)-2-
fluorocyclohexyl 4-nitrobenzoate (2.57)85 
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4-Nitro-benzoyl chloride (205 mg, 1.11 mmol) was added to 3-fluoro-4-hydroxy-
cyclohexanecarboxylic acid ethyl ester 2.50 (106 mg, 0.56 mmol) in pyridine (3 mL) 
under nitrogen and and was left to stir over night. Water (6 mL) was added, and the 
solution was extracted with ethyl acetate (3×20 mL). The organic extracts were 
combined and successively washed with oxalic acid solution (10%, 20 mL), cold 
NaHCO3 solution (10%, 20 mL), and water (2× 20 mL) and dried over Na2SO4, filtered, 
evaporated in vacuo and purified by flash chromatography on silica eluting with a 
mixture of petrol and ethyl acetate ( 95:5) to give the title compound 2.57 as white 
crystalls (145 mg, 0.43 mmol, 77%): δH (400MHz, CDCl3) 1.28 (t, J = 7.1 Hz, 3H, H9), 
1.47-1.69 (m, 2H, H5, H6), 1.79-1.91 (m, 1H, H3), 2.06-2.11 (m, 1H, H5), 2.27-2.35 
(m, 1H, H6), 2.42-2.56 (m, 2H, H4, H3), 4.17 (q, J = 7.1 Hz, 2H, H8), 4.65 (dddd, J = 
50.4, 11.4, 8.9, 4.9 Hz, 1H, H2), 5.14 (ddt, J = 10.8, 9.0, 5.0 Hz, 1H, H1), 8.22 (d, J = 
8.7 Hz, 2H, H13, H15), 8.29 (d, J = 8.7 Hz, 2H, H12, H16); δc (75 MHz, CDCl3) 14.0 
(C9), 26.1 (C5), 28.2 (d, J = 6.6 Hz, C6), 32.8 (d, J = 19.9 Hz, C3), 40.4 (d, J = 10.6 
Hz, C4), 60.9 (C8), 75.5 (d, J = 17.8 Hz, C1), 91.2 (d, J = 181.6 Hz, C2), 123.6 (s, 2C, 
C13, C15), 130.9 (s, 2C, C12, C16), 135.5 (C11), 150.7 (s,1C), 164.1 (C10), 173.3 
(C7); δF (282 MHz, CDCl3) -181.9 (d, J = 50.8 Hz) HRMS (ESI) m / z 357.1452 
[M+NH4]+ (Calcd. 357.1456 for C16H18FO6+NH4+), X-ray structure available. 
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General procedure for the synthesis of (1S*, 3S*, 4S*)-ethyl 3-fluoro-4-
(methylsulfonyloxy)cyclohexanecarboxylate (2.60)89 
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DMAP (349 mg, 2.82 mmol) was added to a solution of (1R*, 3R*, 4R*)-ethyl-3-fluoro-
4-hydroxycyclohexanecarboxylate 2.50 (261 mg, 1.37 mmol) and N-
Ethyldiisopropylamine (530.4 mg, 4.1 mmol) in DCM (25 mL) at -10°C stirring under 
nitrogen and was left to stir for 30 minutes. Mesyl chloride (325 mg, 2.84 mmol) was 
added and left to stir for a further 2 hours at -10°C stirring under nitrogen to completion. 
Iced water (10 mL) was added and the organic phase was extracted. The aqueous phase 
was extracted with diethyl ether (3×10 mL). The DCM and diethyl ether extracts were 
combined, washed with NaCl saturated aqueous solution (2×10 mL), dried over MgSO4, 
filtered, and evaporated in vacuo and purified by flash chromatography on silica eluting 
with a mixture of petroleum ether and ethyl acetate (9 : 1), to give the title compound 
2.60 as a white solid (170 mg, 0.634 mmol, 60%): δH (400 MHz, CDCl3) 1.25 (t, J = 7.1 
Hz, 3H, H9), 1.49-1.82 (m, 3H, H2, H5, H6), 2.02-2.11 (m, 1H, H6), 2.25-2.48 (m, 3H, 
H1, H2, H5), 3.06 (m, 3H, H10), 4.09 (q, J = 7.1 Hz, 2H, H8), 4.44-4.63 (m, 2H, H3, 
H4), δC (75 MHz, CDCl3) 173.0 (C7), 91.2 (d, J = 180.5 Hz, C3), 82.0 (d, J = 17.1 Hz, 
C4), 60.8 (C8), 40.0 (d, J = 10.3 Hz, C1), 38.1 (C10), 32.7 (d, J = 20.0 Hz, C2), 29.9 (d, 
J = 1.7 Hz), 29.8 (d, J = 6.3 Hz, C5), 13.9 (C9); δC (282 MHz, CDCl3) -179.6 (d, J = 
50.8 Hz); HRMS (ESI) m/z 286.1120 [M+NH4]+ (Calcd. for C10H17FO5S +NH4+ 
286.1119); IR (neat film): νmax(cm-1) 2933 (-OEt), 1721 (C=O). 
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General procedure for the synthesis of (1S*, 3S*, 4R*)-ethyl 4-acetoxy-3-
fluorocyclohexanecarboxylate (2.61)92 
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(1S*, 3S*, 4S*)-ethyl 3-fluoro-4-(methylsulfonyloxy)cyclohexanecarboxylate 2.60 (30 
mg, 0.11 mmol) was added to a solution of sodium acetate (185 mg, 2.8 mmol) in DMF 
water 80: 20 mixture (5 mL) was refluxed under nitrogen for 2 days. Ethyl acetate (10 
mL) was added. The mixture was washed with water (3×5 mL). The organic phase was 
dried over MgSO4, filtered, and evaporated in vacuo and purified by flash 
chromatography on silica eluting with a mixture of petroleum ether and DCM (1 : 1), to 
give the title compound 2.61 as (3 mg, 12.9 µmol, 12%) 
δH (400MHz, CD3OD) 1.28 (t, J = 7.1 Hz, 3H, H9), 1.32 (s, 3H), 1.54-1.68 (m, 2H), 
1.76-1.84 (m, 1H), 1.91-2.04 (m, 2H), 2.11-2.21 (m, 1H), 2.43-2.51 (m, 1H, H1), 3.99-
4.05 (m, 1H, H4), 4.16 (q, J = 7.1 Hz, 2H, H8), 4.56 (dddd, J = 47.2, 10.4, 4.2, 2.7 Hz, 
1H, H3); δC (75 MHz, CD3OD) 15.3 (C9), 23.9 (C11), 30.6 (d, J = 21.2 Hz, C2), 30.6 
(d, J = 6.7 Hz, C5), 31.6 (C6), 42.0 (d, J = 9.5 Hz, C1), 62.5 (C8), 69.1 (d, J = 17.4 Hz, 
C4), 94.2 (d, J = 176.8 Hz, C3), 177.1 (C10), 177.1 (C7); MS (CI) m/z 250.2 [M+NH4]+ 
(Calcd. for C10H17FO5S +NH4+ 250.2)  
 
General procedure for the synthesis of (1S*, 3S*, 4S*)-ethyl-3-fluoro-4-
(trifluoromethylsulfonyloxy) cyclohexanecarboxylate (2.62) 
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Pyridine (0.1 mL, 1.23 mmol) and a racemic mixture of (1R*, 3R*, 4R*)-ethyl 3-fluoro-
4-hydroxycyclohexanecarboxylate 2.50 (120 mg, 0.632 mmol) in dry dichloromethane 
(1 mL) was added drop wise over a period of 10 minutes to a solution of 
trifluoromethanesulfonic anhydride (355 mg, 1.26 mmol) in dry dichloromethane (1 
mL) previously stirred for 10 minutes at 0 °C under nitrogen. The reaction mixture was 
stirred for an extra 30 minutes at 0 °C, then stirred at room temperature. The reaction 
went to completion after 2 hours and dichloromethane (10 mL) was added. The organic 
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solution was washed with ice cold water (3× 5 mL), dried over MgSO4, filtered and the 
solvent removed in vacuo, to give the crude title compound 2.62 as a colourless oil (137 
mg, 67%). 
δH (400 MHz, CDCl3) 1.26 (t, J = 7.2 Hz, 3), 1.70-1.82 (m, 2H), 2.06-2.03 (m, 1H), 
2.10-2.15 (m, 1H), 2.33-2.42 (m, 2H), 2.51-2.55 (m, 1H), 4.14 (q, J = 7.1 Hz, 2H), 
4.50-4.63 (m, 1H), 4.80-4.83 (m, 1H); HRMS (EI) m/z 322.0495 [M]+. (Calcd. for 
C10H14F4O5S 322.0498). 
 
General procedure for the synthesis of (1R*, 2S*, 4S*)-4-(ethoxycarbonyl)-2-
fluorocyclohexyl benzoate (2.63) 
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Tetrabutylammonium benzoate (666 mg, 1.8 mmol) was added to a racemic mixture of 
(1S*, 3S*, 4S*)-ethyl-3-fluoro-4-(trifluoromethylsulfonyloxy) cyclohexanecarboxylate 
2.62 (131 mg, 0.41 mmol) in freshly distilled toluene (18 mL) and stirred under nitrogen 
over night. The solvent was removed in vacuo. The product was purified by 2 
successive flash chromatography: the first one on silica eluting with a mixture of hexane 
and ethyl acetate (95: 5), the second one on silica eluting with dichloromethane, to give 
the title compound 2.63 as white solid crystals (75 mg, 61%).  
δH (300 MHz, CDCl3) 1.26 (t, J = 7.1 Hz, 3H, H9), 1.60-1.66 (m, 1H, H6), 1.75-1.92 
(m, 2H, H5, H6), 2.17-2.32 (m, 3H, H3, H3, H5), 2.48 (dddd, J = 9.4, 9.4, 4.7, Hz, 1H, 
H4), 4.16 (q, J = 7.1 Hz, 2H, H8), 4.71 (dddd, J = 46.5, 10.1, 4.5, 2.8 Hz, 1H, H2), 5.46 
(dddd, J = 11.0, 5.3, 2.6, 2.6 Hz, 1H, H1), 7.44 (dd, J = 7.5, 7.5 Hz, 2H, H13, H15), 
7.56 (tt, J = 7.4, 1.4 Hz,, 1H, H14), 8.06 (dd, J = 8.4, 1.4 Hz, 2H, H12, H16); δC (75 
MHz, CDCl3) 14.0 (C9), 22.4 (C6), 26.3 (C5), 29.6 (d, J = 21.2 Hz, 1C, C3), 39.5 (d, J 
= 9.2 Hz, 1C, C4), 60.6 (C8), 69.7 (d, J = 16.8 Hz, 1C, C1), 89.6 (d, J = 182.8 Hz, 1C, 
C1), 128.4 (C13, C15), 129.7 (C12, C16), 130.1 (C11), 133.2 (C14), 165.8 (C10), 173.8 
(C7); δF (282 MHz, CDCl3) -185.7; HRMS (ESI) m/z 312.1606 [M+NH4]+ (Calcd. for 
C16H19FO4+NH4+ 312.1611); IR (neat film): νmax(cm-1) 2964.5 (-OEt), 1728.7 (C=O), 
1602.0, 1584.0, 865.2 (aromatic). 
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General procedure for the synthesis of (1R*, 3R*, 4S*)-ethyl-3-fluoro-4-
hydroxycyclohexanecarboxylate (2.58) 
F
O O
1 2
3
4
5
6
7
8
9
OH
 
A catalytic amount of sodium was stirred in dry ethanol (2 mL) under nitrogen to form 
sodium ethoxide in situ. A racemic mixture of (1R*, 2S*, 4S*)-4-(ethoxycarbonyl)-2-
fluorocyclohexyl benzoate 2.63 (75 mg, 0.25 mmol) in dry ethanol (2 mL) was added to 
the previous sodium ethoxide solution and stirred under nitrogen over night. pH 7 
phosphate buffer was added (20 mL) until pH was close to neutral, then the ethanol was 
removed in vacuo. The aqueous solution was extracted with ethyl acetate (3× 20 mL). 
The organic extracts were combined and washed with saturated NaHCO3 (30 mL), 
saturated aqueous NaCl solution (30 mL), dried on MgSO4, and filtered. The solvent 
was removed in vacuo and purified by flash chromatography on silica eluting with a 
mixture of hexane and ethyl acetate (9:1) to give the title compound 2.58 as a yellow oil 
(42 mg, 0.22 mmol, 88%) and compound 2.59 as a yellow oil (2 mg, 0.01 mmol, 4%).  
δH (300 MHz, CDCl3) 1.25 (t, J = 7.1 Hz, 3H, CH2-CH3), 1.40-1.53 (m, 1H, H5), 1.69-
1.70 (m, 1H, H6), 1.77-1.90 (m, 1H, H6), 1.97-2.25 (m, 3H, H2, H2, H5), 2.29-2.38 (m, 
1H, H1), 4.06-4.11 (m(o), 1H, H4), 4.14 (q, J = 7.1 Hz, 2H, H8), 4.55 (dddd, J = 47.0, 
10.5, 4.8, 2.8 Hz, 1H, H3); δC (75 MHz, CDCl3) 14.0 (CH2-CH3), 21.6 (C6), 28.2 (d, J 
= 20.9 Hz, C2), 29.6 (C5), 40.2 (d, J = 10.3 Hz, C1), 60.6 (C8), 66.9 (d, J = 17.9 Hz, 
C4), 92.5 (d, J = 175.0 Hz, C3), 174.0 (C7); δF (282 MHz, CDCl3) -185.3; HRMS (ESI) 
m/z 191.1078 [M+H]+ (Calcd. for C9H15FO3+H+ 191.1083). 
 
General procedure for the synthesis of (1R*, 3S*, 4S*)-ethyl-3-fluoro-4-
(trifluoromethylsulfonyloxy)cyclohexanecarboxylate (2.64) 
1 2
3
45
6
7
8
9
OTf
F
OO
 
Pyridine (0.07 mL, 0.86 mmol) and a racemic mixture of (1S*, 3R*, 4R*)-ethyl 3-
fluoro-4-hydroxycyclohexanecarboxylate 2.44 (87 mg, 0.46 mmol) in dry 
dichloromethane (1 mL) was added drop wise over a period of 10 minutes to a solution 
of trifluoromethanesulfonic anhydride (242.3 mg, 0.86 mmol) in dry dichloromethane 
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(1 mL) previously stirred for 10 minutes at 0 °C under nitrogen. The reaction mixture 
was stirred for 30 minutes at 0 °C and then stirred at room temperature. The reaction 
went to completion after 2 hours as evident by TLC and dichloromethane (10 mL) was 
added and quenched with adding ice cold water. The organic solution was washed with 
ice cold water (3× 5 mL), dried over MgSO4, filtered and the solvent removed in vacuo, 
to give the crude title compound 2.64 as a colourless oil (113 mg, 76%).  
δH (400 MHz, CDCl3) 1.27 (t, J = 7.14 Hz, 3H), 1.76-1.83 (m, 1H), 1.93-2.06 (m, 3H), 
2.10-2.17 (m, 1H), 2.26-2.41 (m, 1H), 2.75-2.80 (m, 1H), 4.17 (q, J = 7.1 Hz, 2H), 
4.78-4.94 (m, 2H); HRMS (EI) m/z 322.0493 [M]+. (Calcd. for C10H14F4O5S 322.0498). 
 
General procedure for the synthesis of (1R*, 2S*, 4R*)-4-(ethoxycarbonyl)-2-
fluorocyclohexyl benzoate (2.65) 
F
O
O
O
O 1
23
4
5 6
7
8
9
10
11
12 13
14
1516
 
Tetrabutylammonium benzoate (290 mg, 0.80 mmol) was added to a racemic mixture of 
(1R*, 3S*, 4S*)-ethyl-3-fluoro-4-(trifluoromethylsulfonyloxy) cyclohexanecarboxylate 
2.64 (110 mg, 0.34 mmol) in freshly distilled toluene (15 mL) and stirred under nitrogen 
over night.
 
The solvent was removed in vacuo. The product was purified by 2 
successive flash chromatography: the first one on silica eluting with a mixture of hexane 
and ethyl acetate (95: 5), the second one on silica eluting with dichloromethane, to give 
the title compound 2.65 as white crystals (64 mg, 65%).
  
δH (300 MHz, CDCl3) 1.27 (t, J = 7.1 Hz, 1H, H9), 1.61-1.91 (m, 2H, H3, H5), 1.95-
2.07 (m, 2H, H6, H5), 2.09-2.20 (m, 1H, H6), 2.36 -2.45 (m, 1H, H3), 2.76 (tt, J = 12.1, 
3.9 Hz, 1H, H4), 4.15 (q, J = 7.1 Hz, 2H, H8), 4.95-5.13 (m, 2H, H2, H1), 7.45 (t, J = 
7.6 Hz, 2H, H13, H15), 7.57 (t, J = 7.4 Hz, 1H, H14), 8.07 (dd, J = 8.3, 1.1 Hz, 2H, 
H12, H16); δC (75 MHz, CDCl3) 14.0 (C9), 24.7 (d, J = 3.0 Hz, 1C, C5), 26.2 (C6), 
31.9 (d, J = 20.3 Hz, 1C, C3), 36.5 (d, J = 2.0 Hz, 1C, C4), 60.6 (C8), 72.5 (d, J = 17.8 
Hz, 1C, C1), 88.2 (d, J = 177.3 Hz, 1C, C2), 128.4 (C13, C15), 129.8 (C12, C16), 130.0 
(C11), 133.2 (C14), 166.0 (C10), 174.7 (C7); δF (282 MHz, CDCl3) -200.6; HRMS 
(ESI) m/z 312.1608 [M+NH4]+ (Calcd. for C16H19FO4+NH4+ 312.1611); IR (neat film): 
νmax(cm-1) 2956.0 (-OEt), 1729.9 (C=O), 1601.9, 1584.5, 859.1 (aromatic). 
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General procedure for the synthesis of (1S*, 3R*, 4S*)-ethyl-3-fluoro-4-
hydroxycyclohexanecarboxylate (2.59) 
OH
F
OO
1
2
34
5
6
7
8
9
 
A catalytic amount of sodium was stirred in dry ethanol (2 mL) under nitrogen to form 
sodium ethoxide in situ. A racemic mixture of (1R*, 2S*, 4R*)-4-(ethoxycarbonyl)-2-
fluorocyclohexyl benzoate 2.65 (52 mg, 0.176 mmol) in dry ethanol (2 mL) was added 
to the previous sodium ethoxide solution and stirred under nitrogen over night. pH 7 
phosphate buffer was added (15 mL) until pH was close to neutral, then the ethanol was 
removed in vacuo. The aqueous solution was extracted with ethyl acetate (3× 20 mL). 
The organic extracts were combined and washed with saturated NaHCO3 (30 mL), 
saturated aqueous NaCl solution (30 mL), dried on MgSO4, and filtered. The solvent 
was removed in vacuo and purified by flash chromatography on silica eluting with a 
mixture of hexane and ethyl acetate (9:1) to give the title compound 2.59 as transparent 
oil (19 mg, 57%) and the epimerised product 2.58 (11 mg, 33%).
  
δH (300 MHz, CDCl3) 1.25 (t, J = 7.14 Hz, 3H, H9), 1.55-1.70 (m, 2H, H2, H6 ), 1.73-
2.06 (m, 4H, H5, H5, H6, -OH), 2.27-2.37 (m, 1H, H2), 2.62 (tt, J = 11.5, 11.5, 3.9, 3.9 
Hz, 1H, H1), 3.62 (dddd, J = 26.4, 10.9, 4.7, 2.3 Hz, 1H, H4), 4.12 (q, J = 7.14 Hz, 2H, 
H8), 4.86 (dddd, J = 50.23, 4.45, 2.15, 2.15 Hz, 1H, H3); δC (75 MHz, CDCl3) 14.0 
(C9), 26.0 (C6), 28.3 (d, J = 3.25 Hz, 1C, C5), 31.5 (d, J = 20.43 Hz, 1C, C2), 36.7 (d, 
J = 2.27 Hz, 1C, C1), 60.5 (s, 1C, C8), 70.0 (d, J = 19.4 Hz, 1C, C4), 91.1 (d, J = 171.9 
Hz, 1C, C3), 175.1 (C7); δF (282 MHz, CDCl3) -203.1; HRMS (ESI) m/z 208.1340 
[M+NH4]+ (Calcd. for C9H15FO3+NH4+ 208.1343). 
 
3 ADMINISTERING THE SHIKIMIC ACID ANALOGUES 
TO S. HYGROSCOPICUS MG-210 CULTURES 
  
General Procedures 
Microbial culturing was carried out under sterile conditions in a laminar flow cabinet 
(Nuair, NU-440). A New Brunswick orbital incubator was used for the culturing. The 
pH was adjusted using a pH meter (Mettler Toledo – MP-220)    
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Construction of rapQONMLKJI Deficient S. hygroscopicus NRRL 5491  
 
S. hygroscopicus MG2-10 deficient in shikimic acid biosynthesis was constructed by 
double recombination as detailed below:   
Plasmid pMG144 contains homology to terminal regions of the rapQONMLKJI gene 
sequence which, after double recombination, results in disruption of rapQONMLKJI. It 
is based on the suicide vector pMG55 harbouring rpsL to confer dominant sensitivity to 
streptomycin as a positive marker for the second crossover. 
S. hygroscopicus NRRL 5491 was selected for streptomycin resistance to give S. 
hygroscopicus MG1C. S. hygroscopicus MG2-10 was constructed by double 
recombination of pMG144 with S. hygroscopicus MG1C.  
WS spore stocks were prepared by Hrvoje Petkovic on 08.01.04 and a single vial was 
used for the following experiments (19/05/08).   
 
General Procedures 
 
Working stocks were prepared from oatmeal (ISP3) or MAM plates. Strains were 
inoculated to give confluent growth. Cultures were incubated for 2-3 weeks at 28°C. 
White aerial hyphae form initially followed by a downy grey spore covering. The 
vegetative mycelia were cream, no melanin formation was observed. As the plates age 
beyond 2-3 weeks, spores turn black and hygroscopic and are unsuitable for working 
stocks. Spores were harvested from a 30 mL agar plate in 7 mL 20% v/v glycerol by 
washing the plates and filtering aseptically through glass wool to remove vegetative 
debris. Working stocks were aliquoted in 0.5 mL lots and stored at -80°C. 
 
General details on the HPLC used for sample analysis in order to quantify 
rapamycin 
 
The HPLC system comprised an Agilent HP1100 equipped with a Hyperclone 3µm 
BDS C18 130A column 150mm x 4.6mm (Phenomenex) heated to 50 °C. The gradient 
elution was from 55% mobile phase B to 95% mobile phase B over 10 minutes followed 
by an isocratic hold at 95% mobile phase B for 2 minutes with a flow rate of 1 mL/min. 
Mobile phase A was 10% acetonitrile:90% water, containing 10 mM ammonium acetate 
and 0.1% trifluoroacetic acid, mobile phase B was 90% acetonitrile:10% water, 
containing 10 mM ammonium acetate and 0.1% trifluoroacetic acid. Rapamycin 
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analogues were identified by the presence of the characteristic rapamycin triene, centred 
on λ = 278 nm. Samples were quantified based on a rapamycin calibration curve, 
measuring peak area at λ = 280 nm. The HPLC system described above was coupled to 
a Bruker Daltonics Esquire3000 electrospray mass spectrometer. The gradient elution 
was from 50% mobile phase B to 100% mobile phase B over 10 minutes followed by an 
isocratic hold at 100%mobile phase B for 3 minutes with a flow rate of 1 mL/min. 
Mobile phase A was water containing 0.1% formic acid, mobile phase B was 
acetonitrile containing 0.1% formic acid.. Positive negative switching was used over a 
scan range of 500 to 1000 Dalton. 
 
Preparation of HPLC and LC-MS Samples from 
 
-the whole culture broth  
Whole culture broth (0.9 mL) was added to methanol (0.9 mL) in a 2 mL eppendorf, 
and was shaken for 30 minutes. The sample was then centrifuged (10 minutes, 13000 
rpm) and the supernatant (150 µL) was stored for HPLC quantification. 50 µL of each 
sample was injected into an HPLC with diode array detection described above. 
 
- acetonitrile extracts 
Acetonitrile extract (500 µL) was aliquoted in a 2 mL eppendorf and was centrifuged 
(10 minutes at 13000 rpm). The supernatant was aliquoted (200 µL) and was stored for 
HPLC quantification. 50 µL of each sample was injected into the previously described 
HPLC. 
 
- ethyl acetate extracts 
Ethyl acetate (200 µL) was aliquoted in a 2 mL ependorf and the solvent was removed 
using a speedy vac, and methanol (1 mL) was added and was shacked for 5 minutes and 
then was centrifuged for 10 minutes at 13000 rpm. The supernatant was aliquoted (150 
µL) in an HPLC vial. 50 µL of sample was injected into the previously described 
HPLC. 
 
Media preparation: 
Rap V7 Medium (55L) 
Soy flour (toasted nutrisoy)(275 g), white dextrin (1925 g), corn steep solids (220 g), 
ammonium sulphate (110g), lactic acid aqueous solution (80% per volume, 88 mL), 
calcium carbonate (385 g) were dissolved in distilled water and prepared to 55 L. The 
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solution was pH adjusted to 7.5 with sodium hydroxide. The solution was then sterilised 
by autoclaving (121 °C, 20 minutes). Glucose (550 g) was then added under sterile 
conditions after sterilisation. 
MD6 (55L)  
Soy bean flour (toasted nutrisoy) (1650 g), corn starch (1650 g), white dextrin W80 
(1045 g), whole yeast (165 g), corn steep solids (55 g), ammonium sulphate (550 g), 
calcium carbonate (550 g), monopotassium phosphate (KH2PO4, 137.5 g), potassium 
phosphate dibasic (K2HPO4, 137.5 g), sodium chloride (275 g), magnesium sulphate 
heptahydrate (0.1375 g), manganese chloride tetrahydrate (0.55 g), zinc sulphate 
heptahydrate (2.75 g), ferrous sulphate heptahydrate (6.6 g), MES (C6H13NO4S, 1166 g) 
were dissolved in distilled water and prepared to 55 L. The solution was pH adjusted to 
6 using sodium hydroxide. Alpha-amylase (22 mL) was then added under sterile 
conditions. The solution was then sterilised by autoclaving (121 °C, 20 minutes). 
 
3.1 Small Scale Feeding of Shikimic Acid Analogues  
  
Preparation of Starter Cultures  
Under sterile conditions RapV7 media (400 mL) and sterilised 40% (w/v) aqueous 
glucose solution (10 mL) were mixed to homogeneity. S. hygroscopicus MG2-10 spores 
(concentration, 70 µl) were used to inoculate 7 mL portions RapV7-Glucose medium in 
10 sterile 50 mL falcon tubes which were sealed with foam bungs and shaken at 300 
rpm (2.5 cm throw) at 28ºC for 48 hours. 
Preparation of Main Cultures 
Under sterile conditions MD6 media (400 mL), 40% (w/v) fructose aqueous solution 
(20 mL) and filter sterilised 14% (w/v) L-lysine aqueous solution (5.6 mL) were mixed 
to homogeneity. The S. hygroscopicus seed cultures (0.5 mL) were used to inoculate 33 
out of 34 7.45 mL portions of the MD6-fructose-L-lysine medium in 50 mL falcon 
tubes. The uninoculated culture medium was used as negative control. The falcon tubes 
were sealed with foam bungs and were shaken at 300 rpm (2.5 cm throw) at 26ºC for 24 
hours.  
 
 
Administration of Shikimic Acid Analogues  
Compounds 1.94, 1.89, 2.44, 2.50, 2.59, 2.58, 2.47, 2.49 were prepared to a 
concentration of 0.32 molL-1 in methanol and were individually fed in quadruplet (50 
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µL, 16 µmol) to previously prepared S. hygroscopicus MG2-10 cultures to reach a final 
concentration of 2 mmolL-1, except for compound 2.59 which was fed in triplicate. The 
falcon tubes were sealed with foam bungs and were shaken at 300 rpm (2.5 cm throw) 
at 26ºC for 5 days. A single sample of uninoculated media and two unfed S. 
hygroscopicus cultures were used as negative controls. LC-MS samples were prepared 
for analysis from the whole broth. The results of these analyses are reported in the table. 
 
Starter acid 
analogue 
 
Retention 
time Peak area 
Concentrat
ion mgL-1 
Average 
concentration 
MS peaks 
detected 
Uninculated media 
Unfed culture 
Unfed culture 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 0.00 
 
 
                                                                                                                             
 
   
HO CO2H
   
 
1.94 
6.80 
6.80 
6.80 
6.80 
1694.1 
1892.1 
1586.9 
1682.4 
28.24 
31.54 
26.45 
28.05 
28.57 
[M+Na]+ 
847.7 
[M+formate]- 
870.5 
 
 
CO2H
 
1.89                                                         
6.80 
6.80 
6.79 
6.80 
1579.3 
1716.3 
1690.9 
1594.9 
26.33 
28.61 
28.19 
26.59 
27.43 
[M+Na]+ 
847.7 
[M+formate]- 
870.5  
CO2Et
HO
F
 
2.44 
6.47 
6.47 
6.47 
6.46 
639.6 
606.7 
569.6 
617.3 
10.66 
10.11 
9.50 
10.29 
10.14 
[M+Na]+  
866.7 
[M+formate]- 
888.4 
 
   
HO
F
CO2Et
 
 
2.50 
6.59 
6.59 
6.59 
6.59 
1716.1 
1698.9 
1648.6 
1645.1 
28.61 
28.32 
27.48 
27.43 
27.96 
[M+Na]+  
866.7 
[M+formate]- 
888.6  
HO CO2Et
F
 
    
2.59 
 
6.47 
6.47 
6.47 
 
1464.2 
1621.0 
1667.0 
24.41 
27.02 
27.79 
 
26.41 
[M+Na]+ 
866.7 
[M+formate]- 
888.5 
CO2Et
F
HO
 
2.58 
6.58 
6.58 
6.58 
6.58 
184.9 
282.7 
262.7 
304.1 
3.08 
4.71 
4.38 
5.07 
4.31 [M+Na]
+
 
866.7 
F
HO
CO2Et
 
 
2.47 
6.88 
6.88 
6.87 
6.88 
253.1 
283.0 
265.2 
321.2 
4.22 
4.72 
4.42 
5.35 
4.68 
[M+Na]+ 
866.7 and 
[M+formate]- 
888.4 
CO2Et
F
HO
 
2.49 
6.58 
6.58 
6.58 
6.58 
421.9 
462.7 
438.1 
375.8 
7.03 
7.71 
7.30 
6.26 
7.08 [M+Na]+ 866.7 
Table 3.1: Incorporation results for the analytical feeding of the fluorohydrins. 
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3.2 Large scale feeding of the all equatorial fluorohydrin to S. 
hygroscopicus MG-210. 
 
Under sterile conditions MD6 media (2 L), 40% (w/v) fructose aqueous solution (100 
mL) and filter sterilised 14% (w/v) L lysine aqueous solution (28 mL) were mixed 
together to homogeneity. The S. hygroscopicus seed cultures (0.5 mL) were used to 
inoculate 300×7.45 mL portions of the MD6-fructose-L-lysine medium in 50 mL falcon 
tubes. The falcon tubes were sealed with foam bungs and were shaken at 300 rpm (2.5 
cm throw) at 26ºC for 24 hours.  
Compounds 2.50 was prepared in methanol to a concentration of 0.32 molL-1 and was 
fed (50 µL, 16 µmol) to 300 previously prepared S. hygroscopicus MG2-10 cultures to 
reach a final concentration of 2 mmolL-1. The cultures were sealed with foam bungs and 
were shaken at 300 rpm (2.5 cm throw) at 26ºC for 5 days. Four analytical samples from 
the whole broth of four random falcon tubes were analysed by HPLC (Table 3.2). The 
300 cultures were combined in a conical flask (1.5L). The tubes were washed with 
distilled water, and the washings were combined in a different flask (800 mL). The 
whole broth and the washings were analysed in triplicate by HPLC. The whole broth 
and the washings were combined after analysis. The cells were harvested by 
centrifugation (25 minutes at 3500 rpm) and the supernatant (1.8 L) was discarded after 
HPLC analysis in triplicate. Acetonitrile (2.75 L) was added to the cells, stirred for one 
hour and decanted. The cells were extracted a second time with acetonitrile (2.4 L) as 
previously. Both extracts and the aqueous phase were analysed in duplicate by HPLC. 
The second portion of ethyl acetate and the aqueous phase were discarded.  
The acetonitrile extracts were combined, and the solvent removed in vacuo. Ethyl 
acetate (300 mL) and distilled water (400 mL) were added and stirred for 20 minutes 
and centrifuged (10 minutes, 3500 rpm). The organic phase was extracted and ethyl 
acetate (300 mL) was added and the procedure was repeated as before. Both extracts 
were analysed by HPLC in duplicate.  
Ethyl acetate was removed in vacuo, yielding 2.246 g of crude material containing an 
estimated 31 mg of prerapamycin. The crude material was purified by flash 
chromatography on silica eluting with a mixture of ethyl acetate and hexane (6 : 4). All 
fractions were analysed by HPLC. Fractions with a high concentration of prerapamycin 
were combined (1.83 L), and fractions containing lower concentrations of prerapamycin 
were also combined separately (1.8 L). After HPLC analysis (Table 3.2) both fractions 
were combined and the solvent was removed in vacuo. The compound was dissolved in 
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acetonitrile (1.8 mL) and was injected in a preparative HPLC (Column – Waters Xterra 
MS C18, 10 micron, 250 mm x 19 mm diameter; flow rate 20 mL/min; solvent A = 
water, solvent B = acetonitrile; isocratic 45% B, RT of target compound = 21 mins). 
The solvent was removed in vacuo to reveal the target compound as an off-white 
amorphous solid (16.4 mg).The compound was analysed by NMR (1H, 13C, DEPT, 
19F, HMBC, HSQC, COSY, NOESY) and HRMS. The NMR analysis revealed a 
mixture of two compounds (Table 3.3).  
Samples mgL-1 
Average 
concentration 
Volume 
Predicted 
mass 
Total 
predicted 
mass 
Falcon tube 1 23.26 
21.30    
Falcon tube 2 20.18 
Falcon tube 3 20.17 
Falcon tube 4 21.52 
Whole broth 
 
21.79 
20.60 
21.43 
 
21.27 
 32 mg 
 
35 mg Washings 
 
3.86 
3.81 
4.89 
4.19 0.8 L 3 mg 
Supernatant 
 
1.76 
1.65 
1.65 
1.69 1.8 L 3mg 
discarded 
 
CH3CN EXT 1 
 
 
10.25 
10.21 10.23 2.75L 28mg 34mg 
 
 CH3CN EXT 2 
 
2.55 
2.56 2.56 2.4L 6mg 
EtOAc ext 1 
 
 
102.03 
108.61 
105.3 
 
0.3L 
 
31.6mg 
 
31.6 mg 
 
EtOAc ext 2 
 
0.00 
0.00 0 0.3L 0 
Aqu ext 
 
0.00 
0.00 
0 
 
0.4L 
 
0 
DISCARD 
Column fractions with high 
concentration of compound 
9.78 
9.49 
9.32 
 
9.53 
 
 
1.83L 
 
 
17.4 mg 
 
 
22.6 mg 
 
 
Column fractions with low 
concentrations of 
compound 
2.77 
3.04 
2.78 
 
2.86 
 
1.8L 
 
5.2 mg 
 
2 preparative HPLC 
 
 
 
 
 
 
 
 
16.4 mg 
Table 3.2: Estimated and isolated quantities of fluoroprerapamycin 2.66 during the 
gramme scale feeding of compound 2.50 
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Feeding Experiment and fluoro-pre-rapamycin generation: 
 
Fluoro-pre-rapamycin (2.66): HRMS (ESI) m/z 866.5234 (M+Na)+ (Calcd. for 
C48H74NO10F+Na+ 866.5194).  
O OH
O
OHOO
N
O
HO
O
OH
F
1
2
3
4
5
6
8
9
10
11
12
13
14
15
16
17
44
18
19
20
21
22
23
45
24
25
26
27
28
29
303132
33
34
35
36 37 38
39
4041
42
43
46
47
48
7
 
 
Table for NMR Chemical shifts of 2.66 
 
δF (282 MHz, CDCl3) -74.96, -75.85  
 
Proton δH multiplicity coupling δC 
1 - -                    171.5 169.0 
2 5.38 4.37   52.6 55.7 
3a 
3b 
1.78 
2.19 
1.53 
2.41 
  26.2 26.7 
4a 
4b 
1.25 
1.75 
1.51 
1.71 
  20.9 20.5 
5a 
5b 
1.49 
1.74 
1.29 
1.63 
  25.1 24.4 
6a  
6b 
3.25 
3.84 
2.15 
4.47 
 
brd         brd 
 
13.1                        13.4 
44.4 39.1 
8     172.4 171.7 
9a 
9b 
2.57 
2.89 
2.41 
2.69 
d                d 
d                d 
  13.8                      16.1 
  13.7                      16.3 
40.2 38.8 
10     98.6 98.4 
 
10-OH  6.66              br. s    
11 1.49 1.54   38.6 38.6 
12a 
12b 
1.47 
1.62 
1.49 
1.69 
  27.6 27.3 
13a 
13b 
1.34 
1.52 
1.26 
1.57 
  31.9 32.3 
14 3.89 4.22 dddd 11.4, 11.4, 2.0, 2.0 69.6 71.3 
 171
15a 
15b 
1.53 
1.68 
1.46 
1.69 
  40.6 40.6 
16 4.08 4.22 dd 6.2, 6.2 75.6 76.0 
17     138.4 141.6 
18 6.23 6.09 d                d 12.2                        10.5 125.1 122.6 
19 6.33 6.39 dd            dd 14.6, 11.2      14.2, 11.2     127.7 128.6 
20 6.19 6.00 dd            dd 14.7, 10.7      14.2, 10.8 132.2 131.2 
21 6.05 6.06 dd            dd 14.9, 10.4      14.5, 10.6 130.5 130.2 
22 5.31 5.19 dd            dd 14.9, 9.4          14.6, 9.9 139.0 139.4 
23 2.16 2.12   37.3 39.8 
24a 
24b 
1.30 
1.69 
1.37 
1.98 
                dd                         13.2, 4.0  40.3 39.7 
25 2.43 2.44   45.6 46.3 
26     215.5 216.2 
27a 
27b 
2.54 
2.65 
2.45 
2.60 
dd            dd 
dd             
16.7, 3.3          17.7, 2.1 
16.7, 2.7 
46.4 48.0 
28 4.34 4.40   72.0 72.1 
29     139.6 139.7 
30 5.37 5.44 d                d  9.8                           9.8 123.7 125.4 
31 3.25 3.39                 qd                            10, 6.8 46.4 45.6 
32     208.8 209.0 
33a 
33b 
2.61 
2.63 
2.65 
2.95 
dd  
              ddd 
18.3, 9.7        
                 18.6, 9.9, 2.5                   
40.6 39.7 
34 5.13 5.36 ddd 6.5, 6.5, 3.8 75.9 74.4 
35 1.94 1.96   32.6 32.8 
36a 
36b 
1.09 
1.20 
1.05 
1.16 
dd 
m             dd 
3.4, 3.4 
                          7.5, 5.7 
37.5 37.5 
37 1.41 1.45   32.9 33.0 
38a 
38b 
1.46 
1.68 
1.48 
1.66 
  40.7 40.6 
39 4.26 or 
4.31-
4.21 
4.37-
4.22 
dddd 51.3, 10.2, 8.7, 5.0 96.2 (d, 
J = 
173.8 
Hz) 
96.2(d, 
J = 
173.8 
Hz) 
40 3.59 3.61   73.4 73.4 
 
41a 
41b 
1.28 
1.96 
1.29 
2.00 
  30.9 30.9 
42a 
42b 
1.68 
0.84 
1.73 
0.90 
  29.2 
 
29.9 
43 0.95 0.95 d                d 6.5                            6.5                                                                                             16.8 16.9
44 1.65 1.79 s                 s  12.7 15.7 
45 1.02 1.00 d                d 6.3                           6.0 21.6 21.7 
46 1.01 1.03 d                d 6.1                            7.2 16.6 19.1 
47 1.59 1.49 d                d 1.0                            1.1 13.1 11.8 
48 1.08 1.01 d                s 6.8                            7.1 16.2 14.6 
49 0.89 0.90 d               d 6.1                            6.5 16.0 15.0 
 
Table 3.3: 1H and 13C chemical shifts for both fluoroprerapamycins. 
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APPENDIX 1: 1H NMR Spectrum of Fluoroprerapamycin 
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500 MHz, CDCl3
1H NMR spectrum of fluoro-pre-rapamycin (2.66).
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APPENDIX 2: 13C NMR Spectrum of Fluoroprerapamycin 
 
 
500 MHz, CDCl3
13C NMR spectrum of fluoro-pre-rapamycin (2.66).
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APPENDIX 3: DEPT NMR Spectrum of Fluoroprerapamycin 
 
 
 
 
500 MHz, CDCl3
DEPT-90 NMR spectrum of fluoro-pre-rapamycin (2.66).
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APPENDIX 4: COSY NMR Spectrum of Fluoroprerapamycin  
 
 
 
500 MHz, CDCl3
COSY NMR spectrum of fluoro-pre-rapamycin (2.66).
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APPENDIX 5: HSQC NMR Spectrum of Fluoroprerapamycin  
 
 
500 MHz, CDCl3
. HSQC NMR spectrum of fluoro-pre-rapamycin (2.66).
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APPENDIX 6: HMBC NMR Spectrum of Fluoroprerapamycin 
 
 
500 MHz, CDCl3
HMBC NMR spectrum of fluoro-pre-rapamycin (2.66).
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